<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Exjade-II-073-EN PI</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	line-height:13.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;}
h2
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Helvetica",sans-serif;
	font-style:italic;}
h3
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
h4
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h5
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{margin:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	font-size:7.5pt;
	font-family:"Verdana",sans-serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,Comment Text Char Char Char\,Comment Text Char1\,Comment Text Char1 Char";
	mso-style-link:"Comment Text Char\,Comment Text Char Char Char Char\,Comment Text Char1 Char1\,Comment Text Char1 Char Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-name:"Header\,ctdHeader\,h";
	margin:0in;
	font-size:10.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	font-size:8.0pt;
	font-family:"Helvetica",sans-serif;}
span.MsoFootnoteReference
	{font-family:"Verdana",sans-serif;
	vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
em
	{font-weight:bold;
	font-style:normal;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.Text, li.Text, div.Text
	{mso-style-name:"Text\,Graphic\,Graphic Char Char\,Graphic Char Char Char Char Char\,Graphic Char Char Char Char Char Char Char C";
	mso-style-link:"Text Char1";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.TextChar1
	{mso-style-name:"Text Char1";
	mso-style-link:"Text\,Graphic\,Graphic Char Char\,Graphic Char Char Char Char Char\,Graphic Char Char Char Char Char Char Char C";}
p.Nottoc-headings, li.Nottoc-headings, div.Nottoc-headings
	{mso-style-name:"Not toc-headings";
	mso-style-link:"Not toc-headings Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:85.05pt;
	text-indent:-85.05pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.Nottoc-headingsChar
	{mso-style-name:"Not toc-headings Char";
	mso-style-link:"Not toc-headings";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.Table, li.Table, div.Table
	{mso-style-name:Table;
	mso-style-link:"Table Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
span.TableChar
	{mso-style-name:"Table Char";
	mso-style-link:Table;
	font-family:"Arial",sans-serif;}
p.Listlevel1, li.Listlevel1, div.Listlevel1
	{mso-style-name:"List level 1";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:21.25pt;
	text-indent:-21.25pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.bullethead, li.bullethead, div.bullethead
	{mso-style-name:"bullet head";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:12.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.CharCharCharCharCharCharCharCharChar, li.CharCharCharCharCharCharCharCharChar, div.CharCharCharCharCharCharCharCharChar
	{mso-style-name:"Char Char Char Char Char Char Char Char Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Verdana",sans-serif;}
p.CharCharCharCharChar1CharCharCharCharCharChar, li.CharCharCharCharChar1CharCharCharCharCharChar, div.CharCharCharCharChar1CharCharCharCharCharChar
	{mso-style-name:"Char Char Char Char Char1 Char Char Char Char Char Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Tahoma",sans-serif;}
p.Style, li.Style, div.Style
	{mso-style-name:Style;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Verdana",sans-serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";
	font-family:"Arial",sans-serif;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\,Comment Text Char Char Char Char\,Comment Text Char1 Char1\,Comment Text Char1 Char Char";
	mso-style-link:"Comment Text\,Comment Text Char Char Char\,Comment Text Char1\,Comment Text Char1 Char";}
p.CharChar3Char, li.CharChar3Char, div.CharChar3Char
	{mso-style-name:"Char Char3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Tahoma",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.st
	{mso-style-name:st;}
span.TextChar
	{mso-style-name:"Text Char";
	font-family:"MS Mincho";}
span.mw-headline
	{mso-style-name:mw-headline;}
span.searchinsearch
	{mso-style-name:searchinsearch;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-style:italic;}
p.Doctype, li.Doctype, div.Doctype
	{mso-style-name:Doctype;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";
	font-family:"Verdana",sans-serif;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB style='color:black'>ANNEX I</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB style='color:black'>SUMMARY OF PRODUCT
CHARACTERISTICS</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'><img width=21 height=18
src="Exjade-II-073-EN%20PI_files/image001.gif"></span><span lang=EN-GB
style='color:black'>This medicinal product is subject to additional monitoring.
This will allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions. See section
4.8 for how to report adverse reactions.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE MEDICINAL
PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=FR style='font-size:11.0pt;color:black'>EXJADE 125&nbsp;mg dispersible
tablets</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=FR style='font-size:11.0pt;color:black'>EXJADE 250&nbsp;mg dispersible
tablets</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=FR style='font-size:11.0pt;color:black'>EXJADE 500&nbsp;mg dispersible
tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=FR
style='color:black'>2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><i><span lang=FR style='color:black'>&nbsp;</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
125&nbsp;mg dispersible tablets</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Each dispersible tablet contains
125&nbsp;mg deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Excipient </span><span lang=EN-GB
style='color:black'>with known effect</span><span lang=EN-GB style='color:black'>:</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Each dispersible tablet contains 136&nbsp;mg
lactose.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
250&nbsp;mg dispersible tablets</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Each dispersible tablet contains
250&nbsp;mg deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Excipient </span><span lang=EN-GB
style='color:black'>with known effect</span><span lang=EN-GB style='color:black'>:</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Each dispersible tablet contains 272&nbsp;mg
lactose.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
500&nbsp;mg dispersible tablets</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Each dispersible tablet contains
500&nbsp;mg deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Excipient</span><span lang=EN-GB
style='color:black'> with known effect</span><span lang=EN-GB style='color:
black'>:</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Each dispersible tablet contains 544&nbsp;mg
lactose.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>For the full list of excipients, see section
6.1.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>3.       PHARMACEUTICAL <span style='text-transform:uppercase'>form</span></span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Dispersible tablet</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
125&nbsp;mg dispersible tablets</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>White to slightly yellow, round, flat
tablets with bevelled edges and imprints (NVR on one face and J&nbsp;125 on the
other). Approximate tablet dimensions 12&nbsp;mm x 3.6&nbsp;mm.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
250&nbsp;mg dispersible tablets</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>White to slightly yellow, round, flat
tablets with bevelled edges and imprints (NVR on one face and J&nbsp;250 on the
other). Approximate tablet dimensions 15&nbsp;mm x 4.7&nbsp;mm.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
500&nbsp;mg dispersible tablets</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>White to slightly yellow, round, flat
tablets with bevelled edges and imprints (NVR on one face and J&nbsp;500 on the
other). Approximate tablet dimensions 20&nbsp;mm x 5.6&nbsp;mm.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black;text-transform:uppercase'>4.       Clinical particulars</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.1     Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>EXJADE
is indicated for the treatment of chronic iron overload due to frequent blood
transfusions (</span><span lang=EN-GB style='font-family:Symbol;color:black'>³</span><span
lang=EN-GB style='color:black'>7&nbsp;ml/kg/month of packed red blood cells) in
patients with beta thalassaemia major aged 6&nbsp;years and older.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>EXJADE is also indicated for the treatment of
chronic iron overload due to blood transfusions when deferoxamine therapy is
contraindicated or inadequate in the following patient groups:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white'><span lang=EN-GB style='color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>in paediatric patients with
beta thalassaemia major with iron overload due to frequent blood transfusions (</span><span
lang=EN-GB style='font-family:Symbol;color:black'>³</span><span lang=EN-GB
style='color:black'>7&nbsp;ml/kg/month of packed red blood cells) aged 2 to
5&nbsp;years,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white'><span lang=EN-GB style='color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>in adult and paediatric patients
with beta thalassaemia major with iron overload due to infrequent blood
transfusions (</span><span lang=EN-GB style='color:black'>&lt;</span><span
lang=EN-GB style='color:black'>7&nbsp;ml/kg/month of packed red blood cells)
aged 2&nbsp;years and older,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white'><span lang=EN-GB style='color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>in adult and paediatric patients
with other anaemias aged 2&nbsp;years and older.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>EXJADE is also indicated for the treatment of chronic iron
overload requiring chelation therapy when deferoxamine therapy is
contraindicated or inadequate in patients with non&#8209;transfusion&#8209;dependent
thalassaemia syndromes aged 10&nbsp;years and older.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.2     Posology and method of administration</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Treatment with EXJADE should be initiated
and maintained by physicians experienced in the treatment of chronic iron overload.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Posology</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><u><span style='font-size:11.0pt;color:black'>Transfusional
iron overload</span></u></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><u><span style='font-size:11.0pt;color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>It is recommended that treatment be
started after the transfusion of approximately 20&nbsp;units (about
100&nbsp;ml/kg) of packed red blood cells (PRBC) or when there is evidence from
clinical monitoring that chronic iron overload is present (e.g. serum ferritin
&gt;1,000&nbsp;µg/l). Doses (in mg/kg) must be calculated and rounded to the
nearest whole tablet size.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The goals of iron chelation therapy are to
remove the amount of iron administered in transfusions and, as required, to
reduce the existing iron burden.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Caution should be taken during chelation
therapy to minimise the risk of overchelation in all patients (see section&nbsp;4.4).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In case of switching from film&#8209;coated
tablets/granules to dispersible tablets, the dose of dispersible tablets should
be 40% higher than the dose of film&#8209;coated tablets/granules, rounded to
the nearest whole tablet.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The corresponding doses for the different
formulations are shown in the table below.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><u><span style='color:black'>Table&nbsp;1</span></u><span
style='color:black'>        Recommended doses for transfusional iron overload</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=623
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span lang=EN-GB style='color:black'>Film&#8209;coated
  tablets/granules</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Dispersible tablets</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Transfusions</span></b></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Serum ferritin</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Starting dose</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span lang=EN-GB style='color:black'>14&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>20&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>After 20&nbsp;units (about
  100&nbsp;ml/kg) of PRBC</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>or</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&gt;1,000&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Alternative starting doses</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span lang=EN-GB style='color:black'>21&nbsp;mg/kg/day</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>30&nbsp;mg/kg/day</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&gt;14&nbsp;ml/kg/month of PRBC
  (approx. &gt;4&nbsp;units/month for an adult)</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span lang=EN-GB style='color:black'>7&nbsp;mg/kg/day</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>10&nbsp;mg/kg/day</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&lt;7&nbsp;ml/kg/month of PRBC
  (approx. &lt;2&nbsp;units/month for an adult)</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>For patients well managed on
  deferoxamine</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>One third of deferoxamine dose</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>Half of deferoxamine dose</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Monitoring</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Monthly</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Target range</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>500&#8209;1,000&nbsp;µg/</span></b><span
  style='color:black'>l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 rowspan=6 valign=top style='width:78.0pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Adjustment steps</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>(every 3&#8209;6&nbsp;months)</span></p>
  </td>
  <td width=265 colspan=2 valign=top style='width:198.45pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;background:white'><b><span style='color:black'>Increase</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&gt;2,500&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span lang=EN-GB style='color:black'>3.5 &#8209;
  7&nbsp;mg/kg/day</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>Up to 28&nbsp;mg/kg/day</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>5&#8209;10&nbsp;mg/kg/day</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>Up to 40&nbsp;mg/kg/day</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=265 colspan=2 valign=top style='width:198.45pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;background:white'><b><span style='color:black'>Decrease</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span lang=EN-GB style='color:black'>3.5 &#8209;
  7&nbsp;mg/kg/day</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>5&#8209;10&nbsp;mg/kg/day</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&lt;2,500&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>In patients treated with doses
  &gt;21&nbsp;mg/kg/day</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>In patients treated with doses
  &gt;30&nbsp;mg/kg/day</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=265 colspan=2 valign=top style='width:198.45pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal;page-break-after:avoid;background:white'><span style='color:black'>-<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span style='color:black'>When target is reached</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>500&#8209;1,000&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Maximum dose</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span lang=EN-GB style='color:black'>28&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>40&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Consider interruption</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&lt;500&nbsp;µg/l</span></b></p>
  </td>
 </tr>
</table>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Starting dose</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The recommended initial daily dose of
EXJADE dispersible tablets is 20&nbsp;mg/kg body weight.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>An initial daily dose of 30&nbsp;mg/kg may
be considered for patients who require reduction of elevated body iron levels
and who are also receiving more than 14&nbsp;ml/kg/month of packed red blood
cells (approximately &gt;4&nbsp;units/month for an adult).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>An initial daily dose of 10&nbsp;mg/kg may
be considered for patients </span><span lang=EN-GB style='font-size:11.0pt;
color:black'>who do not require reduction of body iron levels and who are also </span><span
style='font-size:11.0pt;color:black'>receiving less than 7&nbsp;ml/kg/month of
packed red blood cells (approximately &lt;2&nbsp;units/month for an adult). The
patients response must be monitored and a dose increase should be considered
if sufficient efficacy is not obtained (see section 5.1).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>For patients already well managed on
treatment with deferoxamine, a starting dose of EXJADE dispersible tablets that
is numerically half that of the deferoxamine dose could be considered (e.g. a
patient receiving 40&nbsp;mg/kg/day of deferoxamine for 5&nbsp;days per week
(or equivalent) could be transferred to a starting daily dose of
20&nbsp;mg/kg/day of EXJADE dispersible tablets). When this results in a daily
dose less than 20&nbsp;mg/kg body weight, the patients response must be
monitored and a dose increase should be considered if sufficient efficacy is
not obtained (see section 5.1).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Dose adjustment</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>It is recommended that serum ferritin be
monitored every month and that the dose of EXJADE be adjusted, if necessary,
every 3 to 6&nbsp;months based on the trends in serum ferritin. Dose
adjustments may be made in steps of 5 to 10&nbsp;mg/kg and are to be tailored
to the individual patients response and therapeutic goals (maintenance or
reduction of iron burden). In patients not adequately controlled with doses of
30&nbsp;mg/kg (e.g. serum ferritin levels persistently above 2,500&nbsp;µg/l
and not showing a decreasing trend over time), doses of up to 40&nbsp;mg/kg may
be considered. The availability of long&#8209;term efficacy and safety data
with EXJADE dispersible tablets used at doses above 30&nbsp;mg/kg is currently
limited (264&nbsp;patients followed for an average of 1&nbsp;year after dose
escalation). If only very poor haemosiderosis control is achieved at doses up
to 30&nbsp;mg/kg, a further increase (to a maximum of 40&nbsp;mg/kg) may not
achieve satisfactory control, and alternative treatment options may be
considered. If no satisfactory control is achieved at doses above
30&nbsp;mg/kg, treatment at such doses should not be maintained and alternative
treatment options should be considered whenever possible. Doses above 40&nbsp;mg/kg
are not recommended because there is only limited experience with doses above
this level.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In patients treated with doses greater
than 30&nbsp;mg/kg, dose reductions in steps of 5 to 10&nbsp;mg/kg should be
considered when control has been achieved (e.g. serum ferritin levels
persistently below 2,500&nbsp;µg/l and showing a decreasing trend over time).
In patients whose serum ferritin level has reached the target (usually between
500 and 1,000&nbsp;µg/l), dose reductions in steps of 5 to 10&nbsp;mg/kg should
be considered to maintain serum ferritin levels within the target range and to
minimise the risk of overchelation. If serum ferritin falls consistently below
500&nbsp;µg/l, an interruption of treatment should be considered (see section
4.4).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><i><u><span style='color:black'>Non&#8209;transfusion&#8209;dependent
thalassaemia syndromes</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><u><span style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Chelation therapy should only be initiated when there is
evidence of iron overload (liver iron concentration [LIC] &#8805;5&nbsp;mg Fe/g
dry weight [dw] or serum ferritin consistently &gt;800&nbsp;</span><span
lang=EN-GB style='color:black'>µg</span><span style='color:black'>/l). LIC is
the preferred method of iron overload determination and should be used wherever
available. Caution should be taken during chelation therapy to minimise the
risk of overchelation in all patients (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In case of switching from film&#8209;coated
tablets/granules to dispersible tablets, the dose of dispersible tablets should
be 40% higher than the dose of film&#8209;coated tablets/granules, rounded to
the nearest whole tablet.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text style='margin-top:0in;background:white'><span style='font-size:
11.0pt;color:black'>The corresponding doses for the different formulations are
shown in the table below.</span></p>

<p class=Text style='margin-top:0in;background:white'><span style='font-size:
11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Table&nbsp;2</span></u><span
style='font-size:11.0pt;color:black'>        Recommended doses for non&#8209;transfusion&#8209;dependent
thalassaemia syndromes</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=614
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Film&#8209;coated
  tablets/granules</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Dispersible tablets</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Liver iron
  concentration (LIC)*</span></b></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Serum ferritin</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Starting dose</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>7&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>10&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&#8805;5&nbsp;mg Fe/g
  dw</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>or</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&gt;800&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Monitoring</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Monthly</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 rowspan=4 valign=top style='width:78.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Adjustment steps</span></b></p>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>(every 3&#8209;6&nbsp;months)</span></p>
  </td>
  <td width=255 colspan=2 valign=top style='width:191.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><b><span style='font-family:"Times New Roman",serif;
  color:black'>Increase</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&#8805;7&nbsp;mg Fe/g
  dw</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>or</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&gt;2,000&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>3.5 &#8209;
  7&nbsp;mg/kg/day</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>5&#8209;10&nbsp;mg/kg/day</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=255 colspan=2 valign=top style='width:191.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><b><span style='font-family:"Times New Roman",serif;
  color:black'>Decrease</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&lt;7&nbsp;mg Fe/g dw</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>or</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='color:black'>&#8804;</span><span style='font-family:"Times New Roman",serif;
  color:black'>2,000&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>3.5 &#8209;
  7&nbsp;mg/kg/day</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>5&#8209;10&nbsp;mg/kg/day</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Maximum dose</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:dotted windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>14&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:dotted windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>20&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:dotted windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;border-bottom:dotted windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;border-bottom:dotted windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:16.9pt'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:16.9pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:16.9pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>7&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:16.9pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>10&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:16.9pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:16.9pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:16.9pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=255 colspan=2 valign=top style='width:191.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><span style='font-family:"Times New Roman",serif;
  color:black'>For adults</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>not assessed</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>and</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='color:black'>&#8804;</span><span style='font-family:"Times New Roman",serif;
  color:black'>2,000&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=255 colspan=2 valign=top style='width:191.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><span style='font-family:"Times New Roman",serif;
  color:black'>For paediatric patients</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Interruption</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&lt;3&nbsp;mg Fe/g dw</span></b></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>or</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&lt;300&nbsp;µg/l</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Retreatment</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><b><span style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><b><span style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></b></p>
  </td>
  <td width=255 colspan=3 valign=top style='width:191.35pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><b><span style='font-family:"Times New Roman",serif;
  color:black'>Not recommended</span></b></p>
  </td>
 </tr>
</table>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='color:black'>*LIC is the preferred method
of iron overload determination.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Starting dose</span></i></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>The recommended initial daily dose of EXJADE dispersible
tablets in patients with non&#8209;transfusion&#8209;dependent thalassaemia
syndromes is 10&nbsp;mg/kg body weight.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Dose adjustment</span></i></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>It is recommended that serum ferritin be monitored every
month to assess the patients response to therapy and to minimise the risk of
overchelation (see section&nbsp;4.4). After every 3 to 6&nbsp;months of
treatment, a dose increase in increments of 5 to 10&nbsp;mg/kg should be
considered if the patients LIC is &#8805;7&nbsp;mg Fe/g dw, or if serum
ferritin is consistently &gt;2,000&nbsp;</span><span lang=EN-GB
style='color:black'>µ</span><span style='color:black'>g/l and not showing a
downward trend, and the patient is tolerating the medicinal product well. Doses
above 20&nbsp;mg/kg are not recommended because there is no experience with
doses above this level in patients with non&#8209;transfusion&#8209;dependent
thalassaemia syndromes.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>In patients in whom LIC was not assessed and serum ferritin
is &#8804;2,000&nbsp;</span><span lang=EN-GB style='color:black'>µg</span><span
style='color:black'>/l, dosing should not exceed 10&nbsp;mg/kg.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>For patients in whom the dose was increased to &gt;10&nbsp;mg/kg,
dose reduction to 10&nbsp;mg/kg or less is recommended when LIC is
&lt;7&nbsp;mg Fe/g dw or serum ferritin is &#8804;2,000&nbsp;</span><span
lang=EN-GB style='color:black'>µg</span><span style='color:black'>/l.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><span lang=EN-GB style='font-size:11.0pt;color:black'>Treatment
cessation</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Once a satisfactory body iron
level has been achieved (LIC &lt;3&nbsp;mg Fe/g dw or serum ferritin
&lt;300&nbsp;</span><span style='font-size:11.0pt;color:black'>µg</span><span
lang=EN-GB style='font-size:11.0pt;color:black'>/l), treatment should be stopped.
There are no data available on the retreatment of patients who reaccumulate
iron after having achieved a satisfactory body iron level and therefore
retreatment cannot be recommended.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><u><span style='font-size:11.0pt;color:black'>Special
populations</span></u></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><span style='font-size:11.0pt;color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Elderly patients (&#8805;65&nbsp;years of age)</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The dosing recommendations for elderly
patients are the same as described above. In clinical studies, elderly patients
experienced a higher frequency of adverse reactions than younger patients (in
particular, diarrhoea) and should be monitored closely for adverse reactions that
may require a dose adjustment.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Paediatric population</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><span lang=EN-GB
style='color:black'>Transfusional iron overload:</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The dosing recommendations for paediatric
patients aged 2 to 17&nbsp;years with transfusional iron overload are the same
as for adult patients (see section&nbsp;4.2). It is recommended that serum
ferritin be monitored every month to assess the patients response to therapy
and to minimise the risk of overchelation (see section&nbsp;4.4). Changes in
weight of paediatric patients over time must be taken into account when
calculating the dose.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In children with transfusional iron
overload aged between 2 and 5&nbsp;years, exposure is lower than in adults (see
section 5.2). This age group may therefore require higher doses than are
necessary in adults. However, the initial dose should be the same as in adults,
followed by individual titration.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span lang=FR-CH style='font-size:11.0pt;color:black'>Non&#8209;transfusion&#8209;dependent
thalassaemia syndromes:</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>In paediatric patients with non&#8209;transfusion&#8209;dependent
thalassaemia syndromes, dosing should not exceed 10&nbsp;mg/kg. In these
patients, closer monitoring of LIC and serum ferritin is essential to avoid
overchelation (see section&nbsp;4.4). In addition to monthly serum ferritin
assessments, LIC should be monitored every three months when serum ferritin is
&#8804;800&nbsp;</span><span lang=EN-GB style='color:black'>µg</span><span
style='color:black'>/l.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span lang=EN-GB style='font-size:11.0pt;color:black'>Children
from birth to 23&nbsp;months:</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The safety and efficacy of EXJADE in
children from birth to 23&nbsp;months of age have not been established. No data
are available.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Patients with renal impairment</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE has not been studied in patients
with renal impairment and is contraindicated in patients with estimated
creatinine clearance &lt;60&nbsp;ml/min (see sections 4.3 and 4.4).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Patients with hepatic impairment</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE is not recommended in patients with
severe hepatic impairment (Child&#8209;Pugh Class C). In patients with moderate
hepatic impairment (Child&#8209;Pugh Class B), the dose should be considerably reduced
followed by progressive increase up to a limit of 50% (see sections 4.4 and
5.2), and EXJADE must be used with caution in such patients. Hepatic function
in all patients should be monitored before treatment, every 2&nbsp;weeks during
the first month and then every month (see section 4.4).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Method of
administration</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>For oral use.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE dispersible tablets must be taken
once daily on an empty stomach at least 30&nbsp;minutes before food, preferably
at the same time each day (see sections 4.5 and 5.2).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The dispersible tablets are dispersed by
stirring in a glass of water or orange or apple juice (100 to 200&nbsp;ml)
until a fine suspension is obtained. After the suspension has been swallowed,
any residue must be resuspended in a small volume of water or juice and
swallowed. The tablets must not be chewed or swallowed whole (see also section
6.2).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.3     Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Hypersensitivity to the active substance or to
any of the excipients</span><span lang=EN-GB style='color:black'> listed in
section 6.1</span><span lang=EN-GB style='color:black'>.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Combination with other iron chelator therapies as the
safety of such combinations has not been established </span><span lang=EN-GB
style='color:black'>(see section 4.5)</span><span style='color:black'>.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Patients with estimated creatinine clearance
&lt;60&nbsp;ml/min.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><b><span lang=EN-GB style='color:black'>4.4     Special
warnings and precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='background:white;border:none;padding:0in'><u><span
lang=EN-GB style='color:black'>Renal function</span></u></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>Deferasirox has </span><span lang=EN-GB
style='color:black'>been studied only in patients with baseline serum
creatinine within the age&#8209;appropriate normal range.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>During
clinical studies, increases in serum creatinine of &gt;33% on &#8805;2&nbsp;consecutive
occasions, sometimes above the upper limit of the normal range, occurred in
about 36% of patients. These were dose&#8209;dependent. About two&#8209;thirds
of the patients showing serum creatinine increase returned below the 33% level
without dose adjustment. In the remaining third the serum creatinine increase
did not always respond to a dose reduction or a dose interruption. In some
cases, only a stabilisation of the serum creatinine values has been observed
after dose reduction. Cases of acute renal failure have been reported following
post&#8209;marketing use of deferasirox (see section 4.8). In some post&#8209;marketing
cases, renal function deterioration has led to renal failure requiring
temporary or permanent dialysis.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>The causes of the rises</span><span lang=EN-GB
style='color:black'> in serum creatinine have not been elucidated.</span><span
lang=EN-GB style='color:black'> Particular attention should therefore be paid
to monitoring of serum creatinine in patients who are concomitantly receiving
medicinal products that depress renal function, and in patients who are
receiving high doses of deferasirox and/or low rates of transfusion
(&lt;7&nbsp;ml/kg/month of packed red blood cells or &lt;2&nbsp;units/month for
an adult). While no increase in renal adverse events was observed after dose
escalation of EXJADE dispersible tablets to doses above 30&nbsp;mg/kg in
clinical studies, an increased risk of renal adverse events with EXJADE dispersible
tablet doses above 30&nbsp;mg/kg cannot be excluded.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>It is recommended that serum creatinine be
assessed in duplicate before initiating therapy. <b>Serum creatinine,
creatinine clearance</b> (estimated with the Cockcroft&#8209;Gault or MDRD
formula in adults and with the Schwartz formula in children) and/or plasma
cystatin C levels<b> should be monitored prior to therapy, weekly in the first
month after initiation </b></span><b><span lang=EN-GB style='color:black'>or
modification </span><span lang=EN-GB style='color:black'>of therapy with EXJADE
(including switch of formulation), and monthly thereafter</span></b><span
lang=EN-GB style='color:black'>. Patients with pre&#8209;existing renal
conditions and patients who are receiving medicinal products that depress renal
function may be more at risk of complications. Care should be taken to maintain
adequate hydration in patients who develop diarrhoea or vomiting.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>There have been post&#8209;marketing reports of
metabolic acidosis occurring during treatment with deferasirox. The majority of
these patients had renal impairment, renal tubulopathy (Fanconi syndrome) or
diarrhoea, or conditions where acid&#8209;base imbalance is a known
complication. Acid&#8209;base balance should be monitored as clinically
indicated in these populations. Interruption of EXJADE therapy should be
considered in patients who develop metabolic acidosis.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>Post-marketing cases of severe forms of renal
tubulopathy (such as Fanconi syndrome) and renal failure associated with
changes in consciousness in the context of hyperammonaemic encephalopathy have
been reported in patients treated with deferasirox, mainly in children. It is
recommended that hyperammonaemic encephalopathy be considered and ammonia
levels measured in patients who develop unexplained changes in mental status
while on Exjade therapy.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><u><span
lang=EN-GB style='color:black'>Table&nbsp;3</span></u><span lang=EN-GB
style='color:black'>        Dose adjustment and interruption of treatment for
renal monitoring</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'>

<table cellpadding=0 cellspacing=0 align=left>
 <tr>
  <td width=1 height=18></td>
 </tr>
 <tr>
  <td></td>
  <td><img width=604 height=417 src="Exjade-II-073-EN%20PI_files/image002.gif"
  alt="	Serum creatinine		Creatinine clearance&#13;&#10;Before initiation of therapy	Twice (2x)	and	Once (1x)&#13;&#10;Contraindicated			&lt;60 ml/min&#13;&#10;Monitoring			&#13;&#10;-	First month after start of therapy or dose modification (including switch of formulation)	Weekly	and	Weekly&#13;&#10;-	Thereafter	Monthly	and	Monthly&#13;&#10;Reduction of daily dose by 10 mg/kg/day (dispersible tablet formulation),&#13;&#10;if following renal parameters are observed at two consecutive visits and cannot be attributed to other causes&#13;&#10;Adult patients	&gt;33% above pre-treatment average	and	Decreases &lt;LLN* (&lt;90 ml/min)&#13;&#10;Paediatric patients	&gt; age appropriate ULN** 	and/or	Decreases &lt;LLN* (&lt;90 ml/min)&#13;&#10;After dose reduction, interrupt treatment, if&#13;&#10;Adult and paediatric	Remains &gt;33% above pre-treatment average	and/or	Decreases &lt;LLN* (&lt;90 ml/min)&#13;&#10;*LLN: lower limit of the normal range&#13;&#10;**ULN: upper limit of the normal range&#13;&#10;&#13;&#10;"></td>
 </tr>
</table>

<span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<br clear=ALL>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>Treatment may be reinitiated depending on the
individual clinical circumstances.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>Dose reduction or interruption may be also
considered if abnormalities occur in levels of markers of renal tubular
function and/or as clinically indicated:</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>        Proteinuria (test should be performed
prior to therapy and monthly thereafter)</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>        Glycosuria in non&#8209;diabetics and
low levels of serum potassium, </span><span lang=EN-GB style='color:black'>phosphate,
magnesium or urate, phosphaturia, aminoaciduria (monitor as needed</span><span
lang=EN-GB style='color:black'>).</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>Renal tubulopathy has been mainly reported in
children and adolescents with beta&#8209;thalassaemia treated with EXJADE.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>Patients should be referred to a renal
specialist, and further specialised investigations (such as renal biopsy) may
be considered if the following occur despite dose reduction and interruption:</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>        </span><span lang=EN-GB
style='color:black'>S</span><span lang=EN-GB style='color:black'>erum
creatinine </span><span lang=EN-GB style='color:black'>remains significantly </span><span
lang=EN-GB style='color:black'>elevated and</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><span lang=EN-GB style='color:black'>        </span><span
lang=EN-GB style='color:black'>Persistent </span><span lang=EN-GB
style='color:black'>abnormality </span><span lang=EN-GB style='color:black'>in
another marker of renal function </span><span lang=EN-GB style='color:black'>(</span><span
lang=EN-GB style='color:black'>e.g. </span><span lang=EN-GB style='color:black'>proteinuria,
Fanconi Syndrome).</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><u><span
lang=EN-GB style='color:black'>Hepatic function</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>Liver
function test elevations have been observed in patients treated with
deferasirox. Post&#8209;marketing cases of hepatic failure, some of which were
fatal, have been reported. Severe forms associated with changes in consciousness
in the context of hyperammonaemic encephalopathy, may occur in patients treated
with deferasirox, particularly in children. It is recommended that
hyperammonaemic encephalopathy be considered and ammonia levels measured in
patients who develop unexplained changes in mental status while on Exjade
therapy. Care should be taken to maintain adequate hydration in patients who
experience volume-depleting events (such as diarrhoea or vomiting),
particularly in children with acute illness. Most reports of hepatic failure
involved patients with significant comorbidities including pre&#8209;existing chronic
liver conditions (including cirrhosis</span><span style='color:black'> </span><span
style='font-size:11.0pt;color:black'>and hepatitis C) and multi-organ failure. The
role of deferasirox as a contributing or aggravating factor cannot be excluded
(see section 4.8).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>It is
recommended that<b> </b>serum transaminases, bilirubin and alkaline phosphatase
be checked before the initiation of treatment, every 2&nbsp;weeks during the
first month and monthly thereafter. If there is a persistent and progressive
increase in serum transaminase levels that cannot be attributed to other
causes, EXJADE should be interrupted. Once the cause of the liver function test
abnormalities has been clarified or after return to normal levels, cautious re&#8209;initiation
of treatment at a lower dose followed by gradual dose escalation may be
considered.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>EXJADE is
not recommended in patients with severe hepatic impairment </span><span
lang=EN-GB style='font-size:11.0pt;color:black'>(Child&#8209;Pugh Class C)</span><span
style='font-size:11.0pt;color:black'> (see section 5.2).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><u><span style='font-size:11.0pt;color:black'>Table&nbsp;4        Summary
of safety monitoring recommendations</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'>

<table cellpadding=0 cellspacing=0 align=left>
 <tr>
  <td width=9 height=5></td>
 </tr>
 <tr>
  <td></td>
  <td><img width=565 height=467 src="Exjade-II-073-EN%20PI_files/image003.gif"
  alt="Test	Frequency&#13;&#10;Serum creatinine	In duplicate prior to therapy.&#13;&#10;Weekly during first month of therapy or after dose modification (including switch of formulation).&#13;&#10;Monthly thereafter.&#13;&#10;Creatinine clearance and/or plasma cystatin C	Prior to therapy.&#13;&#10;Weekly during first month of therapy or after dose modification (including switch of formulation).&#13;&#10;Monthly thereafter.&#13;&#10;Proteinuria	Prior to therapy.&#13;&#10;Monthly thereafter.&#13;&#10;Other markers of renal tubular function (such as glycosuria in non-diabetics and low levels of serum potassium, phosphate, magnesium or urate, phosphaturia, aminoaciduria)	As needed.&#13;&#10;Serum transaminases, bilirubin, alkaline phosphatase	Prior to therapy.&#13;&#10;Every 2 weeks during first month of therapy.&#13;&#10;Monthly thereafter.&#13;&#10;Auditory and ophthalmic testing	Prior to therapy.&#13;&#10;Annually thereafter.&#13;&#10;Body weight, height and sexual development	Prior to therapy.&#13;&#10;Annually in paediatric patients.&#13;&#10;&#13;&#10;"></td>
 </tr>
</table>

<u><span style='font-size:11.0pt;color:black'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

</div>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<br clear=ALL>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>In patients with a short life expectancy (e.g.
high&#8209;risk myelodysplastic syndromes), especially when co&#8209;morbidities
could increase the risk of adverse events, the benefit of EXJADE might be
limited and may be inferior to risks. As a consequence, treatment with EXJADE
is not recommended in these patients.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Caution should be used in elderly patients due
to a higher frequency of adverse reactions (in particular, diarrhoea).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Data in children with non&#8209;transfusion&#8209;dependent
thalassaemia are very limited (see section 5.1). As a consequence, EXJADE
therapy should be closely monitored to detect adverse reactions and to follow
iron burden in the paediatric population. In addition, before treating heavily iron&#8209;overloaded
children with non&#8209;transfusion&#8209;dependent thalassaemia with EXJADE,
the physician should be aware that the consequences of long&#8209;term exposure
in such patients are currently not known.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Gastrointestinal
disorders</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Upper gastrointestinal ulceration and
haemorrhage have been reported in patients, including children and adolescents,
receiving deferasirox. Multiple ulcers have been observed in some patients (see
section 4.8). There have been reports of ulcers complicated with digestive
perforation. Also, there have been reports of fatal gastrointestinal haemorrhages,
especially in elderly patients who had haematological malignancies and/or low
platelet counts. Physicians and patients should remain alert for signs and
symptoms of gastrointestinal ulceration and haemorrhage during EXJADE therapy. In
case of gastrointestinal ulceration or haemorrhage, EXJADE should be
discontinued and additional evaluation and treatment must be promptly initiated.
Caution should be exercised in patients who are taking EXJADE in combination
with substances that have known ulcerogenic potential, such as NSAIDs,
corticosteroids, or oral bisphosphonates, in patients receiving anticoagulants
and in patients with platelet counts below 50,000/mm<sup>3</sup> (50 x 10<sup>9</sup>/l)
(see section 4.5).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><u><span style='font-size:11.0pt;color:black'>Skin disorders</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt;color:black'>Skin rashes may appear during EXJADE
treatment. The rashes resolve spontaneously in most cases. When interruption of
treatment may be necessary, treatment may be reintroduced after resolution of
the rash, at a lower dose followed by gradual dose escalation. In severe cases
this reintroduction could be conducted in combination with a short period of
oral steroid administration. Severe cutaneous adverse reactions (SCARs)
including</span><span style='font-size:11.0pt'> Stevens&#8209;Johnson syndrome
(SJS), toxic epidermal necrolysis (TEN) </span><span lang=EN-GB
style='font-size:11.0pt'>and drug reaction with eosinophilia and systemic symptoms
(DRESS), which could be life&#8209;threatening or fatal, </span><span
style='font-size:11.0pt'>have been reported. If any SCAR is suspected, EXJADE
should be discontinued immediately and should not be reintroduced.</span><span
lang=EN-GB style='font-size:11.0pt'> At the time of prescription, patients
should be advised of the signs and symptoms of severe skin reactions, and be
closely monitored.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Hypersensitivity
reactions</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Cases of serious hypersensitivity
reactions (such as anaphylaxis and angioedema) have been reported in patients
receiving deferasirox, with the onset of the reaction occurring in the majority
of cases within the first month of treatment (see section 4.8). If such
reactions occur, EXJADE should be discontinued and appropriate medical
intervention instituted. Deferasirox should not be reintroduced in patients who
have experienced a hypersensitivity reaction due to the risk of anaphylactic
shock (see section 4.3).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Vision
and hearing</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Auditory (decreased hearing) and ocular
(lens opacities) disturbances have been reported (see section 4.8). Auditory
and ophthalmic testing (including fundoscopy) is recommended before the start
of treatment and at regular intervals thereafter (every 12&nbsp;months). If
disturbances are noted during the treatment, dose reduction or interruption may
be considered.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Blood
disorders</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>There have been post&#8209;marketing
reports of leukopenia, thrombocytopenia or pancytopenia (or aggravation of
these cytopenias) and of aggravated anaemia in patients treated with deferasirox.
Most of these patients had pre&#8209;existing haematological disorders that are
frequently associated with bone marrow failure. However, a contributory or
aggravating</span><span style='font-size:11.0pt;color:navy'> </span><span
style='font-size:11.0pt;color:black'>role cannot be excluded. Interruption of
treatment should be considered in patients who develop unexplained cytopenia.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Other
considerations</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Monthly monitoring of serum ferritin is
recommended in order to assess the patients response to therapy and to avoid
overchelation (see section 4.2). Dose reduction or closer monitoring of renal
and hepatic function, and serum ferritin levels are recommended during periods
of treatment with high doses and when serum ferritin levels are close to the
target range. If serum ferritin falls consistently below 500&nbsp;µg/l (in
transfusional iron overload) or below 300&nbsp;µg/l (in non&#8209;transfusion&#8209;dependent
thalassaemia syndromes), an interruption of treatment should be considered.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The results of the tests for serum
creatinine, serum ferritin and serum transaminases should be recorded and
regularly assessed for trends.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In two clinical studies, growth and sexual
development of paediatric patients treated with deferasirox for up to
5&nbsp;years were not affected (see section&nbsp;4.8). However, as a general
precautionary measure in the management of paediatric patients with
transfusional iron overload, body weight, height and sexual development should
be monitored prior to therapy and at regular intervals (every 12&nbsp;months).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Cardiac dysfunction is a known
complication of severe iron overload. Cardiac function should be monitored in
patients with severe iron overload during long&#8209;term treatment with
EXJADE.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Lactose
content</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The dispersible tablets contain lactose.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Patients with rare hereditary problems of
galactose intolerance, the Lapp lactase deficiency or glucose&#8209;galactose
malabsorption should not take this medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.5     Interaction with other medicinal products and other
forms of interaction</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The safety of deferasirox in combination
with other iron chelators has not been established. Therefore, it </span><span
style='font-size:11.0pt;color:black'>must not be combined with other iron
chelator therapies</span><span style='font-size:11.0pt;color:black'> (see
section 4.3).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Interaction
with food</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The bioavailability of deferasirox was
increased to a variable extent when taken along with food. EXJADE dispersible
tablets must therefore be taken on an empty stomach at least 30&nbsp;minutes
before food, preferably at the same time each day (see sections 4.2 and 5.2).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Agents
that may decrease EXJADE systemic exposure</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox metabolism depends on UGT
enzymes. In a healthy volunteer study, the concomitant administration of deferasirox
(single dose of 30&nbsp;mg/kg, dispersible tablet formulation) and the potent
UGT inducer, rifampicin, (repeated dose of 600&nbsp;mg/day) resulted in a
decrease of deferasirox exposure by 44% (90% CI: 37% - 51%). Therefore, the
concomitant use of EXJADE with potent UGT inducers (e.g. rifampicin,
carbamazepine, phenytoin, phenobarbital, ritonavir) may result in a decrease in
EXJADE efficacy. The patients serum ferritin should be monitored during and
after the combination, and the dose of EXJADE adjusted if necessary.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Cholestyramine significantly reduced the deferasirox
exposure in a mechanistic study to determine the degree of enterohepatic
recycling (see section 5.2).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Interaction
with midazolam and other agents metabolised by CYP3A4</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a healthy volunteer study, the
concomitant administration of deferasirox dispersible tablets and midazolam (a
CYP3A4 probe substrate) resulted in a decrease of midazolam exposure by 17%
(90% CI: 8% - 26%). In the clinical setting, this effect may be more
pronounced. Therefore, due to a possible decrease in efficacy, caution should
be exercised when deferasirox is combined with substances metabolised through
CYP3A4 (e.g. ciclosporin, simvastatin, hormonal contraceptive agents, bepridil,
ergotamine).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoHeader style='page-break-after:avoid;background:white'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>Interaction with repaglinide and other agents metabolised by
CYP2C8</span></u></p>

<p class=MsoHeader style='background:white'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif;color:black'>In a healthy volunteer study,
the concomitant administration of deferasirox as a moderate CYP2C8 inhibitor
(30&nbsp;mg/kg daily, dispersible tablet formulation), with repaglinide, a
CYP2C8 substrate, given as a single dose of 0.5&nbsp;mg, increased repaglinide
AUC and C</span><sub><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>max</span></sub><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:black'> about 2.3&#8209;fold (90% CI
[2.03&#8209;2.63]) and 1.6&#8209;fold (90% CI [1.42&#8209;1.84]), respectively.
Since the interaction has not been established with dosages higher than
0.5&nbsp;mg for repaglinide, the concomitant use of deferasirox with
repaglinide should be avoided. If the combination appears necessary, careful
clinical and blood glucose monitoring should be performed (see section 4.4). An
interaction between deferasirox and other CYP2C8 substrates like paclitaxel
cannot be excluded.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Interaction
with theophylline and other agents metabolised by CYP1A2</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a healthy volunteer study, the
concomitant administration of deferasirox as a CYP1A2 inhibitor (repeated dose
of 30&nbsp;mg/kg/day, dispersible tablet formulation) and the CYP1A2 substrate
theophylline (single dose of 120&nbsp;mg) resulted in an increase of
theophylline AUC by 84% (90% CI: 73% to 95%). The single dose C<sub>max</sub>
was not affected, but an increase of theophylline C<sub>max</sub> is expected
to occur with chronic dosing. Therefore, the concomitant use of deferasirox
with theophylline is not recommended. If deferasirox and theophylline are used
concomitantly, monitoring of theophylline concentration and theophylline dose
reduction should be considered. An interaction between deferasirox and other
CYP1A2 substrates cannot be excluded. For substances that are predominantly
metabolised by CYP1A2 and that have a narrow therapeutic index (e.g. clozapine,
tizanidine), the same recommendations apply as for theophylline.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Other information</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The concomitant administration of deferasirox
and aluminium&#8209;containing antacid preparations has not been formally
studied. Although deferasirox has a lower affinity for aluminium than for iron,
it is not recommended to take deferasirox tablets with aluminium&#8209;containing
antacid preparations.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The concomitant administration of
deferasirox with substances that have known ulcerogenic potential, such as
NSAIDs (including acetylsalicylic acid at high dosage), corticosteroids or oral
bisphosphonates may increase the risk of gastrointestinal toxicity (see section&nbsp;4.4).
The concomitant administration of deferasirox with anticoagulants may also
increase the risk of gastrointestinal haemorrhage. Close clinical monitoring is
required when deferasirox is combined with these substances.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>Concomitant administration of deferasirox and busulfan
resulted in an increase of busulfan exposure (AUC), but the mechanism of the
interaction remains unclear. If possible, evaluation of the pharmacokinetics (AUC,
clearance) of a busulfan test dose should be performed to allow dose
adjustment.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.6     Fertility, pregnancy and lactation</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Pregnancy</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>No clinical data on exposed pregnancies
are available for deferasirox. Studies in animals have shown some reproductive
toxicity at maternally toxic doses (see section 5.3). The potential risk for
humans is unknown.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>As a precaution, it is recommended that
EXJADE is not used during pregnancy unless clearly necessary.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE may decrease the efficacy of hormonal
contraceptives (see section 4.5). Women of childbearing potential are
recommended to use additional or alternative non&#8209;hormonal methods of
contraception when using EXJADE.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Breast&#8209;feeding</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In animal studies, deferasirox was found
to be rapidly and extensively secreted into maternal milk. No effect on the
offspring was noted. It is not known if deferasirox is secreted into human
milk. Breast&#8209;feeding while taking EXJADE is not recommended.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Fertility</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>No fertility data is available for humans.
In animals, no adverse effects on male or female fertility were found (see
section 5.3).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.7     Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXJADE has minor influence on the ability to
drive and use machines. Patients experiencing the uncommon adverse reaction of
dizziness should exercise caution when driving or operating machines (see
section 4.8).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.8     Undesirable effects</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Summary of the safety profile</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The most frequent reactions reported
during chronic treatment with deferasirox dispersible tablets in adult and
paediatric patients include gastrointestinal disturbances (mainly nausea,
vomiting, diarrhoea or abdominal pain) and skin rash. Diarrhoea is reported
more commonly in paediatric patients aged 2 to 5&nbsp;years and in the elderly.
These reactions are dose&#8209;dependent, mostly mild to moderate, generally
transient and mostly resolve even if treatment is continued.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><a
name="OLE_LINK1"><span style='font-size:11.0pt;color:black'>&nbsp;</span></a></p>

<p class=MsoNormal style='background:white'><span style='color:black'>During
clinical studies, dose&#8209;dependent increases in serum creatinine occurred
in about 36% of patients, though most remained within the normal range. Decreases
in mean creatinine clearance have been observed in both paediatric and adult
patients with beta&#8209;thalassemia and iron overload during the first year of
treatment, but there is evidence that this does not decrease further in
subsequent years of treatment. Elevations of liver transaminases have been
reported. Safety monitoring schedules for renal and liver parameters are
recommended. Auditory (decreased hearing) and ocular (lens opacities)
disturbances are uncommon, and yearly examinations are also recommended (see
section 4.4).</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Severe cutaneous adverse reactions
(SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis
(TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) have
been reported with the use of EXJADE (see section 4.4).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Tabulated
list of adverse reactions</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Adverse reactions are ranked below using
the following convention: very common (&#8805;1/10); common (&#8805;1/100 to
&lt;1/10); uncommon (&#8805;1/1,000 to &lt;1/100); rare (&#8805;1/10,000 to
&lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the
available data). Within each frequency grouping, adverse reactions are
presented in order of decreasing seriousness.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:8.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Table&nbsp;5</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Blood and lymphatic system disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span lang=IT
  style='font-family:"Times New Roman",serif;color:black'>Pancytopenia<sup>1</sup>,
  thrombocytopenia<sup>1</sup>, anaemia aggravated<sup>1</sup>,</span><span
  lang=IT style='color:black'> </span><span lang=IT style='font-family:"Times New Roman",serif;
  color:black'>neutropenia<sup>1</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Immune system
  disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Hypersensitivity reactions (including anaphylactic
  reactions and angioedema)<sup>1</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Metabolism and
  nutrition disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Metabolic acidosis</span><sup><span
  style='font-family:"Times New Roman",serif;color:black'>1</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Psychiatric disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Anxiety, sleep disorder</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Common:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Headache</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Dizziness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Eye disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Cataract, maculopathy</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Rare:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Optic neuritis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Ear and labyrinth disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Deafness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Laryngeal pain</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Common:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Diarrhoea,
  constipation, vomiting, nausea, abdominal pain, abdominal distension,
  dyspepsia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Gastrointestinal
  haemorrhage, gastric ulcer (including multiple ulcers), duodenal ulcer,
  gastritis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Rare:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Oesophagitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Gastrointestinal perforation</span><sup><span
  lang=IT style='font-family:"Times New Roman",serif;color:black'>1</span></sup><span
  lang=IT style='font-family:"Times New Roman",serif;color:black'>, acute
  pancreatitis<sup>1</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Hepatobiliary disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Common:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Transaminases
  increased</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Hepatitis,
  cholelithiasis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Hepatic failure<sup>1, 2</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Common:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Rash, pruritus</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Pigmentation disorder</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif;color:black'>Rare:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif;color:black'>Drug reaction with
  eosinophilia and systemic symptoms (DRESS)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span lang=EN-GB
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Stevens&#8209;Johnson syndrome<sup>1</sup>,
  hypersensitivity vasculitis<sup>1</sup>, urticaria<sup>1</sup>, erythema
  multiforme<sup>1</sup>, alopecia<sup>1</sup>, toxic epidermal necrolysis
  (TEN)<sup>1</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Very common:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Blood creatinine
  increased</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Common:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Proteinuria</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  lang=IT style='font-family:"Times New Roman",serif;color:black'>Renal tubular
  disorder<sup>2</sup> (acquired Fanconi syndrome), glycosuria</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span lang=IT
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span lang=FR
  style='font-family:"Times New Roman",serif;color:black'>Acute renal failure<sup>1,
  2</sup>, tubulointerstitial nephritis<sup>1</sup>, nephrolithiasis</span><sup><span
  lang=IT style='font-family:"Times New Roman",serif;color:black'>1</span></sup><span
  lang=FR style='font-family:"Times New Roman",serif;color:black'>, renal
  tubular necrosis<sup>1</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>General disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Pyrexia, oedema,
  fatigue</span></p>
  </td>
 </tr>
</table>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt;
background:white'><sup><span lang=EN-GB style='font-size:11.0pt;color:black'>1</span></sup><span
lang=EN-GB style='font-size:10.0pt;color:black'>           </span><span
lang=EN-GB style='font-size:11.0pt;color:black'>Adverse reactions reported
during post&#8209;marketing experience. These are derived from spontaneous
reports for which it is not always possible to reliably establish frequency or
a causal relationship to exposure to the medicinal product.</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt;
background:white'><sup><span lang=EN-GB style='font-size:11.0pt;color:black'>2</span></sup><span
lang=EN-GB style='font-size:11.0pt;color:black'>        Severe forms associated
with changes in consciousness in the context of hyperammonaemic encephalopathy have
been reported.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Description
of selected adverse reactions</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Gallstones and related biliary disorders
were reported in about 2% of patients. Elevations of liver transaminases were
reported as an adverse reaction in 2% of patients. Elevations of transaminases
greater than 10&nbsp;times the upper limit of the normal range, suggestive of
hepatitis, were uncommon (0.3%). During post&#8209;marketing experience,
hepatic failure, sometimes fatal, has been reported with deferasirox (see
section 4.4). There have been post&#8209;marketing reports of metabolic
acidosis. The majority of these patients had renal impairment, renal
tubulopathy (Fanconi syndrome) or diarrhoea, or conditions where acid&#8209;base
imbalance is a known complication (see section 4.4). Cases of serious acute
pancreatitis were observed without documented underlying biliary conditions. As
with other iron chelator treatment, high&#8209;frequency hearing loss and
lenticular opacities (early cataracts) have been uncommonly observed in
patients treated with deferasirox (see section 4.4).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span style='color:black'>Creatinine
clearance in transfusional iron overload</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a retrospective meta&#8209;analysis of
2,102&nbsp;adult and paediatric beta&#8209;thalassaemia patients with
transfusional iron overload treated with deferasirox dispersible tablets in two
randomised and four open label studies of up to five years duration, a mean
creatinine clearance decrease of 13.2% in adult patients (95% CI: &#8209;14.4%
to &#8209;12.1%; n=935) and 9.9% (95% CI: &#8209;11.1% to &#8209;8.6%; n=1,142)
in paediatric patients was observed during the first year of treatment. In 250&nbsp;patients
who were followed for up to five years, no further decrease in mean creatinine
clearance levels was observed.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span style='color:black'>Clinical
study in patients with non&#8209;transfusion&#8209;dependent thalassaemia
syndromes</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a 1&#8209;year study in patients with
non&#8209;transfusion&#8209;dependent thalassaemia syndromes and iron overload
(dispersible tablets at a dose of 10&nbsp;mg/kg/day), diarrhoea (9.1%), rash
(9.1%), and nausea (7.3%) were the most frequent study drug&#8209;related
adverse events. Abnormal serum creatinine and creatinine clearance values were
reported in 5.5% and 1.8% of patients, respectively. Elevations of liver
transaminases greater than 2&nbsp;times the baseline and 5&nbsp;times the upper
limit of normal were reported in 1.8% of patients.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><u><span lang=EN-GB style='font-size:11.0pt;
color:black'>Paediatric population</span></u></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In two clinical studies, growth and sexual
development of paediatric patients treated with deferasirox for up to
5&nbsp;years were not affected (see section&nbsp;4.4).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Diarrhoea is reported more
commonly in paediatric patients aged 2 to 5&nbsp;years than in older patients.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Renal tubulopathy has been
mainly reported in children and adolescents with beta&#8209;thalassaemia
treated with </span><span style='font-size:11.0pt;color:black'>deferasirox</span><span
lang=EN-GB style='font-size:11.0pt;color:black'>.</span><span lang=EN-GB
style='color:black'> </span><span lang=EN-GB style='font-size:11.0pt;
color:black'>In post-marketing reports, a high proportion of cases of metabolic
acidosis occurred in children in the context of Fanconi syndrome.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Acute pancreatitis has been reported,
particularly in children and adolescents.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text style='margin-top:0in;page-break-after:avoid;background:white'><u><span
style='font-size:11.0pt;color:black'>Reporting of suspected adverse reactions</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Reporting suspected adverse
reactions after authorisation of the medicinal product is important. It allows
continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions <span
style='background:#D9D9D9'>via the national reporting system listed in </span></span><span
style='color:black'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='font-size:11.0pt;background:#D9D9D9'>Appendix V</span></a></span><span
lang=EN-GB style='font-size:11.0pt;color:black'>.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.9     Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Early signs of acute overdose are
digestive effects such as abdominal pain, diarrhoea, nausea and vomiting.
Hepatic and renal disorders have been reported, including cases of liver enzyme
and creatinine increased with recovery after treatment discontinuation. An
erroneously administered single dose of 90&nbsp;mg/kg led to Fanconi syndrome
which resolved after treatment.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>There is no specific antidote
for deferasirox. Standard procedures for management of overdose may be
indicated as well as symptomatic treatment, </span><span style='font-size:11.0pt;
color:black'>as medically appropriate.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>5.       PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>5.1     Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Pharmacotherapeutic group: Iron
chelating agents, ATC code: V03AC03</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Mechanism
of action</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox is an orally active chelator
that is highly selective for iron (III). It is a tridentate ligand that binds
iron with high affinity in a 2:1 ratio. Deferasirox promotes excretion of iron,
primarily in the faeces. Deferasirox has low affinity for zinc and copper, and
does not cause constant low serum levels of these metals.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Pharmacodynamic
effects</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In an iron&#8209;balance metabolic study
in iron&#8209;overloaded adult thalassaemic patients, deferasirox at daily
doses of 10, 20 and 40&nbsp;mg/kg (dispersible tablet formulation) induced the
mean net excretion of 0.119, 0.329 and 0.445&nbsp;mg&nbsp;Fe/kg body
weight/day, respectively.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Clinical
efficacy and safety</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Clinical efficacy studies were conducted
with deferasirox dispersible tablets.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox has been investigated in
411&nbsp;adult (age </span><span style='font-size:11.0pt;font-family:Symbol;
color:black'>³</span><span style='font-size:11.0pt;color:black'>16&nbsp;years)
and 292&nbsp;paediatric patients (aged&nbsp;2 to &lt;16&nbsp;years) with
chronic iron overload due to blood transfusions. Of the paediatric patients 52
were aged&nbsp;2 to 5&nbsp;years. The underlying conditions requiring
transfusion included beta&#8209;thalassaemia, sickle cell disease and other
congenital and acquired anaemias (myelodysplastic syndromes [MDS], Diamond&#8209;Blackfan
syndrome, aplastic anaemia and other very rare anaemias).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Daily treatment with the deferasirox
dispersible tablet formulation at doses of 20 and 30&nbsp;mg/kg for one year in
frequently transfused adult and paediatric patients with beta&#8209;thalassaemia
led to reductions in indicators of total body iron; liver iron concentration
was reduced by about &#8209;0.4 and &#8209;8.9&nbsp;mg&nbsp;Fe/g liver (biopsy
dry weight (dw)) on average, respectively, and serum ferritin was reduced by
about &#8209;36 and &#8209;926&nbsp;µg/l on average, respectively. At these
same doses the ratios of iron excretion: iron intake were 1.02 (indicating net
iron balance) and 1.67 (indicating net iron removal), respectively. Deferasirox
induced similar responses in iron&#8209;overloaded patients with other anaemias.
Daily doses of 10&nbsp;mg/kg (dispersible tablet formulation) for one year
could maintain liver iron and serum ferritin levels and induce net iron balance
in patients receiving infrequent transfusions or exchange transfusions. Serum
ferritin assessed by monthly monitoring reflected changes in liver iron
concentration indicating that trends in serum ferritin can be used to monitor
response to therapy. Limited clinical data (29&nbsp;patients with normal
cardiac function at baseline) using MRI indicate that treatment with deferasirox
10&#8209;30&nbsp;mg/kg/day (dispersible tablet formulation) for 1&nbsp;year may
also reduce levels of iron in the heart (on average, MRI T2* increased from
18.3 to 23.0&nbsp;milliseconds).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The principal analysis of the pivotal
comparative study in 586&nbsp;patients suffering from beta&#8209;thalassaemia
and transfusional iron overload did not demonstrate non&#8209;inferiority of deferasirox
dispersible tablets to deferoxamine in the analysis of the total patient
population. It appeared from a post&#8209;hoc analysis of this study that, in
the subgroup of patients with liver iron concentration &#8805;7&nbsp;mg Fe/g dw
treated with deferasirox dispersible tablets (20 and 30&nbsp;mg/kg) or
deferoxamine (35 to &#8805;50&nbsp;mg/kg), the non&#8209;inferiority criteria
were achieved. However, in patients with liver iron concentration &lt;7&nbsp;mg
Fe/g dw treated with deferasirox dispersible tablets (5 and 10&nbsp;mg/kg) or
deferoxamine (20 to 35&nbsp;mg/kg), non&#8209;inferiority was not established
due to imbalance in the dosing of the two chelators. This imbalance occurred
because patients on deferoxamine were allowed to remain on their pre&#8209;study
dose even if it was higher than the protocol specified dose. Fifty&#8209;six&nbsp;patients
under the age of 6&nbsp;years participated in this pivotal study, 28 of them
receiving deferasirox dispersible tablets.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>It appeared from preclinical and clinical
studies that deferasirox dispersible tablets could be as active as deferoxamine
when used in a dose ratio of 2:1 (i.e. a dose of deferasirox dispersible
tablets that is numerically half of the deferoxamine dose). However, this
dosing recommendation was not prospectively assessed in the clinical studies.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In addition, in patients with liver iron
concentration &#8805;7&nbsp;mg Fe/g dw with various rare anaemias or sickle
cell disease, deferasirox dispersible tablets up to 20 and 30&nbsp;mg/kg
produced a decrease in liver iron concentration and serum ferritin comparable
to that obtained in patients with beta&#8209;thalassaemia.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>A placebo-controlled randomised study was
performed in 225&nbsp;patients with MDS (Low/Int-1 risk) and transfusional iron
overload. The results of this study suggest that there is a positive impact of
deferasirox on event-free survival (EFS, a composite endpoint including
non-fatal cardiac or liver events) and serum ferritin levels. The safety
profile was consistent with previous studies in adult MDS patients.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>In
a 5-year observational study in which 267&nbsp;children aged 2 to
&lt;6&nbsp;years (at enrollment) with transfusional haemosiderosis received
deferasirox, there were no clinically meaningful differences in the safety and
tolerability profile of Exjade in paediatric patients aged 2 to
&lt;6&nbsp;years compared to the overall adult and older paediatric population,
including increases in serum creatinine of &gt;33% and above the upper limit of
normal on &#8805;2&nbsp;consecutive occasions (3.1%), and elevation of alanine
aminotransferase (ALT) greater than 5&nbsp;times the upper limit of normal
(4.3%). Single events of increase in ALT and aspartate aminotransferase were
reported in 20.0% </span><span style='color:black'>and</span><span lang=EN-GB
style='color:black'> 8.3%, respectively, of the 145&nbsp;patients who completed
the study.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a study to assess the safety of deferasirox
film-coated and dispersible tablets, 173 adult and paediatric patients with
transfusion dependent thalassaemia or myelodysplastic syndrome were treated for
24&nbsp;weeks. A comparable safety profile for film-coated and dispersible
tablets was observed.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In patients with non&#8209;transfusion&#8209;dependent
thalassaemia syndromes and iron overload, treatment with deferasirox
dispersible tablets was assessed in a 1&#8209;year, randomised, double&#8209;blind,
placebo&#8209;controlled study. The study compared the efficacy of two
different deferasirox dispersible tablet regimens (starting doses of 5 and 10&nbsp;mg/kg/day,
55&nbsp;patients in each arm) and of matching placebo (56&nbsp;patients). The
study enrolled 145&nbsp;adult and 21&nbsp;paediatric patients. The primary
efficacy parameter was the change in liver iron concentration (LIC) from
baseline after 12&nbsp;months of treatment. One of the secondary efficacy
parameters was the change in serum ferritin between baseline and fourth
quarter. At a starting dose of 10&nbsp;mg/kg/day, deferasirox dispersible
tablets led to reductions in indicators of total body iron. On average, liver
iron concentration decreased by 3.80&nbsp;mg Fe/g dw in patients treated with deferasirox
dispersible tablets (starting dose 10&nbsp;mg/kg/day) and increased by 0.38&nbsp;mg
Fe/g dw in patients treated with placebo (p&lt;0.001). On average, serum
ferritin decreased by 222.0&nbsp;µg/l in patients treated with deferasirox
dispersible tablets (starting dose 10&nbsp;mg/kg/day) and increased by 115&nbsp;µg/l
in patients treated with placebo (p&lt;0.001).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>5.2     Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Absorption</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox (dispersible tablet
formulation) is absorbed following oral administration with a median time to
maximum plasma concentration (t<sub>max</sub>) of about 1.5 to 4&nbsp;hours.
The absolute bioavailability (AUC) of deferasirox (dispersible tablet
formulation) is about 70% compared to an intravenous dose. Total exposure (AUC)
was approximately doubled when taken along with a high&#8209;fat breakfast (fat
content &gt;50% of calories) and by about 50% when taken along with a standard
breakfast. The bioavailability (AUC) of deferasirox was moderately (approx.
1325%) elevated when taken 30&nbsp;minutes before meals with normal or high
fat content.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Distribution</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox is highly (99%) protein bound
to plasma proteins, almost exclusively serum albumin, and has a small volume of
distribution of approximately 14&nbsp;litres in adults.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Biotransformation</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Glucuronidation is the main metabolic
pathway for deferasirox, with subsequent biliary excretion. Deconjugation of
glucuronidates in the intestine and subsequent reabsorption (enterohepatic
recycling) is likely to occur: in a healthy volunteer study, the administration
of cholestyramine after a single dose of deferasirox resulted in a 45% decrease
in deferasirox exposure (AUC).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox is mainly glucuronidated by
UGT1A1 and to a lesser extent UGT1A3. CYP450&#8209;catalysed (oxidative)
metabolism of deferasirox appears to be minor in humans (about 8%). No
inhibition of deferasirox metabolism by hydroxyurea was observed <i>in vitro</i></span><span
lang=EN-GB style='font-size:11.0pt;color:black'>.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Elimination</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox and its metabolites are
primarily excreted in the faeces (84% of the dose). Renal excretion of
deferasirox and its metabolites is minimal (8% of the dose). The mean
elimination half&#8209;life (t<sub>1/2</sub>) ranged from 8 to 16&nbsp;hours.
The transporters MRP2 and MXR (BCRP) are involved in the biliary excretion of
deferasirox.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Linearity / non&#8209;linearity</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The C<sub>max</sub> and AUC<sub>0&#8209;24h</sub>
of deferasirox increase approximately linearly with dose under steady&#8209;state
conditions. Upon multiple dosing exposure increased by an accumulation factor
of 1.3 to 2.3</span><span lang=EN-GB style='font-size:11.0pt;color:black'>.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Characteristics in patients</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><span style='font-size:11.0pt;color:black'>Paediatric
patients</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The overall exposure of adolescents </span><span
lang=EN-GB style='font-size:11.0pt;color:black'>(12 to &#8804;17</span><span
style='font-size:11.0pt;color:black'>&nbsp;</span><span lang=EN-GB
style='font-size:11.0pt;color:black'>years) </span><span style='font-size:11.0pt;
color:black'>and children </span><span lang=EN-GB style='font-size:11.0pt;
color:black'>(2 to &lt;12&nbsp;years)</span><span style='font-size:11.0pt;
color:black'> to deferasirox after single and multiple doses was lower than
that in adult patients.</span><span lang=EN-GB style='font-size:11.0pt;
color:black'> In children younger than 6&nbsp;years old exposure was about 50%
lower than in adults. Since dosing is individually adjusted according to
response this is not expected to have clinical consequences.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><span style='font-size:11.0pt;color:black'>Gender</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Females have a moderately lower apparent
clearance (by 17.5%) for deferasirox compared to males. </span><span
lang=EN-GB style='font-size:11.0pt;color:black'>Since dosing is individually
adjusted according to response this is not expected to have clinical
consequences.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><span style='font-size:11.0pt;color:black'>Elderly
patients</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>The pharmacokinetics of
deferasirox have not been studied in elderly </span><span style='font-size:
11.0pt;color:black'>patients (aged&nbsp;65 or older).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><span style='font-size:11.0pt;color:black'>Renal or
hepatic impairment</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The pharmacokinetics of deferasirox have
not been studied in patients with renal impairment. The pharmacokinetics of
deferasirox were not influenced by liver transaminase levels up to 5&nbsp;times
the upper limit of the normal range.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a clinical study using single doses of
20&nbsp;mg/kg deferasirox dispersible tablets, the average exposure was
increased by 16% in subjects with mild hepatic impairment (Child&#8209;Pugh
Class A) and by 76% in subjects with moderate hepatic impairment (Child&#8209;Pugh
Class B) compared to subjects with normal hepatic function. The average C<sub>max</sub>
of deferasirox in subjects with mild or moderate hepatic impairment was increased
by 22%. Exposure was increased 2.8&#8209;fold in one subject with severe
hepatic impairment (Child&#8209;Pugh Class C) (see sections 4.2 and 4.4).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>5.3     Preclinical safety data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Non&#8209;clinical data reveal no special
hazard for humans based on conventional studies of safety pharmacology,
repeated dose toxicity, genotoxicity or carcinogenic potential. The main
findings were kidney toxicity and lens opacity (cataracts). Similar findings
were observed in neonatal and juvenile animals. The kidney toxicity is
considered mainly due to iron deprivation in animals that were not previously
overloaded with iron.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Tests of genotoxicity <i>in vitro</i> were
negative (Ames test, chromosomal aberration test) while deferasirox caused
formation of micronuclei <i>in vivo</i> in the bone marrow, but not liver, of
non&#8209;iron&#8209;loaded rats at lethal doses. No such effects were observed
in iron&#8209;preloaded rats. Deferasirox was not carcinogenic when
administered to rats in a 2&#8209;year study and transgenic p53+/- heterozygous
mice in a 6&#8209;month study.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The potential for toxicity to reproduction
was assessed in rats and rabbits. Deferasirox was not teratogenic, but caused
increased frequency of skeletal variations and stillborn pups in rats at high
doses that were severely toxic to the non&#8209;iron&#8209;overloaded mother</span><span
lang=EN-GB style='font-size:11.0pt;color:black'>. </span><span
style='font-size:11.0pt;color:black'>Deferasirox did not cause other effects on
fertility or reproduction</span><span lang=EN-GB style='font-size:11.0pt;
color:black'>.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.       PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.1     List of excipients</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Lactose monohydrate</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Crospovidone type A</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Cellulose, microcrystalline</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Povidone</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Sodium laurilsulfate</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Silica, colloidal anhydrous</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Magnesium stearate</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Dispersion in carbonated drinks or milk is
not recommended due to foaming and slow dispersion, respectively.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.3     Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>3&nbsp;years</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.4     Special precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Store in the original package in order to
protect from moisture.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.5     Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>PVC/PE/PVDC/Aluminium blisters.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
125&nbsp;mg dispersible tablets</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Packs containing 28, 84&nbsp;or
252&nbsp;dispersible tablets.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
250&nbsp;mg dispersible tablets</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Packs containing 28, 84&nbsp;or
252&nbsp;dispersible tablets.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
500&nbsp;mg dispersible tablets</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Unit packs containing 28, 84 or
252&nbsp;dispersible tablets and multipacks containing 294 (3&nbsp;packs of
98)&nbsp;dispersible tablets.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.6     Special precautions for disposal</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>No special requirements.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>7.       MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>8.       MARKETING AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span lang=FR style='font-size:11.0pt;color:black'>EXJADE
125&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=FR-CH style='color:black'>EU/1/06/356/00</span><span lang=PT
style='color:black'>1</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=FR style='color:black'>EU/1/06/356/00</span><span lang=PT
style='color:black'>2</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>EU/1/06/356/00</span><span lang=PT style='color:black'>7</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span lang=FR-CH style='font-size:11.0pt;color:black'>EXJADE
250&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=FR style='color:black'>EU/1/06/356/00</span><span lang=PT
style='color:black'>3</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=FR style='color:black'>EU/1/06/356/00</span><span lang=PT
style='color:black'>4</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>EU/1/06/356/008</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=PT>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span lang=FR-CH style='font-size:11.0pt;color:black'>EXJADE
500&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>EU/1/06/356/00</span><span lang=PT
style='color:black'>5</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>EU/1/06/356/00</span><span lang=PT
style='color:black'>6</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>EU/1/06/356/009</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>EU/1/06/356/010</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Date of first authorisation: 28
August 2006</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Date of latest renewal:</span><span lang=EN-GB
style='color:black'> 18 April 2016</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><b><span lang=EN-GB style='color:black'>10.     DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Detailed information on this </span><span
lang=EN-GB style='color:black'>medicinal</span><span lang=EN-GB
style='color:black'> product </span><span lang=EN-GB style='color:black'>is
available on the website of the European Medicines Agency </span><span
lang=EN-GB style='color:black'><a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'><img border=0 width=21 height=18
src="Exjade-II-073-EN%20PI_files/image004.gif"></span><span lang=EN-GB
style='color:black'>This medicinal product is subject to additional monitoring.
This will allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions. See section
4.8 for how to report adverse reactions.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;background:white'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE MEDICINAL
PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE 90&nbsp;mg film&#8209;coated
tablets</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE 180&nbsp;mg film&#8209;coated
tablets</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE 360&nbsp;mg film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span style='color:black'>2.       QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><i><span style='color:black'>&nbsp;</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
90&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Each film&#8209;coated tablet contains
90&nbsp;mg deferasirox.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
180&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Each film&#8209;coated tablet contains
180&nbsp;mg deferasirox.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
360&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Each film&#8209;coated tablet contains
360&nbsp;mg deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>For the full list of excipients, see section
6.1.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>3.       PHARMACEUTICAL <span style='text-transform:uppercase'>form</span></span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Film&#8209;coated tablet</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
90&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=Text style='margin-top:0in;background:white'><span style='font-size:
11.0pt;color:black'>Light blue, ovaloid, biconvex film&#8209;coated tablet with
bevelled edges and imprints (NVR on one face and 90 on the other). Approximate
tablet dimensions 10.7&nbsp;mm x 4.2&nbsp;mm.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
180&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Medium blue, ovaloid, biconvex film&#8209;coated
tablet with bevelled edges and imprints (NVR on one face and 180 on the other).
Approximate tablet dimensions 14&nbsp;mm x 5.5&nbsp;mm.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
360&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Dark blue, ovaloid, biconvex film&#8209;coated
tablet with bevelled edges and imprints (NVR on one face and 360 on the other).
Approximate tablet dimensions 17&nbsp;mm x 6.7&nbsp;mm.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black;text-transform:uppercase'>4.       Clinical particulars</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.1     Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>EXJADE
is indicated for the treatment of chronic iron overload due to frequent blood
transfusions (</span><span lang=EN-GB style='font-family:Symbol;color:black'>³</span><span
lang=EN-GB style='color:black'>7&nbsp;ml/kg/month of packed red blood cells) in
patients with beta thalassaemia major aged 6&nbsp;years and older.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>EXJADE is also indicated for the treatment of
chronic iron overload due to blood transfusions when deferoxamine therapy is
contraindicated or inadequate in the following patient groups:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white'><span lang=EN-GB style='color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>in paediatric patients with
beta thalassaemia major with iron overload due to frequent blood transfusions (</span><span
lang=EN-GB style='font-family:Symbol;color:black'>³</span><span lang=EN-GB
style='color:black'>7&nbsp;ml/kg/month of packed red blood cells) aged 2 to
5&nbsp;years,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white'><span lang=EN-GB style='color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>in adult and paediatric patients
with beta thalassaemia major with iron overload due to infrequent blood
transfusions (</span><span lang=EN-GB style='color:black'>&lt;</span><span
lang=EN-GB style='color:black'>7&nbsp;ml/kg/month of packed red blood cells)
aged 2&nbsp;years and older,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white'><span lang=EN-GB style='color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>in adult and paediatric patients
with other anaemias aged 2&nbsp;years and older.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>EXJADE is also indicated for the treatment of chronic iron
overload requiring chelation therapy when deferoxamine therapy is
contraindicated or inadequate in patients with non&#8209;transfusion&#8209;dependent
thalassaemia syndromes aged 10&nbsp;years and older.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.2     Posology and method of administration</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Treatment with EXJADE should be initiated
and maintained by physicians experienced in the treatment of chronic iron
overload.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Posology</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><u><span style='font-size:11.0pt;color:black'>Transfusional
iron overload</span></u></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>It is recommended that treatment be
started after the transfusion of approximately 20&nbsp;units (about
100&nbsp;ml/kg) of packed red blood cells (PRBC) or when there is evidence from
clinical monitoring that chronic iron overload is present (e.g. serum ferritin
&gt;1,000&nbsp;µg/l). Doses (in mg/kg) must be calculated and rounded to the
nearest whole tablet size.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The goals of iron chelation therapy are to
remove the amount of iron administered in transfusions and, as required, to
reduce the existing iron burden.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Caution should be taken during chelation
therapy to minimise the risk of overchelation in all patients (see section&nbsp;4.4).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE film&#8209;coated tablets demonstrate
higher bioavailability compared to the EXJADE dispersible tablet formulation
(see section&nbsp;5.2). In case of switching from dispersible tablets to film&#8209;coated
tablets, the dose of the film&#8209;coated tablets should be 30% lower than the
dose of the dispersible tablets, rounded to the nearest whole tablet.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The corresponding doses for the different
formulations are shown in the table below.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><u><span style='color:black'>Table&nbsp;1</span></u><span
style='color:black'>        Recommended doses for transfusional iron overload</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=623
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span lang=EN-GB style='color:black'>Film&#8209;coated
  tablets/granules</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Dispersible tablets</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Transfusions</span></b></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Serum ferritin</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Starting dose</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span lang=EN-GB style='color:black'>14&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>20&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>After 20&nbsp;units (about
  100&nbsp;ml/kg) of PRBC</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>or</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&gt;1,000&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Alternative starting doses</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span lang=EN-GB style='color:black'>21&nbsp;mg/kg/day</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>30&nbsp;mg/kg/day</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&gt;14&nbsp;ml/kg/month of PRBC
  (approx. &gt;4&nbsp;units/month for an adult)</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span lang=EN-GB style='color:black'>7&nbsp;mg/kg/day</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>10&nbsp;mg/kg/day</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&lt;7&nbsp;ml/kg/month of PRBC
  (approx. &lt;2&nbsp;units/month for an adult)</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>For patients well managed on
  deferoxamine</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>One third of deferoxamine dose</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>Half of deferoxamine dose</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Monitoring</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Monthly</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Target range</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>500&#8209;1,000&nbsp;µg/</span></b><span
  style='color:black'>l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 rowspan=6 valign=top style='width:78.0pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Adjustment steps</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>(every 3&#8209;6&nbsp;months)</span></p>
  </td>
  <td width=265 colspan=2 valign=top style='width:198.45pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;background:white'><b><span style='color:black'>Increase</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&gt;2,500&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span lang=EN-GB style='color:black'>3.5 &#8209;
  7&nbsp;mg/kg/day</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>Up to 28&nbsp;mg/kg/day</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>5&#8209;10&nbsp;mg/kg/day</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>Up to 40&nbsp;mg/kg/day</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=265 colspan=2 valign=top style='width:198.45pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;background:white'><b><span style='color:black'>Decrease</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span lang=EN-GB style='color:black'>3.5 &#8209;
  7&nbsp;mg/kg/day</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>5&#8209;10&nbsp;mg/kg/day</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&lt;2,500&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>In patients treated with doses &gt;21&nbsp;mg/kg/day</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>In patients treated with doses
  &gt;30&nbsp;mg/kg/day</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=265 colspan=2 valign=top style='width:198.45pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal;page-break-after:avoid;background:white'><span style='color:black'>-<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span style='color:black'>When target is reached</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>500&#8209;1,000&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Maximum dose</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span lang=EN-GB style='color:black'>28&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>40&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Consider interruption</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&lt;500&nbsp;µg/l</span></b></p>
  </td>
 </tr>
</table>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Starting dose</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The recommended initial daily dose of
EXJADE film&#8209;coated tablets is 14&nbsp;mg/kg body weight.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>An initial daily dose of 21&nbsp;mg/kg may
be considered for patients who require reduction of elevated body iron levels
and who are also receiving more than 14&nbsp;ml/kg/month of packed red blood
cells (approximately &gt;4&nbsp;units/month for an adult).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>An initial daily dose of 7&nbsp;mg/kg may
be considered for patients </span><span lang=EN-GB style='font-size:11.0pt;
color:black'>who do not require reduction of body iron levels and who are also </span><span
style='font-size:11.0pt;color:black'>receiving less than 7&nbsp;ml/kg/month of
packed red blood cells (approximately &lt;2&nbsp;units/month for an adult). The
patients response must be monitored and a dose increase should be considered
if sufficient efficacy is not obtained (see section 5.1).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>For patients already well managed on
treatment with deferoxamine, a starting dose of EXJADE film&#8209;coated
tablets that is numerically one third that of the deferoxamine dose could be
considered (e.g. a patient receiving 40&nbsp;mg/kg/day of deferoxamine for
5&nbsp;days per week (or equivalent) could be transferred to a starting daily
dose of 14&nbsp;mg/kg/day of EXJADE film&#8209;coated tablets). When this
results in a daily dose less than 14&nbsp;mg/kg body weight, the patients
response must be monitored and a dose increase should be considered if
sufficient efficacy is not obtained (see section 5.1).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Dose adjustment</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>It is recommended that serum ferritin be
monitored every month and that the dose of EXJADE be adjusted, if necessary,
every 3 to 6&nbsp;months based on the trends in serum ferritin. Dose
adjustments may be made in steps of 3.5 to 7&nbsp;mg/kg and are to be tailored to
the individual patients response and therapeutic goals (maintenance or
reduction of iron burden). In patients not adequately controlled with doses of 21&nbsp;mg/kg
(e.g. serum ferritin levels persistently above 2,500&nbsp;µg/l and not showing
a decreasing trend over time), doses of up to 28&nbsp;mg/kg may be considered.
The availability of long&#8209;term efficacy and safety data from clinical
studies conducted with EXJADE dispersible tablets used at doses above
30&nbsp;mg/kg is currently limited (264&nbsp;patients followed for an average
of 1&nbsp;year after dose escalation). If only very poor haemosiderosis control
is achieved at doses up to 21&nbsp;mg/kg, a further increase (to a maximum of 28&nbsp;mg/kg)
may not achieve satisfactory control, and alternative treatment options may be
considered. If no satisfactory control is achieved at doses above 21&nbsp;mg/kg,
treatment at such doses should not be maintained and alternative treatment
options should be considered whenever possible. Doses above 28&nbsp;mg/kg are
not recommended because there is only limited experience with doses above this
level (see section 5.1).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In patients treated with doses greater
than 21&nbsp;mg/kg, dose reductions in steps of 3.5 to 7&nbsp;mg/kg should be
considered when control has been achieved (e.g. serum ferritin levels
persistently below 2,500&nbsp;µg/l and showing a decreasing trend over time).
In patients whose serum ferritin level has reached the target (usually between
500 and 1,000&nbsp;µg/l), dose reductions in steps of 3.5 to 7&nbsp;mg/kg
should be considered to maintain serum ferritin levels within the target range
and to minimise the risk of overchelation. If serum ferritin falls consistently
below 500&nbsp;µg/l, an interruption of treatment should be considered (see
section 4.4).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><i><u><span style='color:black'>Non&#8209;transfusion&#8209;dependent
thalassaemia syndromes</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><u><span style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Chelation therapy should only be initiated when there is
evidence of iron overload (liver iron concentration [LIC] &#8805;5&nbsp;mg Fe/g
dry weight [dw] or serum ferritin consistently &gt;800&nbsp;</span><span
lang=EN-GB style='color:black'>µg</span><span style='color:black'>/l). LIC is
the preferred method of iron overload determination and should be used wherever
available. Caution should be taken during chelation therapy to minimise the
risk of overchelation in all patients (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXJADE film&#8209;coated tablets demonstrate
higher bioavailability compared to the EXJADE dispersible tablet formulation
(see section 5.2). In case of switching from dispersible tablets to film&#8209;coated
tablets, the dose of the film&#8209;coated tablets should be 30% lower than the
dose of </span><span style='color:black'>the dispersible tablets</span><span
lang=EN-GB style='color:black'>, rounded to the nearest whole tablet.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>The corresponding doses for the different formulations are
shown in the table below.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Table&nbsp;2</span></u><span
style='font-size:11.0pt;color:black'>        Recommended doses for non&#8209;transfusion&#8209;dependent
thalassaemia syndromes</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=614
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Film&#8209;coated
  tablets/granules</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Dispersible tablets</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Liver iron
  concentration (LIC)*</span></b></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Serum ferritin</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Starting dose</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>7&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>10&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&#8805;5&nbsp;mg Fe/g
  dw</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>or</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&gt;800&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Monitoring</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Monthly</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 rowspan=4 valign=top style='width:78.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Adjustment steps</span></b></p>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>(every 3&#8209;6&nbsp;months)</span></p>
  </td>
  <td width=255 colspan=2 valign=top style='width:191.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><b><span style='font-family:"Times New Roman",serif;
  color:black'>Increase</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&#8805;7&nbsp;mg Fe/g
  dw</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>or</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&gt;2,000&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>3.5 &#8209;
  7&nbsp;mg/kg/day</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>5&#8209;10&nbsp;mg/kg/day</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=255 colspan=2 valign=top style='width:191.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><b><span style='font-family:"Times New Roman",serif;
  color:black'>Decrease</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&lt;7&nbsp;mg Fe/g dw</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>or</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='color:black'>&#8804;</span><span style='font-family:"Times New Roman",serif;
  color:black'>2,000&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>3.5 &#8209;
  7&nbsp;mg/kg/day</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>5&#8209;10&nbsp;mg/kg/day</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Maximum dose</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:dotted windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>14&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:dotted windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>20&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:dotted windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;border-bottom:dotted windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;border-bottom:dotted windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:16.9pt'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:16.9pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:16.9pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>7&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:16.9pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>10&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:16.9pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:16.9pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:16.9pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=255 colspan=2 valign=top style='width:191.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><span style='font-family:"Times New Roman",serif;
  color:black'>For adults</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>not assessed</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>and</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='color:black'>&#8804;</span><span style='font-family:"Times New Roman",serif;
  color:black'>2,000&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=255 colspan=2 valign=top style='width:191.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><span style='font-family:"Times New Roman",serif;
  color:black'>For paediatric patients</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Interruption</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&lt;3&nbsp;mg Fe/g dw</span></b></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>or</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&lt;300&nbsp;µg/l</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Retreatment</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><b><span style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><b><span style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></b></p>
  </td>
  <td width=255 colspan=3 valign=top style='width:191.35pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><b><span style='font-family:"Times New Roman",serif;
  color:black'>Not recommended</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>*LIC is the preferred method of iron overload
determination.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Starting dose</span></i></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>The recommended initial daily dose of EXJADE film&#8209;coated
tablets in patients with non&#8209;transfusion&#8209;dependent thalassaemia
syndromes is 7&nbsp;mg/kg body weight.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Dose adjustment</span></i></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>It is recommended that serum ferritin be monitored every
month to assess the patients response to therapy and to minimise the risk of
overchelation (see section&nbsp;4.4). After every 3 to 6&nbsp;months of
treatment, a dose increase in increments of 3.5 to 7&nbsp;mg/kg should be
considered if the patients LIC is &#8805;7&nbsp;mg Fe/g dw, or if serum
ferritin is consistently &gt;2,000&nbsp;</span><span lang=EN-GB
style='color:black'>µ</span><span style='color:black'>g/l and not showing a
downward trend, and the patient is tolerating the medicinal product well. Doses
above 14&nbsp;mg/kg are not recommended because there is no experience with
doses above this level in patients with non&#8209;transfusion&#8209;dependent
thalassaemia syndromes.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>In patients in whom LIC was not assessed and serum ferritin
is &#8804;2,000&nbsp;</span><span lang=EN-GB style='color:black'>µg</span><span
style='color:black'>/l, dosing should not exceed 7&nbsp;mg/kg.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>For patients in whom the dose was increased to &gt;7&nbsp;mg/kg,
dose reduction to 7&nbsp;mg/kg or less is recommended when LIC is &lt;7&nbsp;mg
Fe/g dw or serum ferritin is &#8804;2,000&nbsp;</span><span lang=EN-GB
style='color:black'>µg</span><span style='color:black'>/l.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><span lang=EN-GB style='font-size:11.0pt;color:black'>Treatment
cessation</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Once a satisfactory body iron
level has been achieved (LIC &lt;3&nbsp;mg Fe/g dw or serum ferritin
&lt;300&nbsp;</span><span style='font-size:11.0pt;color:black'>µg</span><span
lang=EN-GB style='font-size:11.0pt;color:black'>/l), treatment should be
stopped. There are no data available on the retreatment of patients who
reaccumulate iron after having achieved a satisfactory body iron level and
therefore retreatment cannot be recommended.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><u><span style='font-size:11.0pt;color:black'>Special
populations</span></u></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Elderly patients (&#8805;65&nbsp;years of age)</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The dosing recommendations for elderly
patients are the same as described above. In clinical studies, elderly patients
experienced a higher frequency of adverse reactions than younger patients (in
particular, diarrhoea) and should be monitored closely for adverse reactions
that may require a dose adjustment.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Paediatric population</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>Transfusional
iron overload:</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The dosing recommendations for paediatric
patients aged 2 to 17&nbsp;years with transfusional iron overload are the same
as for adult patients (see section&nbsp;4.2). It is recommended that serum
ferritin be monitored every month to assess the patients response to therapy
and to minimise the risk of overchelation (see section&nbsp;4.4). Changes in
weight of paediatric patients over time must be taken into account when
calculating the dose.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In children with transfusional iron
overload aged between 2 and 5&nbsp;years, exposure is lower than in adults (see
section 5.2). This age group may therefore require higher doses than are
necessary in adults. However, the initial dose should be the same as in adults,
followed by individual titration.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span lang=FR-CH style='font-size:11.0pt;color:black'>Non&#8209;transfusion&#8209;dependent
thalassaemia syndromes:</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>In paediatric patients with non&#8209;transfusion&#8209;dependent
thalassaemia syndromes, dosing should not exceed 7&nbsp;mg/kg. In these
patients, closer monitoring of LIC and serum ferritin is essential to avoid
overchelation (see section&nbsp;4.4). In addition to monthly serum ferritin
assessments, LIC should be monitored every three months when serum ferritin is
&#8804;800&nbsp;</span><span lang=EN-GB style='color:black'>µg</span><span
style='color:black'>/l.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span lang=EN-GB style='font-size:11.0pt;color:black'>Children
from birth to 23&nbsp;months:</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The safety and efficacy of EXJADE in
children from birth to 23&nbsp;months of age have not been established. No data
are available.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Patients with renal impairment</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE has not been studied in patients
with renal impairment and is contraindicated in patients with estimated
creatinine clearance &lt;60&nbsp;ml/min (see sections 4.3 and 4.4).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Patients with hepatic impairment</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE is not recommended in patients with
severe hepatic impairment (Child&#8209;Pugh Class C). In patients with moderate
hepatic impairment (Child&#8209;Pugh Class B), the dose should be considerably
reduced followed by progressive increase up to a limit of 50% (see sections 4.4
and 5.2), and EXJADE must be used with caution in such patients. Hepatic
function in all patients should be monitored before treatment, every
2&nbsp;weeks during the first month and then every month (see section 4.4).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Method of
administration</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>For oral use.</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>The
film&#8209;coated tablets should be swallowed whole with some water. </span><span
style='color:black'>For patients who are unable to swallow whole tablets, the
film&#8209;coated tablets may be crushed and administered by sprinkling the
full dose onto soft food, e.g. yogurt or apple sauce (pureed apple). The dose
should be immediately and completely consumed, and not stored for future use.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The film&#8209;coated tablets should be
taken once a day, preferably at the same time each day, and may be taken on an
empty stomach or with a light meal (see sections 4.5 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.3     Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Hypersensitivity to the active substance or to
any of the excipients</span><span lang=EN-GB style='color:black'> listed in
section 6.1</span><span lang=EN-GB style='color:black'>.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Combination with other iron chelator therapies as the
safety of such combinations has not been established </span><span lang=EN-GB
style='color:black'>(see section 4.5)</span><span style='color:black'>.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Patients with estimated creatinine clearance
&lt;60&nbsp;ml/min.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.4     Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='page-break-after:avoid;background:white;border:none;
padding:0in'><u><span lang=EN-GB style='color:black'>Renal function</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>Deferasirox has </span><span lang=EN-GB
style='color:black'>been studied only in patients with baseline serum
creatinine within the age&#8209;appropriate normal range.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>During
clinical studies, increases in serum creatinine of &gt;33% on &#8805;2&nbsp;consecutive
occasions, sometimes above the upper limit of the normal range, occurred in
about 36% of patients. These were dose&#8209;dependent. About two&#8209;thirds
of the patients showing serum creatinine increase returned below the 33% level
without dose adjustment. In the remaining third the serum creatinine increase
did not always respond to a dose reduction or a dose interruption. In some
cases, only a stabilisation of the serum creatinine values has been observed
after dose reduction. Cases of acute renal failure have been reported following
post&#8209;marketing use of deferasirox (see section 4.8). In some post&#8209;marketing
cases, renal function deterioration has led to renal failure requiring
temporary or permanent dialysis.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>The causes of the rises</span><span lang=EN-GB
style='color:black'> in serum creatinine have not been elucidated.</span><span
lang=EN-GB style='color:black'> Particular attention should therefore be paid
to monitoring of serum creatinine in patients who are concomitantly receiving
medicinal products that depress renal function, and in patients who are
receiving high doses of deferasirox and/or low rates of transfusion
(&lt;7&nbsp;ml/kg/month of packed red blood cells or &lt;2&nbsp;units/month for
an adult). While no increase in renal adverse events was observed after dose
escalation of EXJADE dispersible tablets to doses above 30&nbsp;mg/kg in
clinical studies, an increased risk of renal adverse events with film&#8209;coated
tablet doses above 21&nbsp;mg/kg cannot be excluded.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>It is recommended that serum creatinine be
assessed in duplicate before initiating therapy. <b>Serum creatinine,
creatinine clearance</b> (estimated with the Cockcroft&#8209;Gault or MDRD
formula in adults and with the Schwartz formula in children) and/or plasma
cystatin C levels<b> should be monitored prior to therapy, weekly in the first
month after initiation </b></span><b><span lang=EN-GB style='color:black'>or
modification </span><span lang=EN-GB style='color:black'>of therapy with EXJADE
(including switch of formulation), and monthly thereafter</span></b><span
lang=EN-GB style='color:black'>. Patients with pre&#8209;existing renal
conditions and patients who are receiving medicinal products that depress renal
function may be more at risk of complications. Care should be taken to maintain
adequate hydration in patients who develop diarrhoea or vomiting.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>There have been post&#8209;marketing reports of
metabolic acidosis occurring during treatment with deferasirox. The majority of
these patients had renal impairment, renal tubulopathy (Fanconi syndrome) or
diarrhoea, or conditions where acid&#8209;base imbalance is a known
complication. Acid&#8209;base balance should be monitored as clinically
indicated in these populations. Interruption of EXJADE therapy should be
considered in patients who develop metabolic acidosis.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>Post-marketing cases of severe forms of renal
tubulopathy (such as Fanconi syndrome) and renal failure associated with
changes in consciousness in the context of hyperammonaemic encephalopathy have
been reported in patients treated with deferasirox, mainly in children. It is
recommended that hyperammonaemic encephalopathy be considered and ammonia
levels measured in patients who develop unexplained changes in mental status
while on Exjade therapy.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-before:always;page-break-after:avoid;
background:white;border:none;padding:0in'><u><span lang=EN-GB style='color:
black'>Table&nbsp;3</span></u><span lang=EN-GB style='color:black'>        Dose
adjustment and interruption of treatment for renal monitoring</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white;border:none;
padding:0in'>

<table cellpadding=0 cellspacing=0 align=left>
 <tr>
  <td width=1 height=17></td>
 </tr>
 <tr>
  <td></td>
  <td><img width=604 height=418 src="Exjade-II-073-EN%20PI_files/image005.gif"
  alt="	Serum creatinine		Creatinine clearance&#13;&#10;Before initiation of therapy	Twice (2x)	and	Once (1x)&#13;&#10;Contraindicated			&lt;60 ml/min&#13;&#10;Monitoring			&#13;&#10;-	First month after start of therapy or dose modification (including switch of formulation)	Weekly	and	Weekly&#13;&#10;-	Thereafter	Monthly	and	Monthly&#13;&#10;Reduction of daily dose by 7 mg/kg/day (film-coated tablet formulation),&#13;&#10;if following renal parameters are observed at two consecutive visits and cannot be attributed to other causes&#13;&#10;Adult patients	&gt;33% above pre-treatment average	and	Decreases &lt;LLN* (&lt;90 ml/min)&#13;&#10;Paediatric patients	&gt; age appropriate ULN** 	and/or	Decreases &lt;LLN* (&lt;90 ml/min)&#13;&#10;After dose reduction, interrupt treatment, if&#13;&#10;Adult and paediatric	Remains &gt;33% above pre-treatment average	and/or	Decreases &lt;LLN* (&lt;90 ml/min)&#13;&#10;*LLN: lower limit of the normal range&#13;&#10;**ULN: upper limit of the normal range&#13;&#10;&#13;&#10;"></td>
 </tr>
</table>

<span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<br clear=ALL>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>Treatment may be reinitiated depending on the individual
clinical circumstances.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>Dose reduction or interruption may be also
considered if abnormalities occur in levels of markers of renal tubular
function and/or as clinically indicated:</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>        Proteinuria (test should be performed
prior to therapy and monthly thereafter)</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>        Glycosuria in non&#8209;diabetics and
low levels of serum potassium, </span><span lang=EN-GB style='color:black'>phosphate,
magnesium or urate, phosphaturia, aminoaciduria (monitor as needed</span><span
lang=EN-GB style='color:black'>).</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>Renal tubulopathy has been mainly reported in
children and adolescents with beta&#8209;thalassaemia treated with EXJADE.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>Patients should be referred to a renal
specialist, and further specialised investigations (such as renal biopsy) may
be considered if the following occur despite dose reduction and interruption:</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>        </span><span lang=EN-GB
style='color:black'>S</span><span lang=EN-GB style='color:black'>erum
creatinine </span><span lang=EN-GB style='color:black'>remains significantly </span><span
lang=EN-GB style='color:black'>elevated and</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><span lang=EN-GB style='color:black'>        </span><span
lang=EN-GB style='color:black'>Persistent </span><span lang=EN-GB
style='color:black'>abnormality </span><span lang=EN-GB style='color:black'>in
another marker of renal function </span><span lang=EN-GB style='color:black'>(</span><span
lang=EN-GB style='color:black'>e.g. </span><span lang=EN-GB style='color:black'>proteinuria,
Fanconi Syndrome).</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white;border:none;
padding:0in'><u><span lang=EN-GB style='color:black'>Hepatic function</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white;border:none;padding:0in'><span style='font-size:11.0pt;
color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>Liver
function test elevations have been observed in patients treated with deferasirox.
Post&#8209;marketing cases of hepatic failure, some of which were fatal, have
been reported. Severe forms associated with changes in consciousness in the
context of hyperammonaemic encephalopathy, may occur in patients treated with
deferasirox, particularly in children. It is recommended that hyperammonaemic
encephalopathy be considered and ammonia levels measured in patients who
develop unexplained changes in mental status while on Exjade therapy. Care
should be taken to maintain adequate hydration in patients who experience
volume-depleting events (such as diarrhoea or vomiting), particularly in
children with acute illness. Most reports of hepatic failure involved patients
with significant comorbidities including pre&#8209;existing chronic liver conditions
(including cirrhosis and hepatitis C) and multi-organ failure. The role of deferasirox
as a contributing or aggravating factor cannot be excluded (see section 4.8).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>It is
recommended that<b> </b>serum transaminases, bilirubin and alkaline phosphatase
be checked before the initiation of treatment, every 2&nbsp;weeks during the
first month and monthly thereafter. If there is a persistent and progressive
increase in serum transaminase levels that cannot be attributed to other
causes, EXJADE should be interrupted. Once the cause of the liver function test
abnormalities has been clarified or after return to normal levels, cautious re&#8209;initiation
of treatment at a lower dose followed by gradual dose escalation may be
considered.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>EXJADE is
not recommended in patients with severe hepatic impairment </span><span
lang=EN-GB style='font-size:11.0pt;color:black'>(Child&#8209;Pugh Class C)</span><span
style='font-size:11.0pt;color:black'> (see section 5.2).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white;border:none;padding:0in'><u><span style='font-size:11.0pt;
color:black'>Table&nbsp;4        Summary of safety monitoring recommendations</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'>

<table cellpadding=0 cellspacing=0 align=left>
 <tr>
  <td width=9 height=4></td>
 </tr>
 <tr>
  <td></td>
  <td><img width=565 height=466 src="Exjade-II-073-EN%20PI_files/image006.gif"
  alt="Test	Frequency&#13;&#10;Serum creatinine	In duplicate prior to therapy.&#13;&#10;Weekly during first month of therapy or after dose modification (including switch of formulation).&#13;&#10;Monthly thereafter.&#13;&#10;Creatinine clearance and/or plasma cystatin C	Prior to therapy.&#13;&#10;Weekly during first month of therapy or after dose modification (including switch of formulation).&#13;&#10;Monthly thereafter.&#13;&#10;Proteinuria	Prior to therapy.&#13;&#10;Monthly thereafter.&#13;&#10;Other markers of renal tubular function (such as glycosuria in non-diabetics and low levels of serum potassium, phosphate, magnesium or urate, phosphaturia, aminoaciduria)	As needed.&#13;&#10;Serum transaminases, bilirubin, alkaline phosphatase	Prior to therapy.&#13;&#10;Every 2 weeks during first month of therapy.&#13;&#10;Monthly thereafter.&#13;&#10;Auditory and ophthalmic testing	Prior to therapy.&#13;&#10;Annually thereafter.&#13;&#10;Body weight, height and sexual development	Prior to therapy.&#13;&#10;Annually in paediatric patients.&#13;&#10;&#13;&#10;"></td>
 </tr>
</table>

<u><span style='font-size:11.0pt;color:black'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

</div>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<br clear=ALL>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>In patients with a short life expectancy (e.g.
high&#8209;risk myelodysplastic syndromes), especially when co&#8209;morbidities
could increase the risk of adverse events, the benefit of EXJADE might be
limited and may be inferior to risks. As a consequence, treatment with EXJADE
is not recommended in these patients.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Caution should be used in elderly patients due
to a higher frequency of adverse reactions (in particular, diarrhoea).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Data in children with non&#8209;transfusion&#8209;dependent
thalassaemia are very limited (see section 5.1). As a consequence, EXJADE
therapy should be closely monitored to detect adverse reactions and to follow
iron burden in the paediatric population. In addition, before treating heavily
iron&#8209;overloaded children with non&#8209;transfusion&#8209;dependent
thalassaemia with EXJADE, the physician should be aware that the consequences
of long&#8209;term exposure in such patients are currently not known.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Gastrointestinal
disorders</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Upper gastrointestinal ulceration and
haemorrhage have been reported in patients, including children and adolescents,
receiving deferasirox. Multiple ulcers have been observed in some patients (see
section 4.8). There have been reports of ulcers complicated with digestive
perforation. Also, there have been reports of fatal gastrointestinal
haemorrhages, especially in elderly patients who had haematological
malignancies and/or low platelet counts. Physicians and patients should remain
alert for signs and symptoms of gastrointestinal ulceration and haemorrhage
during EXJADE therapy. In case of gastrointestinal ulceration or haemorrhage, EXJADE
should be discontinued and additional evaluation and treatment must be promptly
initiated. Caution should be exercised in patients who are taking EXJADE in
combination with substances that have known ulcerogenic potential, such as NSAIDs,
corticosteroids, or oral bisphosphonates, in patients receiving anticoagulants
and in patients with platelet counts below 50,000/mm<sup>3</sup> (50 x 10<sup>9</sup>/l)
(see section 4.5).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><u><span style='font-size:11.0pt;color:black'>Skin disorders</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt;color:black'>Skin rashes may appear during EXJADE
treatment. The rashes resolve spontaneously in most cases. When interruption of
treatment may be necessary, treatment may be reintroduced after resolution of
the rash, at a lower dose followed by gradual dose escalation. In severe cases
this reintroduction could be conducted in combination with a short period of
oral steroid administration. Severe cutaneous adverse reactions (SCARs)
including </span><span style='font-size:11.0pt'>Stevens&#8209;Johnson syndrome
(SJS), toxic epidermal necrolysis (TEN) </span><span lang=EN-GB
style='font-size:11.0pt'>and drug reaction with eosinophilia and systemic
symptoms (DRESS), which could be life-threatening or fatal, </span><span
style='font-size:11.0pt'>have been reported. If any SCAR is suspected, EXJADE
should be discontinued immediately and should not be reintroduced.</span><span
lang=EN-GB style='font-size:11.0pt'> At the time of prescription, patients should
be advised of the signs and symptoms of severe skin reactions, and be closely
monitored.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Hypersensitivity
reactions</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Cases of serious hypersensitivity
reactions (such as anaphylaxis and angioedema) have been reported in patients
receiving deferasirox, with the onset of the reaction occurring in the majority
of cases within the first month of treatment (see section 4.8). If such
reactions occur, EXJADE should be discontinued and appropriate medical
intervention instituted. Deferasirox should not be reintroduced in patients who
have experienced a hypersensitivity reaction due to the risk of anaphylactic
shock (see section 4.3).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Vision
and hearing</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Auditory (decreased hearing) and ocular
(lens opacities) disturbances have been reported (see section 4.8). Auditory
and ophthalmic testing (including fundoscopy) is recommended before the start
of treatment and at regular intervals thereafter (every 12&nbsp;months). If
disturbances are noted during the treatment, dose reduction or interruption may
be considered.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Blood
disorders</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>There have been post&#8209;marketing
reports of leukopenia, thrombocytopenia or pancytopenia (or aggravation of
these cytopenias) and of aggravated anaemia in patients treated with deferasirox.
Most of these patients had pre&#8209;existing haematological disorders that are
frequently associated with bone marrow failure. However, a contributory or
aggravating</span><span style='font-size:11.0pt;color:navy'> </span><span
style='font-size:11.0pt;color:black'>role cannot be excluded. Interruption of
treatment should be considered in patients who develop unexplained cytopenia.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Other considerations</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Monthly monitoring of serum ferritin is
recommended in order to assess the patients response to therapy and to avoid
overchelation (see section 4.2). Dose reduction or closer monitoring of renal
and hepatic function, and serum ferritin levels are recommended during periods
of treatments with high doses and when serum ferritin levels are close to the
target range. If serum ferritin falls consistently below 500&nbsp;µg/l (in
transfusional iron overload) or below 300&nbsp;µg/l (in non&#8209;transfusion&#8209;dependent
thalassaemia syndromes), an interruption of treatment should be considered.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The results of the tests for serum
creatinine, serum ferritin and serum transaminases should be recorded and
regularly assessed for trends.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In two clinical studies, growth and sexual
development of paediatric patients treated with deferasirox for up to
5&nbsp;years were not affected (see section&nbsp;4.8). However, as a general
precautionary measure in the management of paediatric patients with
transfusional iron overload, body weight, height and sexual development should
be monitored prior to therapy and at regular intervals (every 12&nbsp;months).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Cardiac dysfunction is a known
complication of severe iron overload. Cardiac function should be monitored in
patients with severe iron overload during long&#8209;term treatment with
EXJADE.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.5     Interaction with other medicinal products and other
forms of interaction</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The safety of deferasirox in combination
with other iron chelators has not been established. Therefore, it </span><span
style='font-size:11.0pt;color:black'>must not be combined with other iron
chelator therapies</span><span style='font-size:11.0pt;color:black'> (see
section 4.3).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Interaction
with food</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The C<sub>max</sub> of deferasirox film&#8209;coated
tablets was increased (by 29%) when taken with a high&#8209;fat meal. EXJADE film&#8209;coated
tablets may be taken either on an empty stomach or with a light meal,
preferably at the same time each day (see sections 4.2 and 5.2).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Agents
that may decrease EXJADE systemic exposure</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox metabolism depends on UGT
enzymes. In a healthy volunteer study, the concomitant administration of deferasirox
(single dose of 30&nbsp;mg/kg, dispersible tablet formulation) and the potent
UGT inducer, rifampicin, (repeated dose of 600&nbsp;mg/day) resulted in a
decrease of deferasirox exposure by 44% (90% CI: 37% - 51%). Therefore, the
concomitant use of EXJADE with potent UGT inducers (e.g. rifampicin,
carbamazepine, phenytoin, phenobarbital, ritonavir) may result in a decrease in
EXJADE efficacy. The patients serum ferritin should be monitored during and
after the combination, and the dose of EXJADE adjusted if necessary.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Cholestyramine significantly reduced the
deferasirox exposure in a mechanistic study to determine the degree of
enterohepatic recycling (see section 5.2).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Interaction
with midazolam and other agents metabolised by CYP3A4</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a healthy volunteer study, the
concomitant administration of deferasirox dispersible tablets and midazolam (a
CYP3A4 probe substrate) resulted in a decrease of midazolam exposure by 17%
(90% CI: 8% - 26%). In the clinical setting, this effect may be more
pronounced. Therefore, due to a possible decrease in efficacy, caution should
be exercised when deferasirox is combined with substances metabolised through
CYP3A4 (e.g. ciclosporin, simvastatin, hormonal contraceptive agents, bepridil,
ergotamine).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Interaction
with repaglinide and other agents metabolised by CYP2C8</span></u></p>

<p class=MsoHeader style='background:white'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif;color:black'>In a healthy volunteer
study, the concomitant administration of deferasirox as a moderate CYP2C8
inhibitor (30&nbsp;mg/kg daily, dispersible tablet formulation), with
repaglinide, a CYP2C8 substrate, given as a single dose of 0.5&nbsp;mg,
increased repaglinide AUC and C</span><sub><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif;color:black'>max</span></sub><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'> about 2.3&#8209;fold (90% CI [2.03&#8209;2.63]) and 1.6-fold (90%
CI [1.42&#8209;1.84]), respectively. Since the interaction has not been
established with dosages higher than 0.5&nbsp;mg for repaglinide, the
concomitant use of deferasirox with repaglinide should be avoided. If the
combination appears necessary, careful clinical and blood glucose monitoring
should be performed (see section 4.4). An interaction between deferasirox and
other CYP2C8 substrates like paclitaxel cannot be excluded.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Interaction
with theophylline and other agents metabolised by CYP1A2</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a healthy volunteer study, the
concomitant administration of deferasirox as a CYP1A2 inhibitor (repeated dose
of 30&nbsp;mg/kg/day, dispersible tablet formulation) and the CYP1A2 substrate
theophylline (single dose of 120&nbsp;mg) resulted in an increase of theophylline
AUC by 84% (90% CI: 73% to 95%). The single dose C<sub>max</sub> was not
affected, but an increase of theophylline C<sub>max</sub> is expected to occur
with chronic dosing. Therefore, the concomitant use of deferasirox with
theophylline is not recommended. If deferasirox and theophylline are used
concomitantly, monitoring of theophylline concentration and theophylline dose
reduction should be considered. An interaction between deferasirox and other
CYP1A2 substrates cannot be excluded. For substances that are predominantly
metabolised by CYP1A2 and that have a narrow therapeutic index (e.g. clozapine,
tizanidine), the same recommendations apply as for theophylline.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><u><span style='color:black'>Other information</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The concomitant administration of deferasirox
and aluminium&#8209;containing antacid preparations has not been formally
studied. Although deferasirox has a lower affinity for aluminium than for iron,
it is not recommended to take deferasirox tablets with aluminium&#8209;containing
antacid preparations.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The concomitant administration of
deferasirox with substances that have known ulcerogenic potential, such as
NSAIDs (including acetylsalicylic acid at high dosage), corticosteroids or oral
bisphosphonates may increase the risk of gastrointestinal toxicity (see section
4.4). The concomitant administration of deferasirox with anticoagulants may
also increase the risk of gastrointestinal haemorrhage. Close clinical
monitoring is required when deferasirox is combined with these substances.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>Concomitant administration of deferasirox and busulfan
resulted in an increase of busulfan exposure (AUC), but the mechanism of the
interaction remains unclear. If possible, evaluation of the pharmacokinetics
(AUC, clearance) of a busulfan test dose should be performed to allow dose
adjustment.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.6     Fertility, pregnancy and lactation</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Pregnancy</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>No clinical data on exposed pregnancies
are available for deferasirox. Studies in animals have shown some reproductive
toxicity at maternally toxic doses (see section 5.3). The potential risk for
humans is unknown.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>As a precaution, it is recommended that
EXJADE is not used during pregnancy unless clearly necessary.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE may decrease the efficacy of
hormonal contraceptives (see section 4.5). Women of childbearing potential are
recommended to use additional or alternative non&#8209;hormonal methods of
contraception when using EXJADE.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Breast&#8209;feeding</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In animal studies, deferasirox was found
to be rapidly and extensively secreted into maternal milk. No effect on the
offspring was noted. It is not known if deferasirox is secreted into human
milk. Breast&#8209;feeding while taking EXJADE is not recommended.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Fertility</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>No fertility data is available for humans.
In animals, no adverse effects on male or female fertility were found (see
section 5.3).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.7     Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXJADE has minor influence on the ability to
drive and use machines. Patients experiencing the uncommon adverse reaction of
dizziness should exercise caution when driving or operating machines (see
section 4.8).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.8     Undesirable effects</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Summary
of the safety profile</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The most frequent reactions reported
during chronic treatment in clinical studies conducted with deferasirox
dispersible tablets in adult and paediatric patients include gastrointestinal
disturbances (mainly nausea, vomiting, diarrhoea or abdominal pain) and skin
rash. Diarrhoea is reported more commonly in paediatric patients aged 2 to
5&nbsp;years and in the elderly. These reactions are dose&#8209;dependent,
mostly mild to moderate, generally transient and mostly resolve even if
treatment is continued.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>During clinical studies dose&#8209;dependent
increases in serum creatinine occurred in about 36% of patients, though most
remained within the normal range. Decreases in mean creatinine clearance have
been observed in both paediatric and adult patients with beta&#8209;thalassemia
and iron overload during the first year of treatment, but there is evidence
that this does not decrease further in subsequent years of treatment.
Elevations of liver transaminases have been reported. Safety monitoring
schedules for renal and liver parameters are recommended. Auditory (decreased
hearing) and ocular (lens opacities) disturbances are uncommon, and yearly
examinations are also recommended (see section 4.4).</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Severe cutaneous adverse reactions
(SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis
(TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) have
been reported with the use of EXJADE (see section 4.4).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Tabulated
list of adverse reactions</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Adverse reactions are ranked below using
the following convention: very common (&#8805;1/10); common (&#8805;1/100 to
&lt;1/10); uncommon (&#8805;1/1,000 to &lt;1/100); rare (&#8805;1/10,000 to
&lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the
available data). Within each frequency grouping, adverse reactions are
presented in order of decreasing seriousness.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:8.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Table&nbsp;5</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Blood and lymphatic system disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span lang=IT
  style='font-family:"Times New Roman",serif;color:black'>Pancytopenia<sup>1</sup>,
  thrombocytopenia<sup>1</sup>, anaemia aggravated<sup>1</sup>,</span><span
  lang=IT style='color:black'> </span><span lang=IT style='font-family:"Times New Roman",serif;
  color:black'>neutropenia<sup>1</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Immune system disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Hypersensitivity reactions (including anaphylactic
  reactions and angioedema)<sup>1</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Metabolism and
  nutrition disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Metabolic acidosis</span><sup><span
  lang=IT style='font-family:"Times New Roman",serif;color:black'>1</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Psychiatric disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Anxiety, sleep disorder</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Common:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Headache</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Dizziness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Eye disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Cataract, maculopathy</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Rare:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Optic neuritis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Ear and labyrinth disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Deafness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Laryngeal pain</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Common:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Diarrhoea,
  constipation, vomiting, nausea, abdominal pain, abdominal distension,
  dyspepsia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Gastrointestinal
  haemorrhage, gastric ulcer (including multiple ulcers), duodenal ulcer,
  gastritis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Rare:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Oesophagitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Gastrointestinal perforation</span><sup><span
  lang=IT style='font-family:"Times New Roman",serif;color:black'>1</span></sup><span
  lang=IT style='font-family:"Times New Roman",serif;color:black'>, acute
  pancreatitis<sup>1</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Hepatobiliary disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Common:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Transaminases
  increased</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Hepatitis,
  cholelithiasis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Hepatic failure<sup>1, 2</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Common:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Rash, pruritus</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Pigmentation disorder</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif;color:black'>Rare:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif;color:black'>Drug reaction with
  eosinophilia and systemic symptoms (DRESS)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span lang=EN-GB
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Stevens&#8209;Johnson syndrome<sup>1</sup>,
  hypersensitivity vasculitis<sup>1</sup>, urticaria<sup>1</sup>, erythema
  multiforme<sup>1</sup>, alopecia<sup>1</sup>, toxic epidermal necrolysis
  (TEN)<sup>1</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Very common:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Blood creatinine
  increased</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Common:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Proteinuria</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  lang=IT style='font-family:"Times New Roman",serif;color:black'>Renal tubular
  disorder<sup>2</sup> (acquired Fanconi syndrome), glycosuria</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span lang=IT
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span lang=FR
  style='font-family:"Times New Roman",serif;color:black'>Acute renal failure<sup>1,
  2</sup>, tubulointerstitial nephritis<sup>1</sup>, nephrolithiasis</span><sup><span
  lang=IT style='font-family:"Times New Roman",serif;color:black'>1</span></sup><span
  lang=FR style='font-family:"Times New Roman",serif;color:black'>, renal
  tubular necrosis<sup>1</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>General disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Pyrexia, oedema,
  fatigue</span></p>
  </td>
 </tr>
</table>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt;
background:white'><sup><span lang=EN-GB style='font-size:11.0pt;color:black'>1</span></sup><span
lang=EN-GB style='font-size:10.0pt;color:black'>           </span><span
lang=EN-GB style='font-size:11.0pt;color:black'>Adverse reactions reported
during post&#8209;marketing experience. These are derived from spontaneous
reports for which it is not always possible to reliably establish frequency or
a causal relationship to exposure to the medicinal product.</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt;
background:white'><sup><span lang=EN-GB style='font-size:11.0pt;color:black'>2</span></sup><span
lang=EN-GB style='font-size:11.0pt;color:black'>        Severe forms associated
with changes in consciousness in the context of hyperammonaemic encephalopathy have
been reported.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Description
of selected adverse reactions</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Gallstones and related biliary disorders
were reported in about 2% of patients. Elevations of liver transaminases were
reported as an adverse reaction in 2% of patients. Elevations of transaminases
greater than 10&nbsp;times the upper limit of the normal range, suggestive of
hepatitis, were uncommon (0.3%). During post&#8209;marketing experience,
hepatic failure, sometimes fatal, has been reported with deferasirox (see
section 4.4). There have been post&#8209;marketing reports of metabolic
acidosis. The majority of these patients had renal impairment, renal
tubulopathy (Fanconi syndrome) or diarrhoea, or conditions where acid&#8209;base
imbalance is a known complication (see section 4.4). Cases of serious acute
pancreatitis were observed without documented underlying biliary conditions. As
with other iron chelator treatment, high&#8209;frequency hearing loss and
lenticular opacities (early cataracts) have been uncommonly observed in
patients treated with deferasirox (see section 4.4).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span style='color:black'>Creatinine
clearance in transfusional iron overload</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a retrospective meta&#8209;analysis of
2,102&nbsp;adult and paediatric beta&#8209;thalassaemia patients with
transfusional iron overload treated with deferasirox dispersible tablets in two
randomised and four open label studies of up to five years duration, a mean
creatinine clearance decrease of 13.2% in adult patients (95% CI: &#8209;14.4%
to &#8209;12.1%; n=935) and 9.9% (95% CI: &#8209;11.1% to &#8209;8.6%; n=1,142)
in paediatric patients was observed during the first year of treatment. In
250&nbsp;patients who were followed for up to five years, no further decrease
in mean creatinine clearance levels was observed.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span style='color:black'>Clinical
study in patients with non&#8209;transfusion&#8209;dependent thalassaemia
syndromes</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a 1&#8209;year study in patients with
non&#8209;transfusion&#8209;dependent thalassaemia syndromes and iron overload
(dispersible tablets at a dose of 10&nbsp;mg/kg/day), diarrhoea (9.1%), rash
(9.1%), and nausea (7.3%) were the most frequent study drug&#8209;related
adverse events. Abnormal serum creatinine and creatinine clearance values were
reported in 5.5% and 1.8% of patients, respectively. Elevations of liver
transaminases greater than 2&nbsp;times the baseline and 5&nbsp;times the upper
limit of normal were reported in 1.8% of patients.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><u><span lang=EN-GB style='font-size:11.0pt;
color:black'>Paediatric population</span></u></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In two clinical studies, growth and sexual
development of paediatric patients treated with deferasirox for up to
5&nbsp;years were not affected (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Diarrhoea is reported more
commonly in paediatric patients aged 2 to 5&nbsp;years than in older patients.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Renal tubulopathy has been
mainly reported in children and adolescents with beta&#8209;thalassaemia
treated with deferasirox.</span><span lang=EN-GB style='color:black'> </span><span
lang=EN-GB style='font-size:11.0pt;color:black'>In post-marketing reports, a
high proportion of cases of metabolic acidosis occurred in children in the context
of Fanconi syndrome.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Acute pancreatitis has been reported,
particularly in children and adolescents.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text style='margin-top:0in;page-break-after:avoid;background:white'><u><span
style='font-size:11.0pt;color:black'>Reporting of suspected adverse reactions</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Reporting suspected adverse
reactions after authorisation of the medicinal product is important. It allows
continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions <span
style='background:#D9D9D9'>via the national reporting system listed in </span></span><span
style='color:black'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='font-size:11.0pt;background:#D9D9D9'>Appendix V</span></a></span><span
lang=EN-GB style='font-size:11.0pt;color:black'>.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.9     Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Early signs of acute overdose are
digestive effects such as abdominal pain, diarrhoea, nausea and vomiting.
Hepatic and renal disorders have been reported, including cases of liver enzyme
and creatinine increased with recovery after treatment discontinuation. An
erroneously administered single dose of 90&nbsp;mg/kg led to Fanconi syndrome
which resolved after treatment.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>There is no specific antidote
for deferasirox. Standard procedures for management of overdose may be
indicated as well as symptomatic treatment,</span><span style='font-size:11.0pt;
color:black'> as medically appropriate.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>5.       PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>5.1     Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Pharmacotherapeutic group: Iron
chelating agents, ATC code: V03AC03</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Mechanism
of action</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox is an orally active chelator
that is highly selective for iron (III). It is a tridentate ligand that binds
iron with high affinity in a 2:1 ratio. Deferasirox promotes excretion of iron,
primarily in the faeces. Deferasirox has low affinity for zinc and copper, and
does not cause constant low serum levels of these metals.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Pharmacodynamic
effects</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In an iron&#8209;balance metabolic study
in iron&#8209;overloaded adult thalassaemic patients, deferasirox at daily
doses of 10, 20 and 40&nbsp;mg/kg (dispersible tablet formulation) induced the
mean net excretion of 0.119, 0.329 and 0.445&nbsp;mg&nbsp;Fe/kg body
weight/day, respectively.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Clinical
efficacy and safety</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Clinical efficacy studies were conducted
with deferasirox dispersible tablets.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox has been investigated in
411&nbsp;adult (age </span><span style='font-size:11.0pt;font-family:Symbol;
color:black'>³</span><span style='font-size:11.0pt;color:black'>16&nbsp;years)
and 292&nbsp;paediatric patients (aged&nbsp;2 to &lt;16&nbsp;years) with
chronic iron overload due to blood transfusions. Of the paediatric patients 52
were aged&nbsp;2 to 5&nbsp;years. The underlying conditions requiring
transfusion included beta&#8209;thalassaemia, sickle cell disease and other
congenital and acquired anaemias (myelodysplastic syndromes [MDS], Diamond&#8209;Blackfan
syndrome, aplastic anaemia and other very rare anaemias).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Daily treatment with the deferasirox
dispersible tablet formulation at doses of 20 and 30&nbsp;mg/kg for one year in
frequently transfused adult and paediatric patients with beta&#8209;thalassaemia
led to reductions in indicators of total body iron; liver iron concentration
was reduced by about &#8209;0.4 and &#8209;8.9&nbsp;mg&nbsp;Fe/g liver (biopsy
dry weight (dw)) on average, respectively, and serum ferritin was reduced by
about &#8209;36 and &#8209;926&nbsp;µg/l on average, respectively. At these
same doses the ratios of iron excretion: iron intake were 1.02 (indicating net
iron balance) and 1.67 (indicating net iron removal), respectively. Deferasirox
induced similar responses in iron&#8209;overloaded patients with other
anaemias. Daily doses of 10&nbsp;mg/kg (dispersible tablet formulation) for one
year could maintain liver iron and serum ferritin levels and induce net iron
balance in patients receiving infrequent transfusions or exchange transfusions.
Serum ferritin assessed by monthly monitoring reflected changes in liver iron
concentration indicating that trends in serum ferritin can be used to monitor
response to therapy. Limited clinical data (29&nbsp;patients with normal
cardiac function at baseline) using MRI indicate that treatment with deferasirox
10&#8209;30&nbsp;mg/kg/day (dispersible tablet formulation) for 1&nbsp;year may
also reduce levels of iron in the heart (on average, MRI T2* increased from
18.3 to 23.0&nbsp;milliseconds).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The principal analysis of the pivotal
comparative study in 586&nbsp;patients suffering from beta&#8209;thalassaemia
and transfusional iron overload did not demonstrate non&#8209;inferiority of deferasirox
dispersible tablets to deferoxamine in the analysis of the total patient
population. It appeared from a post&#8209;hoc analysis of this study that, in
the subgroup of patients with liver iron concentration &#8805;7&nbsp;mg Fe/g dw
treated with deferasirox dispersible tablets (20 and 30&nbsp;mg/kg) or
deferoxamine (35 to &#8805;50&nbsp;mg/kg), the non&#8209;inferiority criteria
were achieved. However, in patients with liver iron concentration &lt;7&nbsp;mg
Fe/g dw treated with deferasirox dispersible tablets (5 and 10&nbsp;mg/kg) or
deferoxamine (20 to 35&nbsp;mg/kg), non&#8209;inferiority was not established
due to imbalance in the dosing of the two chelators. This imbalance occurred
because patients on deferoxamine were allowed to remain on their pre&#8209;study
dose even if it was higher than the protocol specified dose. Fifty&#8209;six&nbsp;patients
under the age of 6&nbsp;years participated in this pivotal study, 28 of them
receiving deferasirox dispersible tablets.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>It appeared from preclinical and clinical
studies that deferasirox dispersible tablets could be as active as deferoxamine
when used in a dose ratio of 2:1 (i.e. a dose of deferasirox dispersible
tablets that is numerically half of the deferoxamine dose). For deferasirox
film&#8209;coated tablets, a dose ratio of 3:1 can be considered (i.e. a dose
of deferasirox film&#8209;coated tablets that is numerically one third of the
deferoxamine dose). However, this dosing recommendation was not prospectively
assessed in the clinical studies.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In addition, in patients with liver iron
concentration &#8805;7&nbsp;mg Fe/g dw with various rare anaemias or sickle
cell disease, deferasirox dispersible tablets up to 20 and 30&nbsp;mg/kg
produced a decrease in liver iron concentration and serum ferritin comparable
to that obtained in patients with beta&#8209;thalassaemia.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>A placebo-controlled randomised study was
performed in 225&nbsp;patients with MDS (Low/Int-1 risk) and transfusional iron
overload. The results of this study suggest that there is a positive impact of
deferasirox on event-free survival (EFS, a composite endpoint including
non-fatal cardiac or liver events) and serum ferritin levels. The safety
profile was consistent with previous studies in adult MDS patients.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a 5-year observational study in which
267&nbsp;children aged 2 to &lt;6&nbsp;years (at enrollment) with transfusional
haemosiderosis received deferasirox, there were no clinically meaningful
differences in the safety and tolerability profile of Exjade in paediatric
patients aged 2 to &lt;6&nbsp;years compared to the overall adult and older
paediatric population, including increases in serum creatinine of &gt;33% and
above the upper limit of normal on &#8805;2&nbsp;consecutive occasions (3.1%),
and elevation of alanine aminotransferase (ALT) greater than 5&nbsp;times the
upper limit of normal (4.3%). Single events of increase in ALT and aspartate
aminotransferase were reported in 20.0% and 8.3%, respectively, of the
145&nbsp;patients who completed the study.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a study to assess the safety of
deferasirox film-coated and dispersible tablets, 173 adult and paediatric
patients with transfusion dependent thalassaemia or myelodysplastic syndrome
were treated for 24&nbsp;weeks. A comparable safety profile for film-coated and
dispersible tablets was observed.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In patients with non&#8209;transfusion&#8209;dependent
thalassaemia syndromes and iron overload, treatment with deferasirox
dispersible tablets was assessed in a 1&#8209;year, randomised, double&#8209;blind,
placebo&#8209;controlled study. The study compared the efficacy of two
different deferasirox dispersible tablet regimens (starting doses of 5 and
10&nbsp;mg/kg/day, 55&nbsp;patients in each arm) and of matching placebo
(56&nbsp;patients). The study enrolled 145&nbsp;adult and 21&nbsp;paediatric
patients. The primary efficacy parameter was the change in liver iron
concentration (LIC) from baseline after 12&nbsp;months of treatment. One of the
secondary efficacy parameters was the change in serum ferritin between baseline
and fourth quarter. At a starting dose of 10&nbsp;mg/kg/day, deferasirox
dispersible tablets led to reductions in indicators of total body iron. On
average, liver iron concentration decreased by 3.80&nbsp;mg Fe/g dw in patients
treated with deferasirox dispersible tablets (starting dose 10&nbsp;mg/kg/day)
and increased by 0.38&nbsp;mg Fe/g dw in patients treated with placebo
(p&lt;0.001). On average, serum ferritin decreased by 222.0&nbsp;µg/l in
patients treated with deferasirox dispersible tablets (starting dose
10&nbsp;mg/kg/day) and increased by 115&nbsp;µg/l in patients treated with
placebo (p&lt;0.001).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>5.2     Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoCommentText style='background:white'><span style='font-size:11.0pt;
color:black'>EXJADE film&#8209;coated tablets demonstrate higher
bioavailability compared to the EXJADE dispersible tablet formulation. After adjustment
of the strength, the film&#8209;coated tablet formulation (360&nbsp;mg
strength) was equivalent to EXJADE dispersible tablets (500&nbsp;mg strength)
with respect to the mean area under the plasma concentration time curve (AUC)
under fasting conditions. The C<sub>max</sub> was increased by 30% (90% CI:
20.3% &#8209; 40.0%); however a clinical exposure/response analysis revealed no
evidence of clinically relevant effects of such an increase.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><u><span style='color:black'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Absorption</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox (dispersible tablet
formulation) is absorbed following oral administration with a median time to
maximum plasma concentration (t<sub>max</sub>) of about 1.5 to 4&nbsp;hours.
The absolute bioavailability (AUC) of deferasirox (dispersible tablet
formulation) is about 70% compared to an intravenous dose. The absolute
bioavailability of the film&#8209;coated tablet formulation has not been
determined. Bioavailability of deferasirox film&#8209;coated tablets was 36% greater
than that with dispersible tablets.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>A food&#8209;effect study involving
administration of the film&#8209;coated tablets to healthy volunteers under
fasting conditions and with a low&#8209;fat (fat content &lt;10% of calories)
or high&#8209;fat (fat content &gt;50% of calories) meal indicated that the AUC
and C<sub>max</sub> were slightly decreased after a low&#8209;fat meal (by 11%
and 16%, respectively). After a high&#8209;fat meal, AUC and C<sub>max</sub>
were increased (by 18% and 29%, respectively). The increases in C<sub>max</sub>
due to the change in formulation and due to the effect of a high&#8209;fat meal
may be additive and therefore, it is recommended that the film&#8209;coated
tablets should be taken either on an empty stomach or with a light meal.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Distribution</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox is highly (99%) protein bound
to plasma proteins, almost exclusively serum albumin, and has a small volume of
distribution of approximately 14&nbsp;litres in adults.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Biotransformation</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Glucuronidation is the main metabolic
pathway for deferasirox, with subsequent biliary excretion. Deconjugation of
glucuronidates in the intestine and subsequent reabsorption (enterohepatic
recycling) is likely to occur: in a healthy volunteer study, the administration
of cholestyramine after a single dose of deferasirox resulted in a 45% decrease
in deferasirox exposure (AUC).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox is mainly glucuronidated by
UGT1A1 and to a lesser extent UGT1A3. CYP450&#8209;catalysed (oxidative)
metabolism of deferasirox appears to be minor in humans (about 8%). No
inhibition of deferasirox metabolism by hydroxyurea was observed <i>in vitro</i></span><span
lang=EN-GB style='font-size:11.0pt;color:black'>.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Elimination</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox and its metabolites are
primarily excreted in the faeces (84% of the dose). Renal excretion of
deferasirox and its metabolites is minimal (8% of the dose). The mean
elimination half&#8209;life (t<sub>1/2</sub>) ranged from 8 to 16&nbsp;hours.
The transporters MRP2 and MXR (BCRP) are involved in the biliary excretion of
deferasirox.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Linearity / non&#8209;linearity</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The C<sub>max</sub> and AUC<sub>0&#8209;24h</sub>
of deferasirox increase approximately linearly with dose under steady&#8209;state
conditions. Upon multiple dosing exposure increased by an accumulation factor
of 1.3 to 2.3</span><span lang=EN-GB style='font-size:11.0pt;color:black'>.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Characteristics in patients</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><span style='font-size:11.0pt;color:black'>Paediatric
patients</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The overall exposure of adolescents </span><span
lang=EN-GB style='font-size:11.0pt;color:black'>(12 to &#8804;17</span><span
style='font-size:11.0pt;color:black'>&nbsp;</span><span lang=EN-GB
style='font-size:11.0pt;color:black'>years) </span><span style='font-size:11.0pt;
color:black'>and children </span><span lang=EN-GB style='font-size:11.0pt;
color:black'>(2 to &lt;12&nbsp;years)</span><span style='font-size:11.0pt;
color:black'> to deferasirox after single and multiple doses was lower than
that in adult patients.</span><span lang=EN-GB style='font-size:11.0pt;
color:black'> In children younger than 6&nbsp;years old exposure was about 50%
lower than in adults. Since dosing is individually adjusted according to
response this is not expected to have clinical consequences.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><span style='font-size:11.0pt;color:black'>Gender</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Females have a moderately lower apparent
clearance (by 17.5%) for deferasirox compared to males. </span><span
lang=EN-GB style='font-size:11.0pt;color:black'>Since dosing is individually
adjusted according to response this is not expected to have clinical
consequences.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><span style='font-size:11.0pt;color:black'>Elderly
patients</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>The pharmacokinetics of
deferasirox have not been studied in elderly </span><span style='font-size:
11.0pt;color:black'>patients (aged&nbsp;65 or older).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><span style='font-size:11.0pt;color:black'>Renal or
hepatic impairment</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The pharmacokinetics of deferasirox have
not been studied in patients with renal impairment. The pharmacokinetics of
deferasirox were not influenced by liver transaminase levels up to 5&nbsp;times
the upper limit of the normal range.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a clinical study using single doses of
20&nbsp;mg/kg deferasirox dispersible tablets, the average exposure was
increased by 16% in subjects with mild hepatic impairment (Child&#8209;Pugh
Class A) and by 76% in subjects with moderate hepatic impairment (Child&#8209;Pugh
Class B) compared to subjects with normal hepatic function. The average C<sub>max</sub>
of deferasirox in subjects with mild or moderate hepatic impairment was
increased by 22%. Exposure was increased 2.8&#8209;fold in one subject with
severe hepatic impairment (Child&#8209;Pugh Class C) (see sections 4.2 and
4.4).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>5.3     Preclinical safety data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Non&#8209;clinical data reveal no special
hazard for humans based on conventional studies of safety pharmacology,
repeated dose toxicity, genotoxicity or carcinogenic potential. The main
findings were kidney toxicity and lens opacity (cataracts). Similar findings
were observed in neonatal and juvenile animals. The kidney toxicity is
considered mainly due to iron deprivation in animals that were not previously
overloaded with iron.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Tests of genotoxicity <i>in vitro</i> were
negative (Ames test, chromosomal aberration test) while deferasirox caused
formation of micronuclei <i>in vivo</i> in the bone marrow, but not liver, of
non&#8209;iron&#8209;loaded rats at lethal doses. No such effects were observed
in iron&#8209;preloaded rats. Deferasirox was not carcinogenic when
administered to rats in a 2&#8209;year study and transgenic p53+/- heterozygous
mice in a 6&#8209;month study.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The potential for toxicity to reproduction
was assessed in rats and rabbits. Deferasirox was not teratogenic, but caused
increased frequency of skeletal variations and stillborn pups in rats at high
doses that were severely toxic to the non&#8209;iron&#8209;overloaded mother</span><span
lang=EN-GB style='font-size:11.0pt;color:black'>. </span><span
style='font-size:11.0pt;color:black'>Deferasirox did not cause other effects on
fertility or reproduction</span><span lang=EN-GB style='font-size:11.0pt;
color:black'>.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.       PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.1     List of excipients</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Tablet
core</span></u><span style='font-size:11.0pt;color:black'>:</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=IT style='font-size:11.0pt;color:black'>Cellulose, microcrystalline</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=IT style='font-size:11.0pt;color:black'>Crospovidone</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=IT style='font-size:11.0pt;color:black'>Povidone</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=IT style='font-size:11.0pt;color:black'>Magnesium stearate</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Silica, colloidal anhydrous</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Poloxamer</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Coating
material</span></u><span style='font-size:11.0pt;color:black'>:</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=IT style='font-size:11.0pt;color:black'>Hypromellose</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=IT style='font-size:11.0pt;color:black'>Titanium dioxide (E171)</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=IT style='font-size:11.0pt;color:black'>Macrogol (4000)</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=IT style='font-size:11.0pt;color:black'>Talc</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=IT style='font-size:11.0pt;color:black'>Indigo carmine aluminium lake
(E132)</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=IT
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.3     Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>3&nbsp;years</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.4     Special precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>This medicinal product does not require
any special storage conditions.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.5     Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>PVC/PVDC/Aluminium blisters.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Unit packs containing 30 or 90&nbsp;film&#8209;coated
tablets</span><span style='font-size:11.0pt;color:black'> </span><span
style='font-size:11.0pt;color:black'>or multipacks containing 300
(10&nbsp;packs of 30) film&#8209;coated tablets.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.6     Special precautions for disposal</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>No special requirements.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>7.       MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>8.       MARKETING AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
90&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>EU/1/06/356/01</span><span lang=PT
style='color:black'>1</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>EU/1/06/356/01</span><span lang=PT
style='color:black'>2</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>EU/1/06/356/01</span><span lang=PT style='color:black'>3</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
180&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>EU/1/06/356/01</span><span lang=PT
style='color:black'>4</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>EU/1/06/356/015</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>EU/1/06/356/01</span><span lang=PT style='color:black'>6</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
360&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>EU/1/06/356/017</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>EU/1/06/356/01</span><span lang=PT
style='color:black'>8</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>EU/1/06/356/019</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=PT>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Date of first authorisation: 28
August 2006</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Date of latest renewal:</span><span lang=EN-GB
style='color:black'> 18 April 2016</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><b><span lang=EN-GB style='color:black'>10.     DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Detailed information on this </span><span
lang=EN-GB style='color:black'>medicinal</span><span lang=EN-GB
style='color:black'> product </span><span lang=EN-GB style='color:black'>is
available on the website of the European Medicines Agency </span><span
lang=EN-GB style='color:black'><a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'><img border=0 width=21 height=18
src="Exjade-II-073-EN%20PI_files/image004.gif"></span><span lang=EN-GB
style='color:black'>This medicinal product is subject to additional monitoring.
This will allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions. See section
4.8 for how to report adverse reactions.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;background:white'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>1.       NAME OF THE MEDICINAL
PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE 90&nbsp;mg granules in sachet</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE 180&nbsp;mg granules in sachet</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE 360&nbsp;mg granules in sachet</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span style='color:black'>2.       QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><i><span style='color:black'>&nbsp;</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
90&nbsp;mg granules</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Each sachet contains 90&nbsp;mg
deferasirox.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
180&nbsp;mg granules</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Each sachet contains 180&nbsp;mg
deferasirox.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
360&nbsp;mg granules</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Each sachet contains 360&nbsp;mg
deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>For the full list of excipients, see section
6.1.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>3.       PHARMACEUTICAL <span style='text-transform:uppercase'>form</span></span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Granules in sachet (granules)</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>White to almost white granules</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black;text-transform:uppercase'>4.       Clinical particulars</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.1     Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>EXJADE
is indicated for the treatment of chronic iron overload due to frequent blood
transfusions (</span><span lang=EN-GB style='font-family:Symbol;color:black'>³</span><span
lang=EN-GB style='color:black'>7&nbsp;ml/kg/month of packed red blood cells) in
patients with beta thalassaemia major aged 6&nbsp;years and older.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>EXJADE is also indicated for the treatment of
chronic iron overload due to blood transfusions when deferoxamine therapy is
contraindicated or inadequate in the following patient groups:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white'><span lang=EN-GB style='color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>in paediatric patients with
beta thalassaemia major with iron overload due to frequent blood transfusions (</span><span
lang=EN-GB style='font-family:Symbol;color:black'>³</span><span lang=EN-GB
style='color:black'>7&nbsp;ml/kg/month of packed red blood cells) aged 2 to
5&nbsp;years,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white'><span lang=EN-GB style='color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>in adult and paediatric
patients with beta thalassaemia major with iron overload due to infrequent
blood transfusions (</span><span lang=EN-GB style='color:black'>&lt;</span><span
lang=EN-GB style='color:black'>7&nbsp;ml/kg/month of packed red blood cells)
aged 2&nbsp;years and older,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white'><span lang=EN-GB style='color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>in adult and paediatric
patients with other anaemias aged 2&nbsp;years and older.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>EXJADE is also indicated for the treatment of chronic iron
overload requiring chelation therapy when deferoxamine therapy is
contraindicated or inadequate in patients with non&#8209;transfusion&#8209;dependent
thalassaemia syndromes aged 10&nbsp;years and older.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.2     Posology and method of administration</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Treatment with EXJADE should be initiated
and maintained by physicians experienced in the treatment of chronic iron
overload.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Posology</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><u><span style='font-size:11.0pt;color:black'>Transfusional
iron overload</span></u></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>It is recommended that treatment be
started after the transfusion of approximately 20&nbsp;units (about
100&nbsp;ml/kg) of packed red blood cells (PRBC) or when there is evidence from
clinical monitoring that chronic iron overload is present (e.g. serum ferritin
&gt;1,000&nbsp;µg/l). Doses (in mg/kg) must be calculated and rounded to the
nearest whole sachet size.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The goals of iron chelation therapy are to
remove the amount of iron administered in transfusions and, as required, to
reduce the existing iron burden.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Caution should be taken during chelation
therapy to minimise the risk of overchelation in all patients (see section&nbsp;4.4).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE granules demonstrate higher
bioavailability compared to the EXJADE dispersible tablet formulation (see section&nbsp;5.2).
In case of switching from dispersible tablets to granules, the dose of the granules
should be 30% lower than the dose of the dispersible tablets, rounded to the
nearest whole sachet.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The corresponding doses for the different
formulations are shown in the table below.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><u><span style='color:black'>Table&nbsp;1</span></u><span
style='color:black'>        Recommended doses for transfusional iron overload</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=623
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span lang=EN-GB style='color:black'>Film&#8209;coated
  tablets/granules</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Dispersible tablets</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Transfusions</span></b></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Serum ferritin</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Starting dose</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span lang=EN-GB style='color:black'>14&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>20&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>After 20&nbsp;units (about 100&nbsp;ml/kg)
  of PRBC</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>or</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&gt;1,000&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Alternative starting doses</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span lang=EN-GB style='color:black'>21&nbsp;mg/kg/day</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>30&nbsp;mg/kg/day</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&gt;14&nbsp;ml/kg/month of PRBC
  (approx. &gt;4&nbsp;units/month for an adult)</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span lang=EN-GB style='color:black'>7&nbsp;mg/kg/day</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>10&nbsp;mg/kg/day</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&lt;7&nbsp;ml/kg/month of PRBC
  (approx. &lt;2&nbsp;units/month for an adult)</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>For patients well managed on
  deferoxamine</span></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>One third of deferoxamine dose</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>Half of deferoxamine dose</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Monitoring</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Monthly</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Target range</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>500&#8209;1,000&nbsp;µg/</span></b><span
  style='color:black'>l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 rowspan=6 valign=top style='width:78.0pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Adjustment steps</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>(every 3&#8209;6&nbsp;months)</span></p>
  </td>
  <td width=265 colspan=2 valign=top style='width:198.45pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;background:white'><b><span style='color:black'>Increase</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&gt;2,500&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span lang=EN-GB style='color:black'>3.5 &#8209;
  7&nbsp;mg/kg/day</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>Up to 28&nbsp;mg/kg/day</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>5&#8209;10&nbsp;mg/kg/day</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>Up to 40&nbsp;mg/kg/day</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=265 colspan=2 valign=top style='width:198.45pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;background:white'><b><span style='color:black'>Decrease</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span lang=EN-GB style='color:black'>3.5 &#8209;
  7&nbsp;mg/kg/day</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>5&#8209;10&nbsp;mg/kg/day</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&lt;2,500&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>In patients treated with doses
  &gt;21&nbsp;mg/kg/day</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>In patients treated with doses
  &gt;30&nbsp;mg/kg/day</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=265 colspan=2 valign=top style='width:198.45pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal;page-break-after:avoid;background:white'><span style='color:black'>-<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span style='color:black'>When target is reached</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>500&#8209;1,000&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Maximum dose</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span lang=EN-GB style='color:black'>28&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>40&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>Consider interruption</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=29 valign=top style='width:21.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=104 valign=top style='width:77.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white'><b><span style='color:black'>&lt;500&nbsp;µg/l</span></b></p>
  </td>
 </tr>
</table>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Starting dose</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The recommended initial daily dose of
EXJADE granules is 14&nbsp;mg/kg body weight.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>An initial daily dose of 21&nbsp;mg/kg may
be considered for patients who require reduction of elevated body iron levels
and who are also receiving more than 14&nbsp;ml/kg/month of packed red blood
cells (approximately &gt;4&nbsp;units/month for an adult).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>An initial daily dose of 7&nbsp;mg/kg may
be considered for patients </span><span lang=EN-GB style='font-size:11.0pt;
color:black'>who do not require reduction of body iron levels and who are also </span><span
style='font-size:11.0pt;color:black'>receiving less than 7&nbsp;ml/kg/month of
packed red blood cells (approximately &lt;2&nbsp;units/month for an adult). The
patients response must be monitored and a dose increase should be considered
if sufficient efficacy is not obtained (see section 5.1).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>For patients already well managed on
treatment with deferoxamine, a starting dose of EXJADE granules that is
numerically one third that of the deferoxamine dose could be considered (e.g. a
patient receiving 40&nbsp;mg/kg/day of deferoxamine for 5&nbsp;days per week
(or equivalent) could be transferred to a starting daily dose of
14&nbsp;mg/kg/day of EXJADE granules). When this results in a daily dose less
than 14&nbsp;mg/kg body weight, the patients response must be monitored and a
dose increase should be considered if sufficient efficacy is not obtained (see
section 5.1).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Dose adjustment</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>It is recommended that serum ferritin be
monitored every month and that the dose of EXJADE be adjusted, if necessary,
every 3 to 6&nbsp;months based on the trends in serum ferritin. Dose
adjustments may be made in steps of 3.5 to 7&nbsp;mg/kg and are to be tailored
to the individual patients response and therapeutic goals (maintenance or
reduction of iron burden). In patients not adequately controlled with doses of
21&nbsp;mg/kg (e.g. serum ferritin levels persistently above 2,500&nbsp;µg/l
and not showing a decreasing trend over time), doses of up to 28&nbsp;mg/kg may
be considered. The availability of long&#8209;term efficacy and safety data from
clinical studies conducted with EXJADE dispersible tablets used at doses above
30&nbsp;mg/kg is currently limited (264&nbsp;patients followed for an average
of 1&nbsp;year after dose escalation). If only very poor haemosiderosis control
is achieved at doses up to 21&nbsp;mg/kg, a further increase (to a maximum of
28&nbsp;mg/kg) may not achieve satisfactory control, and alternative treatment
options may be considered. If no satisfactory control is achieved at doses
above 21&nbsp;mg/kg, treatment at such doses should not be maintained and alternative
treatment options should be considered whenever possible. Doses above
28&nbsp;mg/kg are not recommended because there is only limited experience with
doses above this level (see section 5.1).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In patients treated with doses greater
than 21&nbsp;mg/kg, dose reductions in steps of 3.5 to 7&nbsp;mg/kg should be
considered when control has been achieved (e.g. serum ferritin levels
persistently below 2,500&nbsp;µg/l and showing a decreasing trend over time).
In patients whose serum ferritin level has reached the target (usually between
500 and 1,000&nbsp;µg/l), dose reductions in steps of 3.5 to 7&nbsp;mg/kg
should be considered to maintain serum ferritin levels within the target range and
to minimise the risk of overchelation. If serum ferritin falls consistently
below 500&nbsp;µg/l, an interruption of treatment should be considered (see
section 4.4).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><i><u><span style='color:black'>Non&#8209;transfusion&#8209;dependent
thalassaemia syndromes</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><u><span style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Chelation therapy should only be initiated when there is
evidence of iron overload (liver iron concentration [LIC] &#8805;5&nbsp;mg Fe/g
dry weight [dw] or serum ferritin consistently &gt;800&nbsp;</span><span
lang=EN-GB style='color:black'>µg</span><span style='color:black'>/l). LIC is
the preferred method of iron overload determination and should be used wherever
available. Caution should be taken during chelation therapy to minimise the
risk of overchelation in all patients (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXJADE granules demonstrate higher
bioavailability compared to the EXJADE dispersible tablet formulation (see
section 5.2). In case of switching from dispersible tablets to granules, the
dose of the granules should be 30% lower than the dose of </span><span
style='color:black'>the dispersible tablets</span><span lang=EN-GB
style='color:black'>, rounded to the nearest whole sachet.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>The corresponding doses for the different formulations are
shown in the table below.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Table&nbsp;2</span></u><span
style='font-size:11.0pt;color:black'>        Recommended doses for non&#8209;transfusion&#8209;dependent
thalassaemia syndromes</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=614
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Film&#8209;coated
  tablets/granules</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Dispersible tablets</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Liver iron
  concentration (LIC)*</span></b></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Serum ferritin</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Starting dose</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>7&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>10&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&#8805;5&nbsp;mg Fe/g
  dw</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>or</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&gt;800&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Monitoring</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Monthly</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 rowspan=4 valign=top style='width:78.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Adjustment steps</span></b></p>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>(every 3&#8209;6&nbsp;months)</span></p>
  </td>
  <td width=255 colspan=2 valign=top style='width:191.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><b><span style='font-family:"Times New Roman",serif;
  color:black'>Increase</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&#8805;7&nbsp;mg Fe/g
  dw</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>or</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&gt;2,000&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>3.5 &#8209;
  7&nbsp;mg/kg/day</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>5&#8209;10&nbsp;mg/kg/day</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=255 colspan=2 valign=top style='width:191.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><b><span style='font-family:"Times New Roman",serif;
  color:black'>Decrease</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&lt;7&nbsp;mg Fe/g dw</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>or</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='color:black'>&#8804;</span><span style='font-family:"Times New Roman",serif;
  color:black'>2,000&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>3.5 &#8209;
  7&nbsp;mg/kg/day</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>5&#8209;10&nbsp;mg/kg/day</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Maximum dose</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:dotted windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>14&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:dotted windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>20&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:dotted windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;border-bottom:dotted windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;border-bottom:dotted windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:16.9pt'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:16.9pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:16.9pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>7&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:16.9pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>10&nbsp;mg/kg/day</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:16.9pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:16.9pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:16.9pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=255 colspan=2 valign=top style='width:191.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><span style='font-family:"Times New Roman",serif;
  color:black'>For adults</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>not assessed</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>and</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='color:black'>&#8804;</span><span style='font-family:"Times New Roman",serif;
  color:black'>2,000&nbsp;µg/l</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=255 colspan=2 valign=top style='width:191.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><span style='font-family:"Times New Roman",serif;
  color:black'>For paediatric patients</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Interruption</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&lt;3&nbsp;mg Fe/g dw</span></b></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>or</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>&lt;300&nbsp;µg/l</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=104 valign=top style='width:78.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Retreatment</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><b><span style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><b><span style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></b></p>
  </td>
  <td width=255 colspan=3 valign=top style='width:191.35pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid;background:white'><b><span style='font-family:"Times New Roman",serif;
  color:black'>Not recommended</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>*LIC is the preferred method of iron overload
determination.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Starting dose</span></i></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>The recommended initial daily dose of EXJADE granules in
patients with non&#8209;transfusion&#8209;dependent thalassaemia syndromes is
7&nbsp;mg/kg body weight.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Dose adjustment</span></i></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>It is recommended that serum ferritin be monitored every
month to assess the patients response to therapy and to minimise the risk of
overchelation (see section&nbsp;4.4). After every 3 to 6&nbsp;months of
treatment, a dose increase in increments of 3.5 to 7&nbsp;mg/kg should be
considered if the patients LIC is &#8805;7&nbsp;mg Fe/g dw, or if serum
ferritin is consistently &gt;2,000&nbsp;</span><span lang=EN-GB
style='color:black'>µ</span><span style='color:black'>g/l and not showing a
downward trend, and the patient is tolerating the medicinal product well. Doses
above 14&nbsp;mg/kg are not recommended because there is no experience with
doses above this level in patients with non&#8209;transfusion&#8209;dependent
thalassaemia syndromes.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>In patients in whom LIC was not assessed and serum ferritin
is &#8804;2,000&nbsp;</span><span lang=EN-GB style='color:black'>µg</span><span
style='color:black'>/l, dosing should not exceed 7&nbsp;mg/kg.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>For patients in whom the dose was increased to
&gt;7&nbsp;mg/kg, dose reduction to 7&nbsp;mg/kg or less is recommended when
LIC is &lt;7&nbsp;mg Fe/g dw or serum ferritin is &#8804;2,000&nbsp;</span><span
lang=EN-GB style='color:black'>µg</span><span style='color:black'>/l.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><span lang=EN-GB style='font-size:11.0pt;color:black'>Treatment
cessation</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Once a satisfactory body iron
level has been achieved (LIC &lt;3&nbsp;mg Fe/g dw or serum ferritin
&lt;300&nbsp;</span><span style='font-size:11.0pt;color:black'>µg</span><span
lang=EN-GB style='font-size:11.0pt;color:black'>/l), treatment should be
stopped. There are no data available on the retreatment of patients who
reaccumulate iron after having achieved a satisfactory body iron level and
therefore retreatment cannot be recommended.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><u><span style='font-size:11.0pt;color:black'>Special
populations</span></u></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Elderly patients (&#8805;65&nbsp;years of age)</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The dosing recommendations for elderly
patients are the same as described above. In clinical studies, elderly patients
experienced a higher frequency of adverse reactions than younger patients (in
particular, diarrhoea) and should be monitored closely for adverse reactions
that may require a dose adjustment.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Paediatric population</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>Transfusional
iron overload:</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The dosing recommendations for paediatric
patients aged 2 to 17&nbsp;years with transfusional iron overload are the same
as for adult patients (see section&nbsp;4.2). It is recommended that serum
ferritin be monitored every month to assess the patients response to therapy
and to minimise the risk of overchelation (see section&nbsp;4.4). Changes in
weight of paediatric patients over time must be taken into account when
calculating the dose.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In children with transfusional iron
overload aged between 2 and 5&nbsp;years, exposure is lower than in adults (see
section 5.2). This age group may therefore require higher doses than are
necessary in adults. However, the initial dose should be the same as in adults,
followed by individual titration.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span lang=FR-CH style='font-size:11.0pt;color:black'>Non&#8209;transfusion&#8209;dependent
thalassaemia syndromes:</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>In paediatric patients with non&#8209;transfusion&#8209;dependent
thalassaemia syndromes, dosing should not exceed 7&nbsp;mg/kg. In these
patients, closer monitoring of LIC and serum ferritin is essential to avoid
overchelation (see section&nbsp;4.4). In addition to monthly serum ferritin
assessments, LIC should be monitored every three months when serum ferritin is
&#8804;800&nbsp;</span><span lang=EN-GB style='color:black'>µg</span><span
style='color:black'>/l.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span lang=EN-GB style='font-size:11.0pt;color:black'>Children
from birth to 23&nbsp;months:</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The safety and efficacy of EXJADE in
children from birth to 23&nbsp;months of age have not been established. No data
are available.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Patients with renal impairment</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE has not been studied in patients
with renal impairment and is contraindicated in patients with estimated
creatinine clearance &lt;60&nbsp;ml/min (see sections 4.3 and 4.4).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><i><span lang=EN-GB
style='color:black'>Patients with hepatic impairment</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE is not recommended in patients with
severe hepatic impairment (Child&#8209;Pugh Class C). In patients with moderate
hepatic impairment (Child&#8209;Pugh Class B), the dose should be considerably
reduced followed by progressive increase up to a limit of 50% (see sections 4.4
and 5.2), and EXJADE must be used with caution in such patients. Hepatic
function in all patients should be monitored before treatment, every
2&nbsp;weeks during the first month and then every month (see section 4.4).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Method of
administration</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>For oral use.</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>The
granules should be </span><span style='color:black'>administered by sprinkling
the full dose onto soft food, e.g. yogurt or apple sauce (pureed apple). The
dose should be immediately and completely consumed, and not stored for future
use.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The soft food containing the </span><span
style='color:black'>granules</span><span style='font-size:11.0pt;color:black'>
should be taken with or without a light meal, once a day, preferably at the
same time each day (see sections 4.5 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.3     Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Hypersensitivity to the active substance or to
any of the excipients</span><span lang=EN-GB style='color:black'> listed in
section 6.1</span><span lang=EN-GB style='color:black'>.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Combination with other iron chelator therapies as the
safety of such combinations has not been established </span><span lang=EN-GB
style='color:black'>(see section 4.5)</span><span style='color:black'>.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Patients with estimated creatinine clearance
&lt;60&nbsp;ml/min.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.4     Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='page-break-after:avoid;background:white;border:none;
padding:0in'><u><span lang=EN-GB style='color:black'>Renal function</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>Deferasirox has </span><span lang=EN-GB
style='color:black'>been studied only in patients with baseline serum
creatinine within the age&#8209;appropriate normal range.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>During
clinical studies, increases in serum creatinine of &gt;33% on &#8805;2&nbsp;consecutive
occasions, sometimes above the upper limit of the normal range, occurred in
about 36% of patients. These were dose&#8209;dependent. About two&#8209;thirds
of the patients showing serum creatinine increase returned below the 33% level
without dose adjustment. In the remaining third the serum creatinine increase
did not always respond to a dose reduction or a dose interruption. In some
cases, only a stabilisation of the serum creatinine values has been observed
after dose reduction. Cases of acute renal failure have been reported following
post&#8209;marketing use of deferasirox (see section 4.8). In some post&#8209;marketing
cases, renal function deterioration has led to renal failure requiring
temporary or permanent dialysis.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>The causes of the rises</span><span lang=EN-GB
style='color:black'> in serum creatinine have not been elucidated.</span><span
lang=EN-GB style='color:black'> Particular attention should therefore be paid
to monitoring of serum creatinine in patients who are concomitantly receiving
medicinal products that depress renal function, and in patients who are
receiving high doses of deferasirox and/or low rates of transfusion
(&lt;7&nbsp;ml/kg/month of packed red blood cells or &lt;2&nbsp;units/month for
an adult). While no increase in renal adverse events was observed after dose
escalation of EXJADE dispersible tablets to doses above 30&nbsp;mg/kg in
clinical studies, an increased risk of renal adverse events with granule doses
above 21&nbsp;mg/kg cannot be excluded.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>It is recommended that serum creatinine be
assessed in duplicate before initiating therapy. <b>Serum creatinine,
creatinine clearance</b> (estimated with the Cockcroft&#8209;Gault or MDRD
formula in adults and with the Schwartz formula in children) and/or plasma
cystatin C levels<b> should be monitored prior to therapy, weekly in the first
month after initiation </b></span><b><span lang=EN-GB style='color:black'>or
modification </span><span lang=EN-GB style='color:black'>of therapy with EXJADE
(including switch of formulation), and monthly thereafter</span></b><span
lang=EN-GB style='color:black'>. Patients with pre&#8209;existing renal
conditions and patients who are receiving medicinal products that depress renal
function may be more at risk of complications. Care should be taken to maintain
adequate hydration in patients who develop diarrhoea or vomiting.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>There have been post&#8209;marketing reports of
metabolic acidosis occurring during treatment with deferasirox. The majority of
these patients had renal impairment, renal tubulopathy (Fanconi syndrome) or
diarrhoea, or conditions where acid&#8209;base imbalance is a known complication.
Acid&#8209;base balance should be monitored as clinically indicated in these
populations. Interruption of EXJADE therapy should be considered in patients
who develop metabolic acidosis.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>Post-marketing cases of severe forms of renal tubulopathy
(such as Fanconi syndrome) and renal failure associated with changes in
consciousness in the context of hyperammonaemic encephalopathy have been
reported in patients treated with deferasirox, mainly in children. It is
recommended that hyperammonaemic encephalopathy be considered and ammonia
levels measured in patients who develop unexplained changes in mental status
while on Exjade therapy.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-before:always;page-break-after:avoid;
background:white;border:none;padding:0in'><u><span lang=EN-GB style='color:
black'>Table&nbsp;3</span></u><span lang=EN-GB style='color:black'>        Dose
adjustment and interruption of treatment for renal monitoring</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white;border:none;
padding:0in'><span style='position:relative;z-index:251668480'><span
style='position:absolute;left:1px;top:-7209px;width:604px;height:1px'><img
width=604 height=1 src="Exjade-II-073-EN%20PI_files/image007.gif"
alt="	Serum creatinine		Creatinine clearance&#13;&#10;Before initiation of therapy	Twice (2x)	and	Once (1x)&#13;&#10;Contraindicated			&lt;60 ml/min&#13;&#10;Monitoring			&#13;&#10;-	First month after start of therapy or dose modification (including switch of formulation)	Weekly	and	Weekly&#13;&#10;-	Thereafter	Monthly	and	Monthly&#13;&#10;Reduction of daily dose by 7 mg/kg/day (film-coated tablet formulation),&#13;&#10;if following renal parameters are observed at two consecutive visits and cannot be attributed to other causes&#13;&#10;Adult patients	&gt;33% above pre-treatment average	and	Decreases &lt;LLN* (&lt;90 ml/min)&#13;&#10;Paediatric patients	&gt; age appropriate ULN** 	and/or	Decreases &lt;LLN* (&lt;90 ml/min)&#13;&#10;After dose reduction, interrupt treatment, if&#13;&#10;Adult and paediatric	Remains &gt;33% above pre-treatment average	and/or	Decreases &lt;LLN* (&lt;90 ml/min)&#13;&#10;*LLN: lower limit of the normal range&#13;&#10;**ULN: upper limit of the normal range&#13;&#10;&#13;&#10;"></span></span><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<br clear=ALL>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>Treatment may be reinitiated depending on the
individual clinical circumstances.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>Dose reduction or interruption may be also considered
if abnormalities occur in levels of markers of renal tubular function and/or as
clinically indicated:</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>        Proteinuria (test should be performed
prior to therapy and monthly thereafter)</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>        Glycosuria in non&#8209;diabetics and
low levels of serum potassium, </span><span lang=EN-GB style='color:black'>phosphate,
magnesium or urate, phosphaturia, aminoaciduria (monitor as needed</span><span
lang=EN-GB style='color:black'>).</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>Renal tubulopathy has been mainly reported in
children and adolescents with beta&#8209;thalassaemia treated with EXJADE.</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>Patients should be referred to a renal specialist,
and further specialised investigations (such as renal biopsy) may be considered
if the following occur despite dose reduction and interruption:</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>        </span><span lang=EN-GB
style='color:black'>S</span><span lang=EN-GB style='color:black'>erum
creatinine </span><span lang=EN-GB style='color:black'>remains significantly </span><span
lang=EN-GB style='color:black'>elevated and</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><span lang=EN-GB style='color:black'>        </span><span
lang=EN-GB style='color:black'>Persistent </span><span lang=EN-GB
style='color:black'>abnormality </span><span lang=EN-GB style='color:black'>in
another marker of renal function </span><span lang=EN-GB style='color:black'>(</span><span
lang=EN-GB style='color:black'>e.g. </span><span lang=EN-GB style='color:black'>proteinuria,
Fanconi Syndrome).</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white;border:none;
padding:0in'><u><span lang=EN-GB style='color:black'>Hepatic function</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white;border:none;padding:0in'><span style='font-size:11.0pt;
color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>Liver
function test elevations have been observed in patients treated with
deferasirox. Post&#8209;marketing cases of hepatic failure, some of which were
fatal, have been reported. Severe forms associated with changes in
consciousness in the context of hyperammonaemic encephalopathy, may occur in
patients treated with deferasirox, particularly in children. It is recommended
that hyperammonaemic encephalopathy be considered and ammonia levels measured
in patients who develop unexplained changes in mental status while on Exjade
therapy. Care should be taken to maintain adequate hydration in patients who
experience volume-depleting events (such as diarrhoea or vomiting),
particularly in children with acute illness. Most reports of hepatic failure
involved patients with significant comorbidities including pre&#8209;existing
chronic liver conditions (including cirrhosis and hepatitis C)</span><span
style='color:black'> </span><span style='font-size:11.0pt;color:black'>and
multi-organ failure. The role of deferasirox as a contributing or aggravating
factor cannot be excluded (see section 4.8).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>It is
recommended that<b> </b>serum transaminases, bilirubin and alkaline phosphatase
be checked before the initiation of treatment, every 2&nbsp;weeks during the
first month and monthly thereafter. If there is a persistent and progressive
increase in serum transaminase levels that cannot be attributed to other
causes, EXJADE should be interrupted. Once the cause of the liver function test
abnormalities has been clarified or after return to normal levels, cautious re&#8209;initiation
of treatment at a lower dose followed by gradual dose escalation may be
considered.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>EXJADE is
not recommended in patients with severe hepatic impairment </span><span
lang=EN-GB style='font-size:11.0pt;color:black'>(Child&#8209;Pugh Class C)</span><span
style='font-size:11.0pt;color:black'> (see section 5.2).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white;border:none;padding:0in'><u><span style='font-size:11.0pt;
color:black'>Table&nbsp;4        Summary of safety monitoring recommendations</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='position:relative;z-index:251666432'><span
style='position:absolute;left:9px;top:-8272px;width:565px;height:1px'><img
width=565 height=1 src="Exjade-II-073-EN%20PI_files/image008.gif"
alt="Test	Frequency&#13;&#10;Serum creatinine	In duplicate prior to therapy.&#13;&#10;Weekly during first month of therapy or after dose modification (including switch of formulation).&#13;&#10;Monthly thereafter.&#13;&#10;Creatinine clearance and/or plasma cystatin C	Prior to therapy.&#13;&#10;Weekly during first month of therapy or after dose modification (including switch of formulation).&#13;&#10;Monthly thereafter.&#13;&#10;Proteinuria	Prior to therapy.&#13;&#10;Monthly thereafter.&#13;&#10;Other markers of renal tubular function (such as glycosuria in non-diabetics and low levels of serum potassium, phosphate, magnesium or urate, phosphaturia, aminoaciduria)	As needed.&#13;&#10;Serum transaminases, bilirubin, alkaline phosphatase	Prior to therapy.&#13;&#10;Every 2 weeks during first month of therapy.&#13;&#10;Monthly thereafter.&#13;&#10;Auditory and ophthalmic testing	Prior to therapy.&#13;&#10;Annually thereafter.&#13;&#10;Body weight, height and sexual development	Prior to therapy.&#13;&#10;Annually in paediatric patients.&#13;&#10;&#13;&#10;"></span></span><u><span
style='font-size:11.0pt;color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white;
border:none;padding:0in'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

</div>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<br clear=ALL>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>In patients with a short life expectancy (e.g.
high&#8209;risk myelodysplastic syndromes), especially when co&#8209;morbidities
could increase the risk of adverse events, the benefit of EXJADE might be
limited and may be inferior to risks. As a consequence, treatment with EXJADE
is not recommended in these patients.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Caution should be used in elderly patients due
to a higher frequency of adverse reactions (in particular, diarrhoea).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Data in children with non&#8209;transfusion&#8209;dependent
thalassaemia are very limited (see section 5.1). As a consequence, EXJADE
therapy should be closely monitored to detect adverse reactions and to follow
iron burden in the paediatric population. In addition, before treating heavily
iron&#8209;overloaded children with non&#8209;transfusion&#8209;dependent
thalassaemia with EXJADE, the physician should be aware that the consequences
of long&#8209;term exposure in such patients are currently not known.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Gastrointestinal
disorders</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Upper gastrointestinal ulceration and
haemorrhage have been reported in patients, including children and adolescents,
receiving deferasirox. Multiple ulcers have been observed in some patients (see
section 4.8). There have been reports of ulcers complicated with digestive
perforation. Also, there have been reports of fatal gastrointestinal
haemorrhages, especially in elderly patients who had haematological
malignancies and/or low platelet counts. Physicians and patients should remain
alert for signs and symptoms of gastrointestinal ulceration and haemorrhage
during EXJADE therapy. In case of gastrointestinal ulceration or haemorrhage, EXJADE
should be discontinued and additional evaluation and treatment must be promptly
initiated. Caution should be exercised in patients who are taking EXJADE in
combination with substances that have known ulcerogenic potential, such as
NSAIDs, corticosteroids, or oral bisphosphonates, in patients receiving
anticoagulants and in patients with platelet counts below 50,000/mm<sup>3</sup>
(50 x 10<sup>9</sup>/l) (see section 4.5).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><u><span style='font-size:11.0pt;color:black'>Skin disorders</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt;color:black'>Skin rashes may appear during EXJADE
treatment. The rashes resolve spontaneously in most cases. When interruption of
treatment may be necessary, treatment may be reintroduced after resolution of
the rash, at a lower dose followed by gradual dose escalation. In severe cases
this reintroduction could be conducted in combination with a short period of
oral steroid administration. Severe cutaneous adverse reactions (SCARs)
including</span><span style='font-size:11.0pt'> Stevens&#8209;Johnson syndrome
(SJS), toxic epidermal necrolysis (TEN) </span><span lang=EN-GB
style='font-size:11.0pt'>and drug reaction with eosinophilia and systemic
symptoms (DRESS), which could be life&#8209;threatening or fatal, </span><span
style='font-size:11.0pt'>have been reported. If any SCAR is suspected, EXJADE
should be discontinued immediately and should not be reintroduced.</span><span
lang=EN-GB style='font-size:11.0pt'> At the time of prescription, patients
should be advised of the signs and symptoms of severe skin reactions, and be
closely monitored.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Hypersensitivity
reactions</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Cases of serious hypersensitivity
reactions (such as anaphylaxis and angioedema) have been reported in patients
receiving deferasirox, with the onset of the reaction occurring in the majority
of cases within the first month of treatment (see section 4.8). If such
reactions occur, EXJADE should be discontinued and appropriate medical
intervention instituted. Deferasirox should not be reintroduced in patients who
have experienced a hypersensitivity reaction due to the risk of anaphylactic
shock (see section 4.3).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Vision
and hearing</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Auditory (decreased hearing) and ocular
(lens opacities) disturbances have been reported (see section 4.8). Auditory
and ophthalmic testing (including fundoscopy) is recommended before the start
of treatment and at regular intervals thereafter (every 12&nbsp;months). If
disturbances are noted during the treatment, dose reduction or interruption may
be considered.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Blood
disorders</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>There have been post&#8209;marketing
reports of leukopenia, thrombocytopenia or pancytopenia (or aggravation of
these cytopenias) and of aggravated anaemia in patients treated with
deferasirox. Most of these patients had pre&#8209;existing haematological
disorders that are frequently associated with bone marrow failure. However, a
contributory or aggravating</span><span style='font-size:11.0pt;color:navy'> </span><span
style='font-size:11.0pt;color:black'>role cannot be excluded. Interruption of
treatment should be considered in patients who develop unexplained cytopenia.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Other
considerations</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Monthly monitoring of serum ferritin is
recommended in order to assess the patients response to therapy and to avoid
overchelation (see section 4.2). Dose reduction or closer monitoring of renal
and hepatic function, and serum ferritin levels are recommended during periods
of treatments with high doses and when serum ferritin levels are close to the
target range. If serum ferritin falls consistently below 500&nbsp;µg/l (in
transfusional iron overload) or below 300&nbsp;µg/l (in non&#8209;transfusion&#8209;dependent
thalassaemia syndromes), an interruption of treatment should be considered.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The results of the tests for serum
creatinine, serum ferritin and serum transaminases should be recorded and
regularly assessed for trends.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In two clinical studies, growth and sexual
development of paediatric patients treated with deferasirox for up to
5&nbsp;years were not affected (see section&nbsp;4.8). However, as a general
precautionary measure in the management of paediatric patients with
transfusional iron overload, body weight, height and sexual development should
be monitored prior to therapy and at regular intervals (every 12&nbsp;months).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Cardiac dysfunction is a known
complication of severe iron overload. Cardiac function should be monitored in
patients with severe iron overload during long&#8209;term treatment with
EXJADE.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.5     Interaction with other medicinal products and other
forms of interaction</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The safety of deferasirox in combination
with other iron chelators has not been established. Therefore, it </span><span
style='font-size:11.0pt;color:black'>must not be combined with other iron
chelator therapies</span><span style='font-size:11.0pt;color:black'> (see
section 4.3).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Interaction
with food</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>There were no clinically relevant changes
in deferasirox pharmacokinetics when EXJADE granules were administered with
food. Although there was no significant effect (increase in the extent of
absorption AUC by 18-19%; no change in C<sub>max</sub>) of a high-fat meal on
deferasirox pharmacokinetics, it is recommended that deferasirox granules be
taken either with or without a light meal (see section 5.2).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Agents
that may decrease EXJADE systemic exposure</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox metabolism depends on UGT
enzymes. In a healthy volunteer study, the concomitant administration of deferasirox
(single dose of 30&nbsp;mg/kg, dispersible tablet formulation) and the potent
UGT inducer, rifampicin, (repeated dose of 600&nbsp;mg/day) resulted in a
decrease of deferasirox exposure by 44% (90% CI: 37% - 51%). Therefore, the
concomitant use of EXJADE with potent UGT inducers (e.g. rifampicin,
carbamazepine, phenytoin, phenobarbital, ritonavir) may result in a decrease in
EXJADE efficacy. The patients serum ferritin should be monitored during and
after the combination, and the dose of EXJADE adjusted if necessary.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Cholestyramine significantly reduced the
deferasirox exposure in a mechanistic study to determine the degree of
enterohepatic recycling (see section 5.2).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Interaction
with midazolam and other agents metabolised by CYP3A4</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a healthy volunteer study, the
concomitant administration of deferasirox dispersible tablets and midazolam (a
CYP3A4 probe substrate) resulted in a decrease of midazolam exposure by 17%
(90% CI: 8% - 26%). In the clinical setting, this effect may be more
pronounced. Therefore, due to a possible decrease in efficacy, caution should
be exercised when deferasirox is combined with substances metabolised through
CYP3A4 (e.g. ciclosporin, simvastatin, hormonal contraceptive agents, bepridil,
ergotamine).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Interaction
with repaglinide and other agents metabolised by CYP2C8</span></u></p>

<p class=MsoHeader style='background:white'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif;color:black'>In a healthy volunteer
study, the concomitant administration of deferasirox as a moderate CYP2C8
inhibitor (30&nbsp;mg/kg daily, dispersible tablet formulation), with
repaglinide, a CYP2C8 substrate, given as a single dose of 0.5&nbsp;mg,
increased repaglinide AUC and C</span><sub><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif;color:black'>max</span></sub><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'> about 2.3&#8209;fold (90% CI [2.03&#8209;2.63]) and 1.6-fold (90%
CI [1.42&#8209;1.84]), respectively. Since the interaction has not been
established with dosages higher than 0.5&nbsp;mg for repaglinide, the
concomitant use of deferasirox with repaglinide should be avoided. If the
combination appears necessary, careful clinical and blood glucose monitoring
should be performed (see section 4.4). An interaction between deferasirox and
other CYP2C8 substrates like paclitaxel cannot be excluded.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Interaction
with theophylline and other agents metabolised by CYP1A2</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a healthy volunteer study, the
concomitant administration of deferasirox as a CYP1A2 inhibitor (repeated dose
of 30&nbsp;mg/kg/day, dispersible tablet formulation) and the CYP1A2 substrate
theophylline (single dose of 120&nbsp;mg) resulted in an increase of
theophylline AUC by 84% (90% CI: 73% to 95%). The single dose C<sub>max</sub>
was not affected, but an increase of theophylline C<sub>max</sub> is expected
to occur with chronic dosing. Therefore, the concomitant use of deferasirox
with theophylline is not recommended. If deferasirox and theophylline are used
concomitantly, monitoring of theophylline concentration and theophylline dose
reduction should be considered. An interaction between deferasirox and other
CYP1A2 substrates cannot be excluded. For substances that are predominantly
metabolised by CYP1A2 and that have a narrow therapeutic index (e.g. clozapine,
tizanidine), the same recommendations apply as for theophylline.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><u><span style='color:black'>Other information</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The concomitant administration of deferasirox
and aluminium&#8209;containing antacid preparations has not been formally
studied. Although deferasirox has a lower affinity for aluminium than for iron,
it is not recommended to take deferasirox granules with aluminium&#8209;containing
antacid preparations.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The concomitant administration of
deferasirox with substances that have known ulcerogenic potential, such as
NSAIDs (including acetylsalicylic acid at high dosage), corticosteroids or oral
bisphosphonates may increase the risk of gastrointestinal toxicity (see section
4.4). The concomitant administration of deferasirox with anticoagulants may
also increase the risk of gastrointestinal haemorrhage. Close clinical
monitoring is required when deferasirox is combined with these substances.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>Concomitant administration of deferasirox and busulfan
resulted in an increase of busulfan exposure (AUC), but the mechanism of the
interaction remains unclear. If possible, evaluation of the pharmacokinetics
(AUC, clearance) of a busulfan test dose should be performed to allow dose
adjustment.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.6     Fertility, pregnancy and lactation</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Pregnancy</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>No clinical data on exposed pregnancies
are available for deferasirox. Studies in animals have shown some reproductive
toxicity at maternally toxic doses (see section 5.3). The potential risk for
humans is unknown.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>As a precaution, it is recommended that
EXJADE is not used during pregnancy unless clearly necessary.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE may decrease the efficacy of hormonal
contraceptives (see section 4.5). Women of childbearing potential are
recommended to use additional or alternative non&#8209;hormonal methods of
contraception when using EXJADE.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Breast&#8209;feeding</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In animal studies, deferasirox was found
to be rapidly and extensively secreted into maternal milk. No effect on the
offspring was noted. It is not known if deferasirox is secreted into human
milk. Breast&#8209;feeding while taking EXJADE is not recommended.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Fertility</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>No fertility data is available for humans.
In animals, no adverse effects on male or female fertility were found (see
section 5.3).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.7     Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXJADE has minor influence on the ability to
drive and use machines. Patients experiencing the uncommon adverse reaction of dizziness
should exercise caution when driving or operating machines (see section 4.8).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.8     Undesirable effects</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Summary
of the safety profile</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The most frequent reactions reported
during chronic treatment in clinical studies conducted with deferasirox
dispersible tablets in adult and paediatric patients include gastrointestinal
disturbances (mainly nausea, vomiting, diarrhoea or abdominal pain) and skin
rash. Diarrhoea is reported more commonly in paediatric patients aged 2 to
5&nbsp;years and in the elderly. These reactions are dose&#8209;dependent,
mostly mild to moderate, generally transient and mostly resolve even if
treatment is continued.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>During clinical studies dose&#8209;dependent
increases in serum creatinine occurred in about 36% of patients, though most
remained within the normal range. Decreases in mean creatinine clearance have
been observed in both paediatric and adult patients with beta&#8209;thalassemia
and iron overload during the first year of treatment, but there is evidence
that this does not decrease further in subsequent years of treatment.
Elevations of liver transaminases have been reported. Safety monitoring
schedules for renal and liver parameters are recommended. Auditory (decreased
hearing) and ocular (lens opacities) disturbances are uncommon, and yearly
examinations are also recommended (see section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black'>Severe
cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS),
toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and
systemic symptoms (DRESS) have been reported with the use of EXJADE (see
section 4.4).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Tabulated
list of adverse reactions</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Adverse reactions are ranked below using
the following convention: very common (&#8805;1/10); common (&#8805;1/100 to
&lt;1/10); uncommon (&#8805;1/1,000 to &lt;1/100); rare (&#8805;1/10,000 to
&lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the
available data). Within each frequency grouping, adverse reactions are presented
in order of decreasing seriousness.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:8.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Table&nbsp;5</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Blood and lymphatic system disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span lang=IT
  style='font-family:"Times New Roman",serif;color:black'>Pancytopenia<sup>1</sup>,
  thrombocytopenia<sup>1</sup>, anaemia aggravated<sup>1</sup>,</span><span
  lang=IT style='color:black'> </span><span lang=IT style='font-family:"Times New Roman",serif;
  color:black'>neutropenia<sup>1</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Immune system
  disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Hypersensitivity reactions (including
  anaphylactic reactions and angioedema)<sup>1</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  style='font-family:"Times New Roman",serif;color:black'>Metabolism and
  nutrition disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Metabolic acidosis</span><sup><span
  lang=IT style='font-family:"Times New Roman",serif;color:black'>1</span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Psychiatric disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Anxiety, sleep disorder</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Nervous system disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Common:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Headache</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Dizziness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Eye disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Cataract, maculopathy</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Rare:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Optic neuritis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Ear and labyrinth disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Deafness</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Respiratory, thoracic and mediastinal disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Laryngeal pain</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Gastrointestinal disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Common:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Diarrhoea, constipation,
  vomiting, nausea, abdominal pain, abdominal distension, dyspepsia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Gastrointestinal
  haemorrhage, gastric ulcer (including multiple ulcers), duodenal ulcer,
  gastritis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Rare:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Oesophagitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Gastrointestinal perforation</span><sup><span
  lang=IT style='font-family:"Times New Roman",serif;color:black'>1</span></sup><span
  lang=IT style='font-family:"Times New Roman",serif;color:black'>, acute
  pancreatitis<sup>1</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Hepatobiliary disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Common:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Transaminases
  increased</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Hepatitis,
  cholelithiasis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Hepatic failure<sup>1, 2</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Common:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Rash, pruritus</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Pigmentation disorder</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif;color:black'>Rare:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-family:"Times New Roman",serif;color:black'>Drug reaction with
  eosinophilia and systemic symptoms (DRESS)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span lang=EN-GB
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Stevens&#8209;Johnson syndrome<sup>1</sup>,
  hypersensitivity vasculitis<sup>1</sup>, urticaria<sup>1</sup>, erythema
  multiforme<sup>1</sup>, alopecia<sup>1</sup>, toxic epidermal necrolysis
  (TEN)<sup>1</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>Renal and urinary disorders</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Very common:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Blood creatinine
  increased</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Common:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Proteinuria</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  lang=IT style='font-family:"Times New Roman",serif;color:black'>Renal tubular
  disorder</span><sup><span lang=FR-CH style='font-family:"Times New Roman",serif;
  color:black'>2</span></sup><span lang=IT style='font-family:"Times New Roman",serif;
  color:black'> (acquired Fanconi syndrome), glycosuria</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border:none;border-left:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span lang=IT
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span style='font-family:
  "Times New Roman",serif;color:black'>Not known:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;background:white'><span lang=FR
  style='font-family:"Times New Roman",serif;color:black'>Acute renal failure<sup>1,
  2</sup>, tubulointerstitial nephritis<sup>1</sup>, nephrolithiasis</span><sup><span
  lang=IT style='font-family:"Times New Roman",serif;color:black'>1</span></sup><span
  lang=FR style='font-family:"Times New Roman",serif;color:black'>, renal
  tubular necrosis<sup>1</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=580 colspan=3 valign=top style='width:435.0pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><b><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black;layout-grid-mode:
  line'>General disorders and administration site conditions</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Uncommon:</span></p>
  </td>
  <td width=419 valign=top style='width:314.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid;background:white'><span
  style='font-family:"Times New Roman",serif;color:black'>Pyrexia, oedema,
  fatigue</span></p>
  </td>
 </tr>
</table>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt;
background:white'><sup><span lang=EN-GB style='font-size:11.0pt;color:black'>1</span></sup><span
lang=EN-GB style='font-size:10.0pt;color:black'>           </span><span
lang=EN-GB style='font-size:11.0pt;color:black'>Adverse reactions reported
during post&#8209;marketing experience. These are derived from spontaneous
reports for which it is not always possible to reliably establish frequency or
a causal relationship to exposure to the medicinal product.</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt;
background:white'><sup><span lang=EN-GB style='font-size:11.0pt;color:black'>2</span></sup><span
lang=EN-GB style='font-size:11.0pt;color:black'>        Severe forms associated
with changes in consciousness in the context of hyperammonaemic encephalopathy have
been reported.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Description
of selected adverse reactions</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Gallstones and related biliary disorders
were reported in about 2% of patients. Elevations of liver transaminases were
reported as an adverse reaction in 2% of patients. Elevations of transaminases
greater than 10&nbsp;times the upper limit of the normal range, suggestive of
hepatitis, were uncommon (0.3%). During post&#8209;marketing experience,
hepatic failure, sometimes fatal, has been reported with deferasirox (see
section 4.4). There have been post&#8209;marketing reports of metabolic
acidosis. The majority of these patients had renal impairment, renal
tubulopathy (Fanconi syndrome) or diarrhoea, or conditions where acid&#8209;base
imbalance is a known complication (see section 4.4). Cases of serious acute
pancreatitis were observed without documented underlying biliary conditions. As
with other iron chelator treatment, high&#8209;frequency hearing loss and
lenticular opacities (early cataracts) have been uncommonly observed in
patients treated with deferasirox (see section 4.4).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span style='color:black'>Creatinine
clearance in transfusional iron overload</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a retrospective meta&#8209;analysis of
2,102&nbsp;adult and paediatric beta&#8209;thalassaemia patients with
transfusional iron overload treated with deferasirox dispersible tablets in two
randomised and four open label studies of up to five years duration, a mean
creatinine clearance decrease of 13.2% in adult patients (95% CI: &#8209;14.4%
to &#8209;12.1%; n=935) and 9.9% (95% CI: &#8209;11.1% to &#8209;8.6%; n=1,142)
in paediatric patients was observed during the first year of treatment. In
250&nbsp;patients who were followed for up to five years, no further decrease
in mean creatinine clearance levels was observed.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span style='color:black'>Clinical
study in patients with non&#8209;transfusion&#8209;dependent thalassaemia
syndromes</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a 1&#8209;year study in patients with
non&#8209;transfusion&#8209;dependent thalassaemia syndromes and iron overload
(dispersible tablets at a dose of 10&nbsp;mg/kg/day), diarrhoea (9.1%), rash
(9.1%), and nausea (7.3%) were the most frequent study drug&#8209;related
adverse events. Abnormal serum creatinine and creatinine clearance values were
reported in 5.5% and 1.8% of patients, respectively. Elevations of liver
transaminases greater than 2&nbsp;times the baseline and 5&nbsp;times the upper
limit of normal were reported in 1.8% of patients.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><u><span lang=EN-GB style='font-size:11.0pt;
color:black'>Paediatric population</span></u></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In two clinical studies, growth and sexual
development of paediatric patients treated with deferasirox for up to
5&nbsp;years were not affected (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Diarrhoea is reported more
commonly in paediatric patients aged 2 to 5&nbsp;years than in older patients.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Renal tubulopathy has been
mainly reported in children and adolescents with beta&#8209;thalassaemia
treated with deferasirox.</span><span lang=EN-GB style='color:black'> </span><span
lang=EN-GB style='font-size:11.0pt;color:black'>In post-marketing reports, a
high proportion of cases of metabolic acidosis occurred in children in the
context of Fanconi syndrome.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Acute pancreatitis has been reported,
particularly in children and adolescents.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text style='margin-top:0in;page-break-after:avoid;background:white'><u><span
style='font-size:11.0pt;color:black'>Reporting of suspected adverse reactions</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Reporting suspected adverse
reactions after authorisation of the medicinal product is important. It allows
continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions <span
style='background:#D9D9D9'>via the national reporting system listed in </span></span><span
style='color:black'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='font-size:11.0pt;background:#D9D9D9'>Appendix V</span></a></span><span
lang=EN-GB style='font-size:11.0pt;color:black'>.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.9     Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Early signs of acute overdose are
digestive effects such as abdominal pain, diarrhoea, nausea and vomiting.
Hepatic and renal disorders have been reported, including cases of liver enzyme
and creatinine increased with recovery after treatment discontinuation. An
erroneously administered single dose of 90&nbsp;mg/kg led to Fanconi syndrome
which resolved after treatment.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>There is no specific antidote
for deferasirox. Standard procedures for management of overdose may be
indicated as well as symptomatic treatment,</span><span style='font-size:11.0pt;
color:black'> as medically appropriate.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>5.       PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>5.1     Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Pharmacotherapeutic group: Iron
chelating agents, ATC code: V03AC03</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Mechanism
of action</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox is an orally active chelator
that is highly selective for iron (III). It is a tridentate ligand that binds
iron with high affinity in a 2:1 ratio. Deferasirox promotes excretion of iron,
primarily in the faeces. Deferasirox has low affinity for zinc and copper, and
does not cause constant low serum levels of these metals.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Pharmacodynamic
effects</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In an iron&#8209;balance metabolic study
in iron&#8209;overloaded adult thalassaemic patients, deferasirox at daily
doses of 10, 20 and 40&nbsp;mg/kg (dispersible tablet formulation) induced the
mean net excretion of 0.119, 0.329 and 0.445&nbsp;mg&nbsp;Fe/kg body
weight/day, respectively.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>Clinical
efficacy and safety</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Clinical efficacy studies were conducted
with deferasirox dispersible tablets.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox has been investigated in
411&nbsp;adult (age </span><span style='font-size:11.0pt;font-family:Symbol;
color:black'>³</span><span style='font-size:11.0pt;color:black'>16&nbsp;years)
and 292&nbsp;paediatric patients (aged&nbsp;2 to &lt;16&nbsp;years) with
chronic iron overload due to blood transfusions. Of the paediatric patients 52
were aged&nbsp;2 to 5&nbsp;years. The underlying conditions requiring
transfusion included beta&#8209;thalassaemia, sickle cell disease and other
congenital and acquired anaemias (myelodysplastic syndromes [MDS], Diamond&#8209;Blackfan
syndrome, aplastic anaemia and other very rare anaemias).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Daily treatment with the deferasirox
dispersible tablet formulation at doses of 20 and 30&nbsp;mg/kg for one year in
frequently transfused adult and paediatric patients with beta&#8209;thalassaemia
led to reductions in indicators of total body iron; liver iron concentration
was reduced by about &#8209;0.4 and &#8209;8.9&nbsp;mg&nbsp;Fe/g liver (biopsy
dry weight (dw)) on average, respectively, and serum ferritin was reduced by
about &#8209;36 and &#8209;926&nbsp;µg/l on average, respectively. At these
same doses the ratios of iron excretion: iron intake were 1.02 (indicating net
iron balance) and 1.67 (indicating net iron removal), respectively. Deferasirox
induced similar responses in iron&#8209;overloaded patients with other
anaemias. Daily doses of 10&nbsp;mg/kg (dispersible tablet formulation) for one
year could maintain liver iron and serum ferritin levels and induce net iron
balance in patients receiving infrequent transfusions or exchange transfusions.
Serum ferritin assessed by monthly monitoring reflected changes in liver iron
concentration indicating that trends in serum ferritin can be used to monitor
response to therapy. Limited clinical data (29&nbsp;patients with normal
cardiac function at baseline) using MRI indicate that treatment with
deferasirox 10&#8209;30&nbsp;mg/kg/day (dispersible tablet formulation) for
1&nbsp;year may also reduce levels of iron in the heart (on average, MRI T2*
increased from 18.3 to 23.0&nbsp;milliseconds).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The principal analysis of the pivotal
comparative study in 586&nbsp;patients suffering from beta&#8209;thalassaemia
and transfusional iron overload did not demonstrate non&#8209;inferiority of
deferasirox dispersible tablets to deferoxamine in the analysis of the total
patient population. It appeared from a post&#8209;hoc analysis of this study
that, in the subgroup of patients with liver iron concentration
&#8805;7&nbsp;mg Fe/g dw treated with deferasirox dispersible tablets (20 and
30&nbsp;mg/kg) or deferoxamine (35 to &#8805;50&nbsp;mg/kg), the non&#8209;inferiority
criteria were achieved. However, in patients with liver iron concentration
&lt;7&nbsp;mg Fe/g dw treated with deferasirox dispersible tablets (5 and
10&nbsp;mg/kg) or deferoxamine (20 to 35&nbsp;mg/kg), non&#8209;inferiority was
not established due to imbalance in the dosing of the two chelators. This
imbalance occurred because patients on deferoxamine were allowed to remain on
their pre&#8209;study dose even if it was higher than the protocol specified
dose. Fifty&#8209;six&nbsp;patients under the age of 6&nbsp;years participated
in this pivotal study, 28 of them receiving deferasirox dispersible tablets.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>It appeared from preclinical and clinical
studies that deferasirox dispersible tablets could be as active as deferoxamine
when used in a dose ratio of 2:1 (i.e. a dose of deferasirox dispersible
tablets that is numerically half of the deferoxamine dose). For deferasirox granules,
a dose ratio of 3:1 can be considered (i.e. a dose of deferasirox granules that
is numerically one third of the deferoxamine dose). However, this dosing
recommendation was not prospectively assessed in the clinical studies.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In addition, in patients with liver iron
concentration &#8805;7&nbsp;mg Fe/g dw with various rare anaemias or sickle
cell disease, deferasirox dispersible tablets up to 20 and 30&nbsp;mg/kg
produced a decrease in liver iron concentration and serum ferritin comparable
to that obtained in patients with beta&#8209;thalassaemia.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>A placebo-controlled randomised study was
performed in 225&nbsp;patients with MDS (Low/Int-1 risk) and transfusional iron
overload. The results of this study suggest that there is a positive impact of
deferasirox on event-free survival (EFS, a composite endpoint including
non-fatal cardiac or liver events) and serum ferritin levels. The safety
profile was consistent with previous studies in adult MDS patients.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a 5-year observational study in which
267&nbsp;children aged 2 to &lt;6&nbsp;years (at enrollment) with transfusional
haemosiderosis received deferasirox, there were no clinically meaningful
differences in the safety and tolerability profile of Exjade in paediatric
patients aged 2 to &lt;6&nbsp;years compared to the overall adult and older
paediatric population, including increases in serum creatinine of &gt;33% and
above the upper limit of normal on &#8805;2&nbsp;consecutive occasions (3.1%),
and elevation of alanine aminotransferase (ALT) greater than 5&nbsp;times the
upper limit of normal (4.3%). Single events of increase in ALT and aspartate
aminotransferase were reported in 20.0% and 8.3%, respectively, of the
145&nbsp;patients who completed the study.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a study to assess the safety of
deferasirox film-coated and dispersible tablets, 173 adult and paediatric
patients with transfusion dependent thalassaemia or myelodysplastic syndrome
were treated for 24&nbsp;weeks. A comparable safety profile for film-coated and
dispersible tablets was observed.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In patients with non&#8209;transfusion&#8209;dependent
thalassaemia syndromes and iron overload, treatment with deferasirox
dispersible tablets was assessed in a 1&#8209;year, randomised, double&#8209;blind,
placebo&#8209;controlled study. The study compared the efficacy of two
different deferasirox dispersible tablet regimens (starting doses of 5 and
10&nbsp;mg/kg/day, 55&nbsp;patients in each arm) and of matching placebo
(56&nbsp;patients). The study enrolled 145&nbsp;adult and 21&nbsp;paediatric
patients. The primary efficacy parameter was the change in liver iron
concentration (LIC) from baseline after 12&nbsp;months of treatment. One of the
secondary efficacy parameters was the change in serum ferritin between baseline
and fourth quarter. At a starting dose of 10&nbsp;mg/kg/day, deferasirox
dispersible tablets led to reductions in indicators of total body iron. On
average, liver iron concentration decreased by 3.80&nbsp;mg Fe/g dw in patients
treated with deferasirox dispersible tablets (starting dose 10&nbsp;mg/kg/day)
and increased by 0.38&nbsp;mg Fe/g dw in patients treated with placebo
(p&lt;0.001). On average, serum ferritin decreased by 222.0&nbsp;µg/l in
patients treated with deferasirox dispersible tablets (starting dose 10&nbsp;mg/kg/day)
and increased by 115&nbsp;µg/l in patients treated with placebo (p&lt;0.001).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>5.2     Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoCommentText style='background:white'><span style='font-size:11.0pt;
color:black'>EXJADE granules demonstrate higher bioavailability compared to the
EXJADE dispersible tablet formulation. After adjustment of the strength, the granules
formulation (4&nbsp;x&nbsp;90&nbsp;mg strength) was equivalent to EXJADE
dispersible tablets (500&nbsp;mg strength) with respect to the mean area under
the plasma concentration time curve (AUC) under fasting conditions. The C<sub>max</sub>
was increased by 34% (90% CI: 27.9% &#8209; 40.3%); however a clinical
exposure/response analysis revealed no evidence of clinically relevant effects
of such an increase.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><u><span style='color:black'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Absorption</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox (dispersible tablet
formulation) is absorbed following oral administration with a median time to
maximum plasma concentration (t<sub>max</sub>) of about 1.5 to 4&nbsp;hours.
The absolute bioavailability (AUC) of deferasirox (dispersible tablet formulation)
is about 70% compared to an intravenous dose. The absolute bioavailability of
the granule formulation has not been determined. Bioavailability of deferasirox
granules was 52% greater than that with dispersible tablets.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>A food&#8209;effect study involving
administration of the granules to healthy volunteers under fasting conditions
and with a low&#8209;fat (fat content = approximately 30% of calories) or high&#8209;fat
(fat content &gt;50% of calories) meal indicated that the AUC and C<sub>max</sub>
were slightly decreased after a low&#8209;fat meal (by 10% and 11%,
respectively). After a high&#8209;fat meal, only AUC was mildly increased (by
18%). When the granules were administered with apple sauce or yogurt, a food
effect was absent.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Distribution</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox is highly (99%) protein bound to
plasma proteins, almost exclusively serum albumin, and has a small volume of
distribution of approximately 14&nbsp;litres in adults.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Biotransformation</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Glucuronidation is the main metabolic
pathway for deferasirox, with subsequent biliary excretion. Deconjugation of
glucuronidates in the intestine and subsequent reabsorption (enterohepatic
recycling) is likely to occur: in a healthy volunteer study, the administration
of cholestyramine after a single dose of deferasirox resulted in a 45% decrease
in deferasirox exposure (AUC).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox is mainly glucuronidated by
UGT1A1 and to a lesser extent UGT1A3. CYP450&#8209;catalysed (oxidative)
metabolism of deferasirox appears to be minor in humans (about 8%). No
inhibition of deferasirox metabolism by hydroxyurea was observed <i>in vitro</i></span><span
lang=EN-GB style='font-size:11.0pt;color:black'>.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Elimination</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Deferasirox and its metabolites are
primarily excreted in the faeces (84% of the dose). Renal excretion of
deferasirox and its metabolites is minimal (8% of the dose). The mean
elimination half&#8209;life (t<sub>1/2</sub>) ranged from 8 to 16&nbsp;hours.
The transporters MRP2 and MXR (BCRP) are involved in the biliary excretion of
deferasirox.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Linearity / non&#8209;linearity</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The C<sub>max</sub> and AUC<sub>0&#8209;24h</sub>
of deferasirox increase approximately linearly with dose under steady&#8209;state
conditions. Upon multiple dosing exposure increased by an accumulation factor
of 1.3 to 2.3</span><span lang=EN-GB style='font-size:11.0pt;color:black'>.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Characteristics in patients</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><span style='font-size:11.0pt;color:black'>Paediatric
patients</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The overall exposure of adolescents </span><span
lang=EN-GB style='font-size:11.0pt;color:black'>(12 to &#8804;17</span><span
style='font-size:11.0pt;color:black'>&nbsp;</span><span lang=EN-GB
style='font-size:11.0pt;color:black'>years) </span><span style='font-size:11.0pt;
color:black'>and children </span><span lang=EN-GB style='font-size:11.0pt;
color:black'>(2 to &lt;12&nbsp;years)</span><span style='font-size:11.0pt;
color:black'> to deferasirox after single and multiple doses was lower than
that in adult patients.</span><span lang=EN-GB style='font-size:11.0pt;
color:black'> In children younger than 6&nbsp;years old exposure was about 50%
lower than in adults. Since dosing is individually adjusted according to
response this is not expected to have clinical consequences.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><span style='font-size:11.0pt;color:black'>Gender</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Females have a moderately lower apparent
clearance (by 17.5%) for deferasirox compared to males. </span><span
lang=EN-GB style='font-size:11.0pt;color:black'>Since dosing is individually
adjusted according to response this is not expected to have clinical
consequences.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><span style='font-size:11.0pt;color:black'>Elderly
patients</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>The pharmacokinetics of
deferasirox have not been studied in elderly </span><span style='font-size:
11.0pt;color:black'>patients (aged&nbsp;65 or older).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><i><span style='font-size:11.0pt;color:black'>Renal or
hepatic impairment</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The pharmacokinetics of deferasirox have
not been studied in patients with renal impairment. The pharmacokinetics of
deferasirox were not influenced by liver transaminase levels up to 5&nbsp;times
the upper limit of the normal range.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>In a clinical study using single doses of
20&nbsp;mg/kg deferasirox dispersible tablets, the average exposure was
increased by 16% in subjects with mild hepatic impairment (Child&#8209;Pugh
Class A) and by 76% in subjects with moderate hepatic impairment (Child&#8209;Pugh
Class B) compared to subjects with normal hepatic function. The average C<sub>max</sub>
of deferasirox in subjects with mild or moderate hepatic impairment was
increased by 22%. Exposure was increased 2.8&#8209;fold in one subject with
severe hepatic impairment (Child&#8209;Pugh Class C) (see sections 4.2 and
4.4).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>5.3     Preclinical safety data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Non&#8209;clinical data reveal no special
hazard for humans based on conventional studies of safety pharmacology,
repeated dose toxicity, genotoxicity or carcinogenic potential. The main
findings were kidney toxicity and lens opacity (cataracts). Similar findings
were observed in neonatal and juvenile animals. The kidney toxicity is
considered mainly due to iron deprivation in animals that were not previously
overloaded with iron.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Tests of genotoxicity <i>in vitro</i> were
negative (Ames test, chromosomal aberration test) while deferasirox caused
formation of micronuclei <i>in vivo</i> in the bone marrow, but not liver, of
non&#8209;iron&#8209;loaded rats at lethal doses. No such effects were observed
in iron&#8209;preloaded rats. Deferasirox was not carcinogenic when
administered to rats in a 2&#8209;year study and transgenic p53+/- heterozygous
mice in a 6&#8209;month study.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>The potential for toxicity to reproduction
was assessed in rats and rabbits. Deferasirox was not teratogenic, but caused
increased frequency of skeletal variations and stillborn pups in rats at high
doses that were severely toxic to the non&#8209;iron&#8209;overloaded mother</span><span
lang=EN-GB style='font-size:11.0pt;color:black'>. </span><span
style='font-size:11.0pt;color:black'>Deferasirox did not cause other effects on
fertility or reproduction</span><span lang=EN-GB style='font-size:11.0pt;
color:black'>.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.       PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.1     List of excipients</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Cellulose, microcrystalline</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Crospovidone</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Povidone</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Magnesium stearate</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Silica, colloidal anhydrous</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Poloxamer</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.3     Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>3&nbsp;years</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.4     Special precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>This medicinal product does not require
any special storage conditions.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.5     Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Sachets of polyethylene terephthalate (PET)/Aluminium/polyethylene
(PE) foil.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Unit packs containing 30&nbsp;sachets.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.6     Special precautions for disposal</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>No special requirements.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>7.       MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>8.       MARKETING AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span lang=FR style='font-size:11.0pt;color:black'>EXJADE
90&nbsp;mg granules</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=FR style='color:black'>EU/1/06/356/020</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=FR style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span lang=FR style='font-size:11.0pt;color:black'>EXJADE
180&nbsp;mg granules</span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>EU/1/06/356/021</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=FR style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
360&nbsp;mg granules</span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>EU/1/06/356/022</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=PT>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Date of first authorisation: 28
August 2006</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Date of latest renewal:</span><span lang=EN-GB
style='color:black'> 18 April 2016</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><b><span lang=EN-GB style='color:black'>10.     DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Detailed information on this </span><span
lang=EN-GB style='color:black'>medicinal</span><span lang=EN-GB
style='color:black'> product </span><span lang=EN-GB style='color:black'>is
available on the website of the European Medicines Agency </span><span
lang=EN-GB style='color:black'><a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;background:white'><b><span
lang=PT style='color:black'>ANNEX II</span></b></p>

<p class=MsoNormal style='margin-right:70.8pt;background:white'><span lang=PT
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;background:
white'><b><span lang=EN-GB style='color:black'>A.      MANUFACTURER RESPONSIBLE
FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;background:
white'><b><span lang=EN-GB style='color:black'>B.      CONDITIONS </span></b><b><span
lang=EN-GB style='color:black'>OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:84.45pt;text-indent:-27.75pt;background:
white'><b><span lang=EN-GB style='color:black'>C.      OTHER CONDITIONS AND
REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;background:
white'><b><span lang=EN-GB style='color:black'>D.      <span style='text-transform:
uppercase'>conditions or restrictions with regard to the safe and effective use
of the medicinal product</span></span></b></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><b><span lang=EN-GB style='color:black'>A.      MANUFACTURER
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'>Name and address of the manufacturer responsible
for batch release</span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span lang=FR style='font-size:11.0pt;color:black'>EXJADE
125&nbsp;mg, 250&nbsp;mg and 500&nbsp;mg dispersible tablets</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>&nbsp;</span></p>

<p class=MsoBodyText style='line-height:normal;page-break-after:avoid;
background:white'><span lang=DE-CH style='color:black;font-weight:normal;
font-style:normal'>Novartis Pharma GmbH</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=DE-CH style='color:black'>Roonstraße 25</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=DE-CH style='color:black'>D-90429 Nuremberg</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Germany</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><u><span style='font-size:11.0pt;color:black'>EXJADE
90&nbsp;mg, 180&nbsp;mg and 360&nbsp;mg film&#8209;coated tablets</span></u></p>

<p class=MsoBodyText style='line-height:normal;page-break-after:avoid;
background:white'><span lang=DE-CH style='color:black;font-weight:normal;
font-style:normal'>&nbsp;</span></p>

<p class=MsoBodyText style='line-height:normal;background:white'><span
lang=DE-CH style='color:black;font-weight:normal;font-style:normal'>Novartis
Pharma GmbH</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=DE-CH style='color:black'>Roonstraße 25</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=DE-CH style='color:black'>D-90429 Nuremberg</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Germany</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>Novartis Farmacéutica SA</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>Ronda de Santa Maria 158</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>08210 Barberà del Vallès, Barcelona</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Spain</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><u><span style='color:black'>EXJADE 90&nbsp;mg, 180&nbsp;mg and
360&nbsp;mg granules in sachet</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>&nbsp;</span></p>

<p class=MsoBodyText style='line-height:normal;page-break-after:avoid;
background:white'><span lang=DE-CH style='color:black;font-weight:normal;
font-style:normal'>Novartis Pharma GmbH</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=DE-CH style='color:black'>Roonstraße 25</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=DE-CH style='color:black'>D-90429 Nuremberg</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Germany</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>The printed package leaflet of the medicinal product must
state the name and address of the manufacturer responsible for the release of
the concerned batch.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><b><span lang=EN-GB style='color:black'>B.      CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Medicinal product subject to restricted medical
prescription (See Annex I: Summary of Product Characteristics, section 4.2).</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white'><b><span style='color:black'>C.      OTHER CONDITIONS AND REQUIREMENTS
OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white'>&nbsp;</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;background:white'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Periodic Safety Update
Reports</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>The </span><span lang=EN-GB style='color:black'>requirements
for submission of</span><span style='color:black'> periodic safety update
reports for this </span><span lang=EN-GB style='color:black'>medicinal</span><span
lang=EN-GB style='color:black'> </span><span style='color:black'>product </span><span
lang=EN-GB style='color:black'>are set out </span><span style='color:black'>in
the list of Union reference dates (EURD list) provided for under Article
107c(7) of Directive 2001/83/EC and </span><span lang=EN-GB style='color:black'>and
</span><span lang=EN-GB style='color:black'>any subsequent updates </span><span
style='color:black'>published on the European medicines web&#8209;portal.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>D.      CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE
AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;page-break-after:
avoid;background:white'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Risk Management Plan
(RMP)</span></b></p>

<p class=bullethead style='margin-top:0in;line-height:normal;background:white'><span
lang=EN-GB style='color:black;font-weight:normal'>The MAH shall perform the
required pharmacovigilance activities and interventions detailed in the agreed
RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed
subsequent updates of the RMP.</span></p>

<p class=bullethead style='margin-top:0in;line-height:normal;background:white'><span
lang=EN-GB style='color:black;font-weight:normal'>&nbsp;</span></p>

<p class=bullethead style='margin-top:0in;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black;font-weight:normal'>An
updated RMP should be submitted:</span></p>

<p class=bullethead style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><span lang=EN-GB
style='font-family:Symbol;color:black;font-weight:normal'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black;font-weight:normal'>At the
request of the European Medicines Agency;</span></p>

<p class=bullethead style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='font-family:Symbol;color:black;
font-weight:normal'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black;font-weight:normal'>Whenever
the risk management system is modified, especially as the result of new
information being received that may lead to a significant change to the
benefit/risk profile or as the result of an important (pharmacovigilance or
risk minimisation) milestone being reached.</span></p>

<p class=bullethead style='margin-top:0in;line-height:normal;background:white'><span
style='color:black;font-weight:normal'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;page-break-after:
avoid;background:white'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Additional risk
minimisation measures</span></b></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>The MAH must inform the European Medicines Agency and the CHMP of
the results of the surveillance programme in each Member State.</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Prior to launch of EXJADE in each Member State the Marketing
Authorisation Holder (MAH) must agree about the content and format of the
educational programme, including communication media, distribution modalities,
and any other aspects of the programme, with the National Competent Authority.</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>The educational programme is aimed to inform healthcare
professionals and patients to minimise the risks of:</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:.5in;text-align:left;
text-indent:-.25in;background:white'><span lang=EN-GB style='font-family:Symbol;
color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Non&#8209;compliance of the posology and biological monitoring</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:.5in;text-align:left;
text-indent:-.25in;background:white'><span lang=EN-GB style='font-family:Symbol;
color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Medication errors due to switching between formulations
(dispersible</span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'> tablets</span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'> and film&#8209;coated tablets</span><span lang=EN-GB
style='font-family:"Times New Roman",serif;color:black'>/granules</span><span
lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>).</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>The MAH shall ensure that, at launch, in each Member State where
EXJADE is marketed, all healthcare professionals and patients who are expected
to prescribe, dispense and use EXJADE are provided with the following
educational package for </span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>all</span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'> available formulations (e.g. dispersible tablets, film-coated
tablets and granules) for all indications:</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:.5in;text-align:left;
text-indent:-.25in;background:white'><span lang=EN-GB style='font-family:Symbol;
color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Physician educational material</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:.5in;text-align:left;
text-indent:-.25in;background:white'><span lang=EN-GB style='font-family:Symbol;
color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Patient information pack</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Additional periodic distributions after launch should be
performed, notably after substantial safety </span><span lang=EN-GB
style='font-family:"Times New Roman",serif;color:black'>modifications of the </span><span
lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>product
information justifying educational material updates.</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>The MAH shall use distinct outer cartons, blisters and tablets for
all formulations (dispersible</span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'> tablets</span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'> and film&#8209;coated tablet</span><span lang=EN-GB
style='font-family:"Times New Roman",serif;color:black'>s/granules</span><span
lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>).</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
page-break-after:avoid;background:white'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black'>The physician educational material should
contain:</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:.5in;text-align:left;
text-indent:-.25in;page-break-after:avoid;background:white'><span lang=EN-GB
style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>The Summary of Product Characteristics</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:.5in;text-align:left;
text-indent:-.25in;page-break-after:avoid;background:white'><span lang=EN-GB
style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Guide for healthcare professionals</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
page-break-after:avoid;background:white'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
page-break-after:avoid;background:white'><b><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black'>The Guide for healthcare professionals</span></b><span
lang=EN-GB style='font-family:"Times New Roman",serif;color:black'> shall
contain the following key elements:</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='background:white'><span lang=EN-GB
     style='color:black'>Description of available deferasirox formulations
     (e.g. dispersible tablets, film-coated tablets and granules)</span></li>
</ul>

<p class=MsoNormal style='margin-left:1.0in;text-indent:-.25in;background:white'><em><span
lang=EN-GB style='font-family:"Courier New";font-weight:normal'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></em><em><span
lang=EN-GB style='color:black;font-weight:normal'>Different posology regimen</span></em></p>

<p class=MsoNormal style='margin-left:1.0in;text-indent:-.25in;background:white'><em><span
lang=EN-GB style='font-family:"Courier New";color:black;font-weight:normal'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></em><em><span
lang=EN-GB style='color:black;font-weight:normal'>Different conditions of
administration</span></em></p>

<p class=MsoNormal style='margin-left:1.0in;text-indent:-.25in;background:white'><span
lang=EN-GB style='font-family:"Courier New";color:black'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
lang=EN-GB style='color:black'>Dose conversion table when switching from one formulation
to another</span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='color:black;background:white'><span lang=EN-GB>The
     recommended doses and the rules for starting treatment</span></li>
</ul>

<p class=MsoBodyTextIndent align=left style='margin-left:.5in;text-align:left;
text-indent:-.25in;background:white'><span lang=EN-GB style='font-family:Symbol;
color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>The need to monitor serum ferritin monthly</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:.5in;text-align:left;
text-indent:-17.85pt;page-break-after:avoid;background:white'><span lang=EN-GB
style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>That deferasirox causes rises in serum creatinine in some patients</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.0in;text-align:left;
text-indent:-17.85pt;page-break-after:avoid;background:white'><span lang=EN-GB
style='font-family:"Courier New";color:black'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>The need to monitor serum creatinine</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.5in;text-align:left;
text-indent:-.25in;background:white'><span lang=EN-GB style='font-family:Symbol;
color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>On two occasions prior to initiation of treatment</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.5in;text-align:left;
text-indent:-.25in;background:white'><span lang=EN-GB style='font-family:Symbol;
color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Every week during the first month of initiation of treatment or
after therapy modification</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.5in;text-align:left;
text-indent:-.25in;background:white'><span lang=EN-GB style='font-family:Symbol;
color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Monthly thereafter</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.0in;text-align:left;
text-indent:-17.85pt;page-break-after:avoid;background:white'><span lang=EN-GB
style='font-family:"Courier New";color:black'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>The need to reduce by 10&nbsp;mg/kg the dose if serum creatinine
rises:</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.5in;text-align:left;
text-indent:-.25in;background:white'><span lang=EN-GB style='font-family:Symbol;
color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Adults: &gt;33% above baseline and creatinine clearance &lt;LLN
(90&nbsp;ml/min)</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.5in;text-align:left;
text-indent:-.25in;background:white'><span lang=EN-GB style='font-family:Symbol;
color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Paediatrics: either &gt;ULN or creatinine clearance falls to
&lt;LLN at two consecutive visits.</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.25in;text-align:
left;background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.0in;text-align:left;
text-indent:-17.85pt;page-break-after:avoid;background:white'><span lang=EN-GB
style='font-family:"Courier New";color:black'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>The need to interrupt treatment after a dose reduction if serum
creatinine rises:</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.5in;text-align:left;
text-indent:-.25in;background:white'><span lang=EN-GB style='font-family:Symbol;
color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Adults and Paediatrics: remain &gt;33% above baseline or
creatinine clearance &lt;LLN (90&nbsp;ml/min)</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.25in;text-align:
left;background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.0in;text-align:left;
text-indent:-17.85pt;page-break-after:avoid;background:white'><span lang=EN-GB
style='font-family:"Courier New";color:black'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>The need to consider renal biopsy:</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.5in;text-align:left;
text-indent:-17.85pt;background:white'><span lang=EN-GB style='font-family:
Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>When serum creatinine is elevated and if another abnormality has
been detected (e.g. proteinuria, signs of Fanconi syndrome).</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:.5in;text-align:left;
text-indent:-.25in;background:white'><span lang=EN-GB style='font-family:Symbol;
color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>The importance of measuring creatinine clearance</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:35.7pt;text-align:
left;text-indent:-17.85pt;background:white'><span lang=EN-GB style='font-family:
Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Brief overview of methods of measuring creatinine clearance</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:.5in;text-align:left;
text-indent:-.25in;page-break-after:avoid;background:white'><span lang=EN-GB
style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>That rises in serum transaminases may occur in patients treated
with EXJADE</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.0in;text-align:left;
text-indent:-.25in;background:white'><span lang=EN-GB style='font-family:"Courier New";
color:black'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>The need for
liver function tests prior to prescription, then at monthly intervals or more often
if clinically indicated</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.0in;text-align:left;
text-indent:-.25in;background:white'><span lang=EN-GB style='font-family:"Courier New";
color:black'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>Not to
prescribe to patients with pre&#8209;existing severe hepatic disease</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.0in;text-align:left;
text-indent:-17.85pt;background:white'><span lang=EN-GB style='font-family:
"Courier New";color:black'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>The need to interrupt treatment if persistent and progressive
increase in liver enzyme were noted.</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:.5in;text-align:left;
text-indent:-17.85pt;background:white'><span lang=EN-GB style='font-family:
Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>The need for annual auditory and ophthalmic testing</span></p>

<p class=MsoBodyTextIndent align=left style='text-align:left;background:white'><span
lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:.5in;text-align:left;
text-indent:-.25in;page-break-after:avoid;background:white'><span lang=EN-GB
style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>The need for a guidance table highlighting pre&#8209;treatment
measurements of serum creatinine, creatinine clearance, proteinuria, hepatic
enzymes, ferritin, such as:</span></p>

<p class=MsoNormal style='margin-left:.25in;line-height:normal;page-break-after:
avoid;background:white;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=614
 style='width:460.6pt;margin-left:.25in;border-collapse:collapse;border:none'>
 <tr>
  <td width=308 valign=top style='width:230.65pt;border:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white;text-autospace:none'><span lang=EN-GB style='color:black'>Before
  initiating treatment</span></p>
  </td>
  <td width=307 valign=top style='width:229.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:230.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white;text-autospace:none'><span lang=EN-GB style='color:black'>Serum
  creatinine at Day - X</span></p>
  </td>
  <td width=307 valign=top style='width:229.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white;text-autospace:none'><span lang=EN-GB style='color:black'>Value
  1</span></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:230.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white;text-autospace:none'><span lang=EN-GB style='color:black'>Serum
  creatinine at Day - Y</span></p>
  </td>
  <td width=307 valign=top style='width:229.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  background:white;text-autospace:none'><span lang=EN-GB style='color:black'>Value
  2</span></p>
  </td>
 </tr>
</table>

<p class=MsoBodyText style='margin-left:.25in;line-height:normal;background:
white'><span lang=EN-GB style='color:black;font-weight:normal;font-style:normal'>X
and Y are the days (to be determined) when pre&#8209;treatment measurements
should be performed.</span></p>

<p class=MsoBodyText style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;font-weight:normal;font-style:normal'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A warning on the risk of overchelation </span><span
lang=EN-GB>and </span><span lang=EN-GB>on the necessity of close monitoring of
serum ferritin levels and renal and hepatic function.</span></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The rules for treatment dose adjustments and
interruption when target serum ferritin +/- liver iron concentration are
reached.</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:35.7pt;text-align:
left;text-indent:-17.85pt;page-break-after:avoid;background:white'><span
lang=EN-GB style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Recommendations for treatment of</span><span lang=EN-GB
style='font-family:"Times New Roman",serif;color:black'> non&#8209;transfusion&#8209;dependent
thalassaemia (NTDT) syndromes</span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>:</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:72.8pt;text-align:
left;text-indent:-17.5pt;background:white'><span lang=EN-GB style='font-family:
"Courier New";color:black'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Information that only one course of treatment is proposed for NTDT
patients</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:74.2pt;text-align:
left;text-indent:-17.5pt;background:white'><span lang=EN-GB style='font-family:
"Courier New";color:black'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>A warning on the necessity of closer monitoring of liver iron
concentration and serum ferritin in the paediatric population</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:74.2pt;text-align:
left;text-indent:-17.5pt;background:white'><span lang=EN-GB style='font-family:
"Courier New";color:black'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>A warning on the currently unknown safety consequences of long&#8209;term
treatment in the paediatric population</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
page-break-after:avoid;background:white'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Prior to launch of deferasirox film&#8209;coated tablets,
healthcare professionals will receive introductory notification letters as
follows:</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:.5in;text-align:left;
text-indent:-.25in;page-break-after:avoid;background:white'><span lang=EN-GB
style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Pharmacists - a detailed letter explaining the switch between
formulations</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:.5in;text-align:left;
text-indent:-.25in;page-break-after:avoid;background:white'><span lang=EN-GB
style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Prescribers - a letter including the following dossiers:</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.0in;text-align:left;
text-indent:-.25in;page-break-after:avoid;background:white'><span lang=EN-GB
style='font-family:"Courier New";color:black'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>A prescribers guide informing about the switch between
formulations in order to address the important potential risk of medication
error for deferasirox</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.0in;text-align:left;
text-indent:-.25in;page-break-after:avoid;background:white'><span lang=EN-GB
style='font-family:"Courier New";color:black'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>A patients guide informing about the possibility of co&#8209;existing
formulations in the EU market, and the differences concerning their
administration, in order to address the important potential risk of medication
error for deferasirox</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Additionally, prescribers and pharmacists will be informed via a
specific letter regarding the timelines for removing EXJADE dispersible tablets
from the EU market.</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
page-break-after:avoid;background:white'><b><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black'>The patient information pack</span></b><span
lang=EN-GB style='font-family:"Times New Roman",serif;color:black'> should
contain:</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:.5in;text-align:left;
text-indent:-.25in;page-break-after:avoid;background:white'><span lang=EN-GB
style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Patient information leaflet</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:38.5pt;text-align:
left;text-indent:-20.65pt;background:white'><span lang=EN-GB style='font-family:
Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>Patient guide</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
page-break-after:avoid;background:white'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black'>Patient guide should contain the following
key elements:</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.0in;text-align:left;
text-indent:-.25in;background:white'><span lang=EN-GB style='font-family:"Courier New";
color:black'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>Information
on the need for regular monitoring, and when it should be carried out, of serum
creatinine, creatinine clearance, proteinuria, hepatic enzymes, ferritin</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.0in;text-align:left;
text-indent:-.25in;background:white'><span lang=EN-GB style='font-family:"Courier New";
color:black'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>Information
that renal biopsy may be considered if significant renal abnormalities occur</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:1.0in;text-align:left;
text-indent:-.25in;background:white'><span lang=EN-GB style='font-family:"Courier New";
color:black'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>Availability
of several oral formulations (e.g. dispersible tablets, film-coated tablets and
granules) and the main differences associated with these formulations (i.e.,
different posology regimen, different conditions of administration notably with
food)</span></p>

<p class=MsoBodyTextIndent align=left style='margin-left:0in;text-align:left;
background:white'><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;page-break-before:
always;background:white'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Obligation to conduct
post&#8209;authorisation measures</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;background:white'><span
lang=EN-GB style='color:black'>The MAH shall complete, within the stated
timeframe, the below measures:</span></p>

<p class=MsoNormal style='margin-right:-.05pt;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="98%"
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width="83%" valign=top style='width:83.62%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05pt;background:white'><b><span
  lang=EN-GB style='color:black'>Description</span></b></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05pt;background:white'><b><span
  lang=EN-GB style='color:black'>Due date</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="83%" valign=top style='width:83.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='background:white'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>Non&#8209;interventional
  post&#8209;authorisation safety study (PASS): In order to assess the long&#8209;term
  exposure and safety of deferasirox dispersible and film&#8209;coated tablets,
  the MAH should conduct an observational cohort study in paediatric non&#8209;transfusion&#8209;dependent
  thalassaemia patients over 10&nbsp;years old for whom deferoxamine is
  contraindicated or inadequate conducted according to a CHMP&#8209;agreed
  protocol. The clinical study report should be submitted by</span></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='background:white'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>June
  2021</span></p>
  </td>
 </tr>
</table>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB style='color:black'>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB style='color:black'>LABELLING AND PACKAGE
LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB style='color:black'>A. LABELLING</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXJADE 125&nbsp;mg dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Each dispersible tablet contains 125&nbsp;mg of
deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Contains lactose. See leaflet for further
information.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black;background:#D9D9D9'>Dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>28&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black;background:#D9D9D9'>84&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black;background:#D9D9D9'>252&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Take this medicine on an empty stomach.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Disperse tablets in water or fruit juice before
swallowing. Do not swallow whole or chew.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'><img border=0 width=56 height=85
src="Exjade-II-073-EN%20PI_files/image009.jpg"></span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE
STORED OUT OF THE </span></b><b><span lang=EN-GB style='color:black'>SIGHT AND</span><span
lang=EN-GB style='color:black'> REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Keep out of the </span><span lang=EN-GB
style='color:black'>sight and</span><span lang=EN-GB style='color:black'> reach
of children.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Store in the original package in order to
protect from moisture.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED
MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>EU/1/06/356/00</span><span lang=PT style='color:black'>1                     </span><span
lang=FR style='color:black;background:#D9D9D9'>28&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black;background:#D9D9D9'>EU/1/06/356/00</span><span lang=PT
style='color:black;background:#D9D9D9'>2                     </span><span
lang=FR style='color:black;background:#D9D9D9'>84&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black;background:#D9D9D9'>EU/1/06/356/00</span><span lang=PT
style='color:black;background:#D9D9D9'>7                     </span><span
style='color:black;background:#D9D9D9'>252&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXJADE 125&nbsp;mg</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>PC:</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>SN:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>NN:</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>MINIMUM PARTICULARS TO
APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>BLISTERS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXJADE 125&nbsp;mg dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       NAME OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE 250&nbsp;mg dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Each dispersible tablet contains
250&nbsp;mg of deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Contains lactose. See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black;background:#D9D9D9'>Dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>28&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black;background:#D9D9D9'>84&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black;background:#D9D9D9'>252&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Take this medicine on an empty stomach.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Disperse tablets in water or fruit juice before
swallowing. Do not swallow whole or chew.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'><img border=0 width=56 height=85
src="Exjade-II-073-EN%20PI_files/image009.jpg"></span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE
STORED OUT OF THE </span></b><b><span lang=EN-GB style='color:black'>SIGHT AND</span><span
lang=EN-GB style='color:black'> REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Keep out of the </span><span lang=EN-GB
style='color:black'>sight and</span><span lang=EN-GB style='color:black'> reach
of children.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Store in the original package in order to
protect from moisture.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED
MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>EU/1/06/356/00</span><span lang=PT style='color:black'>3                     </span><span
lang=FR style='color:black;background:#D9D9D9'>28&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black;background:#D9D9D9'>EU/1/06/356/00</span><span lang=PT
style='color:black;background:#D9D9D9'>4                     </span><span
lang=FR style='color:black;background:#D9D9D9'>84&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black;background:#D9D9D9'>EU/1/06/356/00</span><span lang=PT
style='color:black;background:#D9D9D9'>8                     252</span><span
style='color:black;background:#D9D9D9'>&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXJADE 250&nbsp;mg</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>PC:</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>SN:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>NN:</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>MINIMUM PARTICULARS TO
APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>BLISTERS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE 250&nbsp;mg dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       NAME OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>CARTON OF UNIT PACK</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE 500&nbsp;mg dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Each dispersible tablet contains
500&nbsp;mg of deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Contains lactose. See leaflet for further
information.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black;background:#D9D9D9'>Dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>28&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black;background:#D9D9D9'>84&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black;background:#D9D9D9'>252&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Take this medicine on an empty stomach.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Disperse tablets in water or fruit juice before
swallowing. Do not swallow whole or chew.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'><img border=0 width=56 height=85
src="Exjade-II-073-EN%20PI_files/image010.jpg"></span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE
STORED OUT OF THE </span></b><b><span lang=EN-GB style='color:black'>SIGHT AND</span><span
lang=EN-GB style='color:black'> REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Keep out of the </span><span lang=EN-GB
style='color:black'>sight and</span><span lang=EN-GB style='color:black'> reach
of children.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Store in the original package in order to
protect from moisture.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED
MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>EU/1/06/356/00</span><span lang=PT style='color:black'>5                     </span><span
lang=FR style='color:black;background:#D9D9D9'>28&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black;background:#D9D9D9'>EU/1/06/356/00</span><span lang=PT
style='color:black;background:#D9D9D9'>6                     </span><span
lang=FR style='color:black;background:#D9D9D9'>84&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black;background:#D9D9D9'>EU/1/06/356/009                     252&nbsp;dispersible
tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE 500&nbsp;mg</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>PC:</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>SN:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>NN:</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>OUTER CARTON OF MULTIPACK (including blue box)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE 500&nbsp;mg dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Each dispersible tablet contains
500&nbsp;mg of deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Contains lactose. See leaflet for further
information.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black;background:#D9D9D9'>Dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Multipack: 294&nbsp;(3&nbsp;packs of
98)&nbsp;dispersible tablets.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Take this medicine on an empty stomach.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Disperse tablets in water or fruit juice before
swallowing. Do not swallow whole or chew.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'><img border=0 width=56 height=85
src="Exjade-II-073-EN%20PI_files/image009.jpg"></span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE
STORED OUT OF THE </span></b><b><span lang=EN-GB style='color:black'>SIGHT AND</span><span
lang=EN-GB style='color:black'> REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Keep out of the </span><span lang=EN-GB
style='color:black'>sight and</span><span lang=EN-GB style='color:black'> reach
of children.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Store in the original package in order to
protect from moisture.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED
MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>EU/1/06/356/010</span><span lang=PT style='color:black'>            </span><span
style='color:black;background:#D9D9D9'>294 (3&nbsp;packs of
98)&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=FR
style='color:black'>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=FR style='font-size:11.0pt;color:black'>EXJADE 500&nbsp;mg</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=FR style='color:black'>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>PC:</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>SN:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>NN:</span><b><u><span
lang=EN-GB style='color:black'><br clear=all style='page-break-before:always'>
</span></u></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>INTERMEDIATE CARTON OF MULTIPACK (without blue
box)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE 500&nbsp;mg dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Each dispersible tablet contains
500&nbsp;mg of deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Contains lactose. See leaflet for further
information.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black;background:#D9D9D9'>Dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>98&nbsp;dispersible tablets. Component of a
multipack. Cannot be sold separately.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Take this medicine on an empty stomach.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Disperse tablets in water or fruit juice before
swallowing. Do not swallow whole or chew.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'><img border=0 width=56 height=85
src="Exjade-II-073-EN%20PI_files/image009.jpg"></span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE
STORED OUT OF THE </span></b><b><span lang=EN-GB style='color:black'>SIGHT AND</span><span
lang=EN-GB style='color:black'> REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Keep out of the </span><span lang=EN-GB
style='color:black'>sight and</span><span lang=EN-GB style='color:black'> reach
of children.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Store in the original package in order to
protect from moisture.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED
MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>EU/1/06/356/010</span><span lang=PT style='color:black'>            </span><span
style='color:black;background:#D9D9D9'>294 (3&nbsp;packs of
98)&nbsp;dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE 500&nbsp;mg</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>MINIMUM PARTICULARS TO
APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>BLISTERS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>EXJADE 500&nbsp;mg dispersible tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       NAME OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON THE
OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>CARTON OF UNIT PACK</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Exjade 90&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Each
tablet contains 90&nbsp;mg of deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>Film&#8209;coated tablets</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>30&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>90&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE
STORED OUT OF THE </span></b><b><span lang=EN-GB style='color:black'>SIGHT AND</span><span
lang=EN-GB style='color:black'> REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Keep out of the </span><span lang=EN-GB
style='color:black'>sight and</span><span lang=EN-GB style='color:black'> reach
of children.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span style='color:black'>EU/1/06/356/01</span><span
lang=PT style='color:black'>1                     </span><span
style='color:black;background:#D9D9D9'>30&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal style='background:white'><span style='color:black;
background:#D9D9D9'>EU/1/06/356/01</span><span lang=PT style='color:black;
background:#D9D9D9'>2</span><span lang=PT style='color:black'>                     </span><span
style='color:black;background:#D9D9D9'>90&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=PT>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
90&nbsp;mg</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>PC:</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>SN:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>NN:</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>OUTER CARTON OF MULTIPACK</span></b><b><span
lang=EN-GB style='color:black'> </span><span lang=EN-GB style='color:black'>(INCLUDING
BLUE BOX)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Exjade 90&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Each
tablet contains 90&nbsp;mg of deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>Film&#8209;coated tablets</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Multipack: 300&nbsp;(10&nbsp;packs of
30)&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE
STORED OUT OF THE </span></b><b><span lang=EN-GB style='color:black'>SIGHT AND</span><span
lang=EN-GB style='color:black'> REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Keep out of the </span><span lang=EN-GB
style='color:black'>sight and</span><span lang=EN-GB style='color:black'> reach
of children.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>EU/1/06/356/013                     </span><span
lang=EN-GB style='color:black;background:#D9D9D9'>300&nbsp;(10&nbsp;packs of
30)&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
90&nbsp;mg</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>PC:</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>SN:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>NN:</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE
BOX)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Exjade 90&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Each
tablet contains 90&nbsp;mg of deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>Film&#8209;coated tablets</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>30&nbsp;film&#8209;coated tablets. Component of
a multipack. Not to be sold separately.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE
STORED OUT OF THE </span></b><b><span lang=EN-GB style='color:black'>SIGHT AND</span><span
lang=EN-GB style='color:black'> REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Keep out of the </span><span lang=EN-GB
style='color:black'>sight and</span><span lang=EN-GB style='color:black'> reach
of children.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>EU/1/06/356/013                     </span><span
lang=EN-GB style='color:black;background:#D9D9D9'>300&nbsp;(10&nbsp;packs of
30)&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
90&nbsp;mg</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>MINIMUM PARTICULARS TO
APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>BLISTERS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
90&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       NAME OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON THE
OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>CARTON OF UNIT PACK</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Exjade 180&nbsp;mg </span><span lang=EN-GB
style='color:black'>film&#8209;coated</span><span style='color:black'> tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Each
tablet contains 180&nbsp;mg of deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>Film&#8209;coated tablets</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>30&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>90&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE
STORED OUT OF THE </span></b><b><span lang=EN-GB style='color:black'>SIGHT AND</span><span
lang=EN-GB style='color:black'> REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Keep out of the </span><span lang=EN-GB
style='color:black'>sight and</span><span lang=EN-GB style='color:black'> reach
of children.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span style='color:black'>EU/1/06/356/014</span><span
lang=PT style='color:black'>                     </span><span style='color:
black;background:#D9D9D9'>30&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal style='background:white'><span style='color:black;
background:#D9D9D9'>EU/1/06/356/015</span><span lang=PT style='color:black'>                     </span><span
style='color:black;background:#D9D9D9'>90&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=PT>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
180&nbsp;mg</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>PC:</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>SN:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>NN:</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>OUTER CARTON OF MULTIPACK</span></b><b><span
lang=EN-GB style='color:black'> </span><span lang=EN-GB style='color:black'>(INCLUDING
BLUE BOX)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Exjade 180&nbsp;mg </span><span lang=EN-GB
style='color:black'>film&#8209;coated</span><span style='color:black'> tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Each
tablet contains 180&nbsp;mg of deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>Film&#8209;coated tablets</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Multipack: 300&nbsp;(10&nbsp;packs of
30)&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE
STORED OUT OF THE </span></b><b><span lang=EN-GB style='color:black'>SIGHT AND</span><span
lang=EN-GB style='color:black'> REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Keep out of the </span><span lang=EN-GB
style='color:black'>sight and</span><span lang=EN-GB style='color:black'> reach
of children.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>EU/1/06/356/016                     <span
style='background:#D9D9D9'>300&nbsp;(10&nbsp;packs of 30)&nbsp;film&#8209;coated
tablets</span></span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
180&nbsp;mg</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>PC:</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>SN:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>NN:</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE
BOX)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Exjade 180&nbsp;mg </span><span lang=EN-GB
style='color:black'>film&#8209;coated</span><span style='color:black'> tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Each
tablet contains 180&nbsp;mg of deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>Film&#8209;coated tablets</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>30&nbsp;film&#8209;coated tablets. Component of
a multipack. Not to be sold separately.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE
STORED OUT OF THE </span></b><b><span lang=EN-GB style='color:black'>SIGHT AND</span><span
lang=EN-GB style='color:black'> REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Keep out of the </span><span lang=EN-GB
style='color:black'>sight and</span><span lang=EN-GB style='color:black'> reach
of children.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>EU/1/06/356/016                     <span
style='background:#D9D9D9'>300&nbsp;(10&nbsp;packs of 30)&nbsp;film&#8209;coated
tablets</span></span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
180&nbsp;mg</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>MINIMUM PARTICULARS TO
APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>BLISTERS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
180&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       NAME OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>CARTON OF UNIT PACK</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Exjade 360&nbsp;mg </span><span lang=EN-GB
style='color:black'>film&#8209;coated</span><span style='color:black'> tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Each
tablet contains 360&nbsp;mg of deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>Film&#8209;coated tablets</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>30&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>90&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE
STORED OUT OF THE </span></b><b><span lang=EN-GB style='color:black'>SIGHT AND</span><span
lang=EN-GB style='color:black'> REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Keep out of the </span><span lang=EN-GB
style='color:black'>sight and</span><span lang=EN-GB style='color:black'> reach
of children.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span style='color:black'>EU/1/06/356/017</span><span
lang=PT style='color:black'>                     </span><span style='color:
black;background:#D9D9D9'>30&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal style='background:white'><span style='color:black;
background:#D9D9D9'>EU/1/06/356/018</span><span lang=PT style='color:black'>                     </span><span
style='color:black;background:#D9D9D9'>90&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=PT>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
360&nbsp;mg</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>PC:</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>SN:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>NN:</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>OUTER CARTON OF MULTIPACK</span></b><b><span
lang=EN-GB style='color:black'> </span><span lang=EN-GB style='color:black'>(INCLUDING
BLUE BOX)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Exjade 360&nbsp;mg </span><span lang=EN-GB
style='color:black'>film&#8209;coated</span><span style='color:black'> tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Each
tablet contains 360&nbsp;mg of deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>Film&#8209;coated tablets</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Multipack: 300&nbsp;(10&nbsp;packs of
30)&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE
STORED OUT OF THE </span></b><b><span lang=EN-GB style='color:black'>SIGHT AND</span><span
lang=EN-GB style='color:black'> REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Keep out of the </span><span lang=EN-GB
style='color:black'>sight and</span><span lang=EN-GB style='color:black'> reach
of children.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>EU/1/06/356/019                     <span
style='background:#D9D9D9'>300&nbsp;(10&nbsp;packs of 30)&nbsp;film&#8209;coated
tablets</span></span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
360&nbsp;mg</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>PC:</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>SN:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>NN:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='background:
#CCCCCC'>&nbsp;</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE
BOX)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>Exjade 360&nbsp;mg </span><span lang=EN-GB
style='color:black'>film&#8209;coated</span><span style='color:black'> tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Each
tablet contains 360&nbsp;mg of deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>Film&#8209;coated tablets</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>30&nbsp;film&#8209;coated tablets. Component of
a multipack. Not to be sold separately.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE
STORED OUT OF THE </span></b><b><span lang=EN-GB style='color:black'>SIGHT AND</span><span
lang=EN-GB style='color:black'> REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Keep out of the </span><span lang=EN-GB
style='color:black'>sight and</span><span lang=EN-GB style='color:black'> reach
of children.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>EU/1/06/356/019                     <span
style='background:#D9D9D9'>300&nbsp;(10&nbsp;packs of 30)&nbsp;film&#8209;coated
tablets</span></span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
360&nbsp;mg</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>MINIMUM PARTICULARS TO
APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>BLISTERS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
360&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       NAME OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>CARTON OF UNIT PACK</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
90&nbsp;mg granules in sachet</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Each
sachet contains 90&nbsp;mg of deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black;
background:#D9D9D9'>Granules in sachet</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>30&nbsp;sachets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE
STORED OUT OF THE </span></b><b><span lang=EN-GB style='color:black'>SIGHT AND</span><span
lang=EN-GB style='color:black'> REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Keep out of the </span><span lang=EN-GB
style='color:black'>sight and</span><span lang=EN-GB style='color:black'> reach
of children.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span style='color:black'>EU/1/06/356/020</span><span
lang=PT style='color:black'>            </span><span style='color:black;
background:#D9D9D9'>30&nbsp;sachets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=PT>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
90&nbsp;mg</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='background:
#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>PC:</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>SN:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>NN:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='background:
#CCCCCC'>&nbsp;</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>MINIMUM PARTICULARS TO
APPEAR ON </span></b><b><span lang=EN-GB style='color:black'>SMALL IMMEDIATE
PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>SACHETS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b><b><span
lang=EN-GB style='color:black'> AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
90&nbsp;mg granules</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       </span></b><b><span lang=EN-GB style='color:black'>METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>5.       CONTENTS BY WEIGHT, BY VOLUME OR BY
UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;background:white'><span
style='color:black'>162&nbsp;mg</span></p>

<p class=MsoNormal style='margin-right:5.65pt;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>CARTON OF UNIT PACK</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
180&nbsp;mg granules in sachet</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Each
sachet contains 180&nbsp;mg of deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black;
background:#D9D9D9'>Granules in sachet</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>30&nbsp;sachets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE
STORED OUT OF THE </span></b><b><span lang=EN-GB style='color:black'>SIGHT AND</span><span
lang=EN-GB style='color:black'> REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Keep out of the </span><span lang=EN-GB
style='color:black'>sight and</span><span lang=EN-GB style='color:black'> reach
of children.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span style='color:black'>EU/1/06/356/021</span><span
lang=PT style='color:black'>            </span><span style='color:black;
background:#D9D9D9'>30&nbsp;sachets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=PT>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
180&nbsp;mg</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='background:
#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>PC:</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>SN:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>NN:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='background:
#CCCCCC'>&nbsp;</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>MINIMUM PARTICULARS TO
APPEAR ON </span></b><b><span lang=EN-GB style='color:black'>SMALL IMMEDIATE
PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>SACHETS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b><b><span
lang=EN-GB style='color:black'> AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
180&nbsp;mg granules</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       </span></b><b><span lang=EN-GB style='color:black'>METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>5.       CONTENTS BY WEIGHT, BY VOLUME OR BY
UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span style='color:black'>324</span><span
lang=EN-GB style='color:black'>&nbsp;mg</span></p>

<p class=MsoNormal style='margin-right:5.65pt;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>CARTON OF UNIT PACK</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
360&nbsp;mg granules in sachet</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Each
sachet contains 360&nbsp;mg of deferasirox.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       PHARMACEUTICAL FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black;
background:#D9D9D9'>Granules in sachet</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>30&nbsp;sachets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE
STORED OUT OF THE </span></b><b><span lang=EN-GB style='color:black'>SIGHT AND</span><span
lang=EN-GB style='color:black'> REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Keep out of the </span><span lang=EN-GB
style='color:black'>sight and</span><span lang=EN-GB style='color:black'> reach
of children.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>9.       SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span style='color:black'>EU/1/06/356/022</span><span
lang=PT style='color:black'>            </span><span style='color:black;
background:#D9D9D9'>30&nbsp;sachets</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span lang=PT>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span style='color:black'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><u><span
lang=EN-GB style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
360&nbsp;mg</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='background:
#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>17.     UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black;background:#D9D9D9'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>18.     UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>PC:</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
lang=EN-GB style='color:black'>SN:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>NN:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='background:
#CCCCCC'>&nbsp;</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>MINIMUM PARTICULARS TO
APPEAR ON </span></b><b><span lang=EN-GB style='color:black'>SMALL IMMEDIATE
PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white;border:none;
padding:0in'><b><span lang=EN-GB style='color:black'>SACHETS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>1.       NAME OF THE MEDICINAL PRODUCT</span></b><b><span
lang=EN-GB style='color:black'> AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Exjade
360&nbsp;mg granules</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>deferasirox</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Oral use</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>2.       </span></b><b><span lang=EN-GB style='color:black'>METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>5.       CONTENTS BY WEIGHT, BY VOLUME OR BY
UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span style='color:black'>648</span><span
lang=EN-GB style='color:black'>&nbsp;mg</span></p>

<p class=MsoNormal style='margin-right:5.65pt;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white;border:none;padding:0in'><b><span lang=EN-GB
style='color:black'>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB style='color:black'>B. PACKAGE LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB style='color:black'>Package leaflet:
Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=FR-CH style='color:black'>EXJADE 125&nbsp;mg
dispersible tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=FR-CH style='color:black'>EXJADE 250&nbsp;mg
dispersible tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB style='color:black'>EXJADE 500&nbsp;mg
dispersible tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB style='color:black'>Deferasirox</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'><img
border=0 width=21 height=18 src="Exjade-II-073-EN%20PI_files/image004.gif"></span><span
lang=EN-GB style='color:black'>This medicine is subject to additional
monitoring. This will allow quick identification of new safety information. You
can help by reporting any side effects you may get. See the end of section 4
for how to report side effects.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><b><span lang=EN-GB style='color:black'>Read all of this leaflet
carefully before you start taking this medicine because it contains important
information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Keep this leaflet. You may
need to read it again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you have any further
questions, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>This medicine has been
prescribed only for you or your child. Do not pass it on to others. It may harm
them, even if their signs of illness are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you get any side effects,
talk to your doctor or pharmacist.</span><span lang=EN-GB style='color:black'> </span><span
lang=EN-GB style='color:black'>This includes</span><span lang=EN-GB
style='color:black'> any possible side effects not listed in this leaflet. See
section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><b><span lang=EN-GB style='color:black'>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>1.       What
EXJADE is and what it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>2.       What you
need to know before you take EXJADE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>3.       How to
take EXJADE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>4.       Possible
side effects</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>5.       How to
store EXJADE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>6.       Contents
of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>1.       </span></b><b><span lang=EN-GB style='color:black'>What
EXJADE is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>What EXJADE is</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>EXJADE contains an active
substance called deferasirox. It is an iron chelator<i> </i>which is a medicine
used to remove the excess iron from the body (also called iron overload). It
traps and removes excess iron which is then excreted mainly in the stools.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>What EXJADE is used for</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Repeated blood transfusions may be
necessary in patients with various types of anaemia (for example thalassaemia,
sickle cell disease or myelodysplastic syndromes (MDS)). However, repeated
blood transfusions can cause a build&#8209;up of excess iron. This is because
blood contains iron and your body does not have a natural way to remove the
excess iron you get with your blood transfusions. In patients with non&#8209;transfusion&#8209;dependent
thalassaemia syndromes, iron overload may also develop over time, mainly due to
increased absorption of dietary iron in response to low blood cell counts. Over
time, the excess iron can damage important organs such as the liver and heart.
Medicines called <i>iron chelators </i>are used to remove the excess iron and
reduce the risk of it causing organ damage.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>EXJADE is used to treat chronic
iron overload caused by frequent blood transfusions in patients with beta
thalassaemia major aged 6&nbsp;years and older.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>EXJADE is also used to treat
chronic iron overload when deferoxamine therapy is contraindicated or
inadequate in patients with beta thalassaemia major with iron overload caused
by infrequent blood transfusions, in patients with other types of anaemias, and
in children aged 2 to 5&nbsp;years.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>EXJADE is also used when
deferoxamine therapy is contraindicated or inadequate to treat patients aged
10&nbsp;years or older who have iron overload associated with their
thalassaemia syndromes, but who are not transfusion dependent.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>2.       What you need to know before you take EXJADE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Do not take EXJADE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
are allergic to deferasirox or any of the other ingredients of this medicine (listed
in section&nbsp;6). If this applies to you, <b>tell your doctor before taking
EXJADE</b>. If you think you may be allergic, ask your doctor for advice.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if you have moderate or severe
kidney disease.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if you are currently taking
any other iron chelator medicines.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>EXJADE is not recommended</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if you are at an advanced
stage of myelodysplastic syndrome (MDS; decreased production of blood cells by
the bone marrow) or have advanced cancer.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>Warnings and
precautions</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>Talk to your
doctor or pharmacist before taking EXJADE:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
have a kidney or liver problem.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
have a cardiac problem due to iron overload.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
notice a marked decrease in your urine output (sign of kidney problem).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
develop a severe rash, or difficulty breathing and dizziness or swelling mainly
of the face and throat (signs of severe allergic reaction, see also section 4
Possible side effects).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='color:black'>-        if you experience a
combination of any of the following symptoms: rash, red skin, blistering of the
lips, eyes, or mouth, skin peeling, high fever, flu-like symptoms, enlarged
lymph nodes (signs of severe skin reaction, see also section 4 Possible side
effects).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
experience a combination of drowsiness, upper right abdominal pain, yellowing
or increased yellowing of your skin or eyes and dark urine (signs of liver
problems).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
experience difficulty thinking, remembering information, or solving problems,
being less alert or aware or feeling very sleepy with low energy (signs of a
high level of ammonia in your blood, which may be associated with liver or
renal problems, see also section&nbsp;4 Possible side effects).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
vomit blood and/or have black stools.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you experience
frequent abdominal pain, particularly after eating or taking EXJADE.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
experience frequent heartburn.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
have a low level of platelets or white blood cells in your blood test.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
have blurred vision.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><span lang=EN-GB
style='color:black'>-        if you have diarrhoea or vomiting.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>If any of these
apply to you, tell your doctor straight away.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;page-break-after:avoid;
background:white'><b><span lang=EN-GB style='font-size:11.0pt;color:black'>Monitoring
your EXJADE treatment</span></b></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>You will have regular blood and
urine tests during treatment. These will monitor the amount of iron in your
body (blood level of <i>ferritin</i>) to see how well EXJADE is working. The
tests will also monitor your kidney function (blood level of creatinine, presence
of protein in the urine) and liver function (blood level of transaminases). Your
doctor may require you to undergo a kidney biopsy, if he/she suspects
significant kidney damage. You may also have MRI (magnetic resonance imaging)
tests to determine the amount of iron in your liver. Your doctor will take
these tests into consideration when deciding on the dose of EXJADE most
suitable for you and will also use these tests to decide when you should stop
taking EXJADE.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Your eyesight and hearing will
be tested each year during treatment as a precautionary measure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>Other medicines
and EXJADE</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Tell your doctor or pharmacist if
you are taking, have recently taken or might take any other medicines. This
includes in particular:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        other
iron chelators, which must not be taken with EXJADE,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        antacids
(medicines used to treat heartburn) containing aluminium, which should not be
taken at the same time of day as EXJADE,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        ciclosporin
(used to prevent the body rejecting a transplanted organ or for other conditions,
such as rheumatoid arthritis or atopic dermatitis),</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>-        simvastatin (used to lower
cholesterol),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        certain
painkillers or anti&#8209;inflammatory medicines (e.g. aspirin, ibuprofen,
corticosteroids),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        oral
bisphosphonates (used to treat osteoporosis),</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>-        anticoagulant medicines
(used to prevent or treat blood clotting),</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>-        hormonal contraceptive
agents (birth control medicines),</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>-        bepridil, ergotamine (used
for heart problems and migraines),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        repaglinide
(used to treat diabetes),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        rifampicin
(used to treat tuberculosis),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        phenytoin,
phenobarbital, carbamazepine (used to treat epilepsy),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        ritonavir
(used in the treatment of HIV infection),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        paclitaxel
(used in cancer treatment),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        theophylline
(used to treat respiratory diseases such as asthma),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        clozapine
(used to treat psychiatric disorders such as schizophrenia),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        tizanidine
(used as a muscle relaxant),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        cholestyramine
(used to lower cholesterol levels in the blood),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        busulfan
(used as a treatment prior to transplantation in order to destroy the original
bone marrow before the transplant).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>Additional tests may be required to
monitor the blood levels of some of these medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Older people (age 65&nbsp;years
and over)</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>EXJADE can be used by people aged
65&nbsp;years and over at the same dose as for other adults. Elderly patients
may experience more side effects (in particular diarrhoea) than younger
patients. They should be monitored closely by their doctor for side effects that
may require a dose adjustment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Children and adolescents</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>EXJADE can be used in children and adolescents
receiving regular blood transfusions aged 2&nbsp;years and over and in children
and adolescents not receiving regular blood transfusions aged 10&nbsp;years and
over. As the patient grows the doctor will adjust the dose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>EXJADE is not recommended for
children aged under 2&nbsp;years.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Pregnancy and breast&#8209;feeding</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>If you are pregnant or breast&#8209;feeding,
think you may be pregnant or are planning to have a baby, ask your doctor for
advice before taking this medicine.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXJADE is not recommended during pregnancy
unless clearly necessary.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>If you are currently using an oral
contraceptive or using a patch contraceptive to prevent pregnancy, you should
use an additional or different type of contraception (e.g. condom), as EXJADE
may reduce the effectiveness of oral and patch contraceptives.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Breast&#8209;feeding is not recommended during
treatment with EXJADE.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Driving and using machines</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>If you feel dizzy after taking EXJADE,
do not drive or operate any tools or machines until you are feeling normal
again.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>EXJADE contains lactose</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>If you have been told by your
doctor that you have an intolerance to some sugars, contact your doctor before
taking this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>3.       </span></b><b><span lang=EN-GB style='color:black'>H</span><span
lang=EN-GB style='color:black'>ow to take EXJADE</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white;text-autospace:
none'><span lang=EN-GB style='color:black'>Treatment with EXJADE will be
overseen by a doctor who is experienced in the treatment of iron overload
caused by blood transfusions.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>Always take this medicine exactly
as your doctor has told you. Check with your doctor or pharmacist if you are
not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>How much EXJADE
to take</span></b></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;page-break-after:avoid;
background:white'><span lang=EN-GB style='font-size:11.0pt;color:black'>The
dose of EXJADE is related to body weight for all patients. Your doctor will
calculate the dose you need and tell you how many tablets to take each day.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>The usual
daily dose for EXJADE dispersible tablets <span style='layout-grid-mode:line'>at
the start of the treatment</span> for patients receiving regular blood
transfusions is 20&nbsp;mg per kilogram body weight. A higher or lower starting
dose may be recommended by your doctor based on your individual treatment needs.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>The usual daily dose for
EXJADE dispersible tablets at the start of the treatment for patients not
receiving regular blood transfusions is 10&nbsp;mg per kilogram body weight.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Depending
on how you respond to treatment, your doctor may later adjust your treatment to
a higher or lower dose.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>The maximum
recommended daily dose for EXJADE dispersible tablets is 40&nbsp;mg per
kilogram body weight for patients receiving regular blood transfusions,
20&nbsp;mg per kilogram body weight for adult patients not receiving regular
blood transfusions and 10&nbsp;mg per kilogram body weight for children and
adolescents not receiving regular blood transfusions.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>Deferasirox also comes as film&#8209;coated
tablets</span><span lang=EN-GB style='color:black'> and granules</span><span
lang=EN-GB style='color:black'>. If you are switching from the film&#8209;coated
tablets </span><span lang=EN-GB style='color:black'>or granules </span><span
lang=EN-GB style='color:black'>to these dispersible tablets, you will need an
adjustment of the dose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>When to take
EXJADE</span></b></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Take EXJADE
once a day, every day, at about the same time each day.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Take the EXJADE
dispersible tablets on an empty stomach.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Then wait
at least 30&nbsp;minutes before eating any food.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Taking EXJADE at the same time
each day will also help you remember when to take your tablets.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=451 valign=top style='width:338.55pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Listlevel1 style='margin:0in;text-indent:0in;page-break-after:avoid;
  background:white'><b><span lang=EN-GB style='font-size:11.0pt;color:black'>How
  to take EXJADE</span></b><span lang=EN-GB style='font-size:11.0pt;color:black'>:</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;
  line-height:normal;background:white'><span lang=EN-GB style='font-family:
  Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><b><span lang=EN-GB style='color:black'>Drop </span></b><span
  lang=EN-GB style='color:black'>the tablet(s) into a glass of water, or apple
  or orange juice (100 to 200&nbsp;ml).</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;
  line-height:normal;background:white'><span lang=EN-GB style='font-family:
  Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><b><span lang=EN-GB style='color:black'>Stir</span></b><span
  lang=EN-GB style='color:black'> until the tablet(s) dissolve completely. The
  liquid in the glass will look cloudy.</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;background:white'><span lang=EN-GB style='font-family:
  Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><b><span lang=EN-GB style='color:black'>Drink</span></b><span
  lang=EN-GB style='color:black'> everything in the glass. Then add a little
  water or juice to what is left in the glass, swirl the liquid around and
  drink that too.</span></p>
  <p class=MsoNormal style='margin-right:-.1pt;background:white'><span
  lang=EN-GB style='color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:11.0pt;background:white'><span
  lang=EN-GB style='color:black'>Do not dissolve the tablets in fizzy drinks or
  milk.</span></p>
  <p class=MsoNormal style='line-height:11.0pt;background:white'><span
  lang=EN-GB style='color:black'>Do not chew, break or crush the tablets.</span></p>
  <p class=MsoNormal style='line-height:11.0pt;background:white'><span
  lang=EN-GB style='color:black'>Do not swallow the tablets whole.</span></p>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
  white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
  white'><span lang=EN-GB style='color:black'><img border=0 width=97 height=84
  id="Picture 10" src="Exjade-II-073-EN%20PI_files/image011.jpg"
  alt="EXJADE_step1"></span></p>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
  white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
  white'><span lang=EN-GB style='color:black'><img border=0 width=102
  height=97 id="Picture 11" src="Exjade-II-073-EN%20PI_files/image012.jpg"
  alt="EXJADE_step2"></span></p>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
  white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
  white'><span lang=EN-GB style='color:black'><img border=0 width=97 height=88
  id="Picture 12" src="Exjade-II-073-EN%20PI_files/image013.jpg"
  alt="EXJADE_Step3"></span></p>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
  white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>How long to take EXJADE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><b><span lang=EN-GB style='color:black'>Continue taking EXJADE every day
for as long as your doctor tells you.</span></b><span lang=EN-GB
style='color:black'> This is a long&#8209;term treatment, possibly lasting for
months or years. Your doctor will regularly monitor your condition to check
that the treatment is having the desired effect (see also section&nbsp;2:
Monitoring your EXJADE treatment).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>If you have questions about how
long to take EXJADE, talk to your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>If you take more EXJADE than you
should</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>If you have taken too much EXJADE,
or if someone else accidentally takes your tablets, contact your doctor or
hospital for advice straight away. Show the doctor the pack of tablets. Urgent
medical treatment may be necessary. </span><span lang=EN-GB style='color:black'>You
may experience effects such as abdominal pain, diarrhoea, nausea and vomiting and
kidney or liver problems that can be serious.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>If you forget to take EXJADE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>If you miss a dose, take it as soon
as you remember on that day. Take your next dose as scheduled. Do not take a
double dose on the next day to make up for the forgotten tablet(s).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>If you stop taking EXJADE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>Do not stop taking EXJADE unless
your doctor tells you to. If you stop taking it, the excess iron will no longer
be removed from your body (see also above section How long to take EXJADE).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.       </span></b><b><span lang=EN-GB style='color:black'>Possible
side effects</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Like all medicines, </span><span
style='font-size:11.0pt;color:black'>this medicine</span><span lang=EN-GB
style='font-size:11.0pt;color:black'> can cause side effects, although not
everybody gets them. Most of the side effects are mild to moderate and will
generally disappear after a few days to a few weeks of treatment.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>Some side
effects could be serious and need immediate medical attention.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><i><span lang=EN-GB style='color:black'>These side
effects are uncommon (may affect up to 1 in 100&nbsp;people) or rare (</span></i><i><span
style='color:black'>may affect up to 1 in 1,000&nbsp;people)</span><span
lang=EN-GB style='color:black'>.</span></i></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you get
a severe rash, or difficulty breathing and dizziness or swelling mainly of the
face and throat (signs of severe allergic reaction),</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience a combination of any of the following symptoms: rash, red skin,
blistering of the lips, eyes, or mouth, skin peeling, high fever, flu-like
symptoms, enlarged lymph nodes, (signs of severe skin reactions),</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
notice a marked decrease in your urine output (sign of kidney problem),</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience a combination of drowsiness, upper right abdominal pain, yellowing
or increased yellowing of your skin or eyes and dark urine (signs of liver
problems),</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience difficulty thinking, remembering information, or solving problems,
being less alert or aware or feeling very sleepy with low energy (signs of a
high level of ammonia in your blood, which may be associated with liver or
renal problems and lead to a change in your brain function),</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
vomit blood and/or have black stools,</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience frequent abdominal pain, particularly after eating or taking EXJADE,</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience frequent heartburn,</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid;background:
white'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience partial loss of vision,</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid;background:
white'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience severe upper stomach pain (pancreatitis),</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><b><span lang=EN-GB style='color:black'>stop taking this medicine and
tell your doctor straight away.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>Some side
effects could become serious.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><i><span lang=EN-GB style='color:black'>These side
effects are uncommon.</span></i></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you get
blurred or cloudy eyesight,</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid;background:
white'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you get
reduced hearing,</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><b><span
style='font-size:11.0pt;color:black'>tell your doctor as soon as possible.</span></b></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
class=Nottoc-headingsChar><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;font-weight:normal'>&nbsp;</span></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>Other side
effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><i><span lang=EN-GB style='color:black'>Very common
(may affect more than 1 in 10&nbsp;people</span></i><span lang=EN-GB
style='color:black'>)</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>Disturbance in kidney
function tests.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
class=Nottoc-headingsChar><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;font-weight:normal'>&nbsp;</span></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><i><span lang=EN-GB style='color:black'>Common (may
affect up to 1 in 10&nbsp;people)</span></i></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Gastrointestinal
disorders, such as nausea, vomiting, diarrhoea, pain in the abdomen, bloating,
constipation, indigestion</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Rash</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Headache</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Disturbance
in liver function tests</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Itching</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid;background:
white'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Disturbance
in urine test (protein in the urine)</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>If any of these affects you
severely, tell your doctor.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;page-break-after:avoid;
background:white'><i><span style='font-size:11.0pt;color:black'>Uncommon (may
affect up to 1 in 100&nbsp;people)</span></i></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Dizziness</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Fever</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Sore throat</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Swelling of
arms or legs</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Change in
the colour of the skin</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Anxiety</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Sleep
disorder</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid;background:
white'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Tiredness</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>If any of these affects you
severely, tell your doctor.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid;background:white'><b><span
style='font-size:11.0pt'>Frequency not known </span></b><span style='font-size:
11.0pt'>(cannot be estimated from the available data).</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>A decrease
in the number of cells involved in blood clotting (thrombocytopenia), in the
number of red blood cells (anaemia aggravated), in the number of white blood
cells (neutropenia) or in the number of all kinds of blood cells (pancytopenia)</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Hair loss</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Kidney
stones</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Low urine
output</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Tear in
stomach or intestine wall that can be painful and cause nausea</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>Severe upper stomach
pain (pancreatitis)</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>Abnormal level of acid
in blood</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid;background:white'><b><span
style='font-size:11.0pt'>Reporting of side effects</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>If you get any side effects</span><span
style='font-size:11.0pt;color:black'>, talk to your doctor or pharmacist.</span><span
style='font-size:11.0pt;color:black'> This includes</span><span lang=EN-GB
style='font-size:11.0pt;color:black'> any possible side effects not listed in
this leaflet. You can also report side effects directly <span style='background:
#D9D9D9'>via the national reporting system listed in </span></span><span
style='color:black'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='font-size:11.0pt;background:#D9D9D9'>Appendix V</span></a></span><span
lang=EN-GB style='font-size:11.0pt;color:black'>. By reporting side effects you
can help provide more information on the safety of this medicine.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>5.       </span></b><b><span lang=EN-GB style='color:black'>How
to store EXJADE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Keep this
medicine out of the </span><span style='font-size:11.0pt;color:black'>sight and</span><span
style='font-size:11.0pt;color:black'> <span lang=EN-GB>reach of children.</span></span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Do not use </span><span
style='font-size:11.0pt;color:black'>this medicine</span><span lang=EN-GB
style='font-size:11.0pt;color:black'> after the expiry date which is stated on
the blister and the carton after EXP. The expiry date refers to the last day of
that month.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Store in
the original package in order to protect from moisture.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Do not use
any pack that is damaged or shows signs of tampering.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Do not
throw away any medicines via wastewater or household waste. Ask your pharmacist
how to throw away medicines you no longer use. These measures will help protect
the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.       Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>What EXJADE contains</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>The active
substance is deferasirox.</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt;
background:white'><span style='font-size:11.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>Each dispersible tablet
of EXJADE 125&nbsp;mg contains 125&nbsp;mg deferasirox.</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt;
background:white'><span style='font-size:11.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>Each dispersible tablet
of EXJADE 250&nbsp;mg contains 250&nbsp;mg deferasirox.</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt;
background:white'><span style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>Each dispersible tablet
of EXJADE 500&nbsp;mg contains 500&nbsp;mg deferasirox.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>The other ingredients are lactose
monohydrate, crospovidone type A, povidone, sodium laurilsulfate,
microcrystalline cellulose, colloidal anhydrous silica and magnesium stearate.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>What EXJADE
looks like and contents of the pack</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>EXJADE is
supplied as dispersible tablets. The tablets are white to slightly yellow,
round and flat.</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt;
background:white'><span style='font-size:11.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>EXJADE 125&nbsp;mg
tablets are stamped J&nbsp;125 on one side and NVR on the other.</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt;
background:white'><span style='font-size:11.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>EXJADE 250&nbsp;mg
tablets are stamped J&nbsp;250 on one side and NVR on the other.</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt;
background:white'><span style='font-size:11.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>EXJADE 500&nbsp;mg
tablets are stamped J&nbsp;500 on one side and NVR on the other.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>EXJADE 125&nbsp;mg, 250&nbsp;mg
and 500&nbsp;mg dispersible tablets are available in unit packs containing 28,
84&nbsp;or 252&nbsp;dispersible tablets.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>EXJADE 500&nbsp;mg dispersible
tablets are also available in multipacks containing 294 (3&nbsp;packs of
98)&nbsp;dispersible tablets.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Not all pack sizes or strengths
may be available in your country.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>Novartis Europharm
Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>Novartis Pharma GmbH</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>Roonstra</span><span lang=PT style='color:
black'>ß</span><span style='color:black'>e 25</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>D-90429 Nuremberg</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span style='color:black'>Germany</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>For any information about this
medicine, please contact the local representative of the Marketing
Authorisation Holder.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=FR-BE style='color:black'>België/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=FR-BE style='color:black'>Novartis Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=FR-BE style='color:black'>Tél/Tel: +32 2 246 16 11</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal;background:
  white'><span lang=FR style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=LT style='color:black'>Lietuva</span></b></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal;
  background:white'><span lang=LT style='color:black'>Novartis Pharma Services
  Inc.</span></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal;
  background:white'><span lang=LT style='color:black'>Tel: +370 5 269 16 50</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-CH style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='background:white'><b><span lang=EN-GB
  style='color:black'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='background:white'><span lang=ES style='color:black'>Novartis
  Bulgaria EOOD</span></p>
  <p class=MsoNormal style='background:white'><span lang=EN-GB
  style='color:black'>&#1058;&#1077;&#1083;</span><span lang=ES
  style='color:black'>.: +359 2 489 98 28</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=NO-BOK style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=DE-CH style='color:black'>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-CH style='color:black'>Novartis Pharma N.V</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-CH style='color:black'>Tél/Tel: </span><span lang=FR-BE
  style='color:black'>+32 2 246 16 11</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-CH style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=NO-BOK style='color:black'>&#268;eská republika</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=NO-BOK style='color:black'>Novartis s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-CH style='color:black'>Tel: +420 225 775 111</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-CH style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=HU style='color:black'>Magyarország</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=HU
  style='color:black'>Novartis Hungária Kft.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=HU
  style='color:black'>Tel.: +36 1 457 65 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=DA style='color:black'>Danmark</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=DA
  style='color:black'>Novartis Healthcare A/S</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=DA
  style='color:black'>Tlf: +45 39 16 84 00</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=MT style='color:black'>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=MT
  style='color:black'>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=MT
  style='color:black'>Tel: +</span><span style='color:black'>356 2122 2872</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=DE style='color:black'>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=DE
  style='color:black'>Novartis Pharma GmbH</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=DE
  style='color:black'>Tel: +49 911 273 0</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=DE
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=NL style='color:black'>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=NL
  style='color:black'>Novartis Pharma B.V.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=NL
  style='color:black'>Tel: +31 26 37 82 555</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=ET style='color:black'>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ET
  style='color:black'>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ET
  style='color:black'>Tel: +372 </span><span lang=EN-GB style='color:black'>66
  30 810</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ET
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=NO-BOK style='color:black'>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=NO-BOK style='color:black'>Novartis Norge AS</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=NO-BOK style='color:black'>Tlf: +47 23 05 20 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=EL style='color:black'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ET
  style='color:black'>Novartis (Hellas) A.E.B.E.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=EL
  style='color:black'>&#932;&#951;&#955;</span><span lang=ET style='color:black'>:
  +30 210 281 17 12</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ET
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=DE-AT style='color:black'>Österreich</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-AT style='color:black'>Novartis Pharma GmbH</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-AT style='color:black'>Tel: +43 1 86 6570</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=ES style='color:black'>España</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ES
  style='color:black'>Novartis Farmacéutica, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ES
  style='color:black'>Tel: +34 93 306 42 00</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ES
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=PL style='color:black'>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=PL
  style='color:black'>Novartis Poland Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=PL
  style='color:black'>Tel.: </span><span lang=NO-BOK style='color:black'>+48 22
  375 4888</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=FR style='color:black'>France</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
  style='color:black'>Novartis Pharma S.A.S.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
  style='color:black'>Tél: +33 1 55 47 66 00</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=PL style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=PT style='color:black'>Portugal</span></b></p>
  <p class=Text align=left style='margin-top:0in;text-align:left;background:
  white'><span lang=ES style='font-size:11.0pt;color:black'>Novartis Farma -
  Produtos Farmacêuticos, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=PT
  style='color:black'>Tel: +351 21 000 8600</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='background:white'><b><span lang=DE-CH
  style='color:black'>Hrvatska</span></b></p>
  <p class=MsoNormal style='background:white'><span lang=DE-CH
  style='color:black'>Novartis Hrvatska d.o.o.</span></p>
  <p class=MsoNormal style='background:white'><span lang=EN-GB
  style='color:black'>Tel. +385 1 6274 220</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='background:white'><b><span lang=IT
  style='color:black'>România</span></b></p>
  <p class=MsoNormal style='background:white'><span lang=IT style='color:black'>Novartis
  Pharma Services </span><span lang=FR style='color:#2F2F2F'>Romania SRL</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=IT
  style='color:black'>Tel: +40 21 31299 01</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=EN-GB style='color:black'>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=EN-GB style='color:black'>Novartis Ireland Limited</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=EN-GB style='color:black'>Tel: +353 1 260 12 55</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=SL style='color:black'>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SL
  style='color:black'>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SL
  style='color:black'>Tel: +386 1 300 75 50</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=IS style='color:black'>Ísland</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=IS
  style='color:black'>Vistor hf.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=IT
  style='color:black'>S</span><span lang=CS style='color:black'>í</span><span
  lang=IT style='color:black'>mi</span><span lang=IS style='color:black'>: +354
  535 7000</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=PT style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=SK style='color:black'>Slovenská republika</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SK
  style='color:black'>Novartis Slovakia s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SK
  style='color:black'>Tel: +421 2 5542 5439</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=SK style='color:black'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=IT style='color:black'>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=IT
  style='color:black'>Novartis Farma S.p.A.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=IT
  style='color:black'>Tel: +39 02 96 54 1</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=FI style='color:black'>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=FI
  style='color:black'>Novartis Finland Oy</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=FI
  style='color:black'>Puh/Tel: </span><span lang=EN-GB style='color:black'>+358
  (0)10 6133 200</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=IT style='color:black'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=EL style='color:black'>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=FR-CH style='color:black'>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=EL
  style='color:black'>&#932;&#951;&#955;: +</span><span lang=IT
  style='color:black'>357 22 690 690</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=FI
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=SV style='color:black'>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SV
  style='color:black'>Novartis Sverige AB</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SV
  style='color:black'>Tel: +46 8 732 32 00</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=FI style='color:black'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=LV style='color:black'>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=IT
  style='color:black'>SIA Novartis Baltics</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=LV
  style='color:black'>Tel: +371 67 887 070</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=LV
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=EN-GB style='color:black'>United Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=EN-GB style='color:black'>Novartis Pharmaceuticals UK Ltd.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=EN-GB style='color:black'>Tel: +44 1276 698370</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SV
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-22.45pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><b><span lang=EN-GB style='color:black'>This leaflet was last revised in</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>Detailed information on this
medicine is available on the European Medicines Agency website: </span><span
lang=EN-GB style='color:black'><a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB style='color:black'>Package leaflet:
Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB style='color:black'>EXJADE 90&nbsp;mg </span></b><b><span
style='color:black'>film&#8209;coated</span></b><b><span lang=EN-GB
style='color:black'> tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB style='color:black'>EXJADE 180&nbsp;mg </span></b><b><span
style='color:black'>film&#8209;coated</span></b><b><span lang=EN-GB
style='color:black'> tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB style='color:black'>EXJADE 360&nbsp;mg </span></b><b><span
style='color:black'>film&#8209;coated</span></b><b><span lang=EN-GB
style='color:black'> tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB style='color:black'>Deferasirox</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'><img
border=0 width=21 height=18 src="Exjade-II-073-EN%20PI_files/image004.gif"></span><span
lang=EN-GB style='color:black'>This medicine is subject to additional
monitoring. This will allow quick identification of new safety information. You
can help by reporting any side effects you may get. See the end of section 4
for how to report side effects.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><b><span lang=EN-GB style='color:black'>Read all of this leaflet
carefully before you start taking this medicine because it contains important
information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Keep this leaflet. You may
need to read it again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you have any further questions,
ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>This medicine has been
prescribed only for you or your child. Do not pass it on to others. It may harm
them, even if their signs of illness are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you get any side effects,
talk to your doctor or pharmacist.</span><span lang=EN-GB style='color:black'> </span><span
lang=EN-GB style='color:black'>This includes</span><span lang=EN-GB
style='color:black'> any possible side effects not listed in this leaflet. See
section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><b><span lang=EN-GB style='color:black'>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>1.       What
EXJADE is and what it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>2.       What you
need to know before you take EXJADE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>3.       How to
take EXJADE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>4.       Possible
side effects</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>5.       How to
store EXJADE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>6.       Contents
of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>1.       </span></b><b><span lang=EN-GB style='color:black'>What
EXJADE is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>What EXJADE is</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>EXJADE contains an active
substance called deferasirox. It is an iron chelator<i> </i>which is a medicine
used to remove the excess iron from the body (also called iron overload). It
traps and removes excess iron which is then excreted mainly in the stools.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>What EXJADE is used for</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Repeated blood transfusions may be
necessary in patients with various types of anaemia (for example thalassaemia,
sickle cell disease or myelodysplastic syndromes (MDS)). However, repeated
blood transfusions can cause a build&#8209;up of excess iron. This is because
blood contains iron and your body does not have a natural way to remove the
excess iron you get with your blood transfusions. In patients with non&#8209;transfusion&#8209;dependent
thalassaemia syndromes, iron overload may also develop over time, mainly due to
increased absorption of dietary iron in response to low blood cell counts. Over
time, the excess iron can damage important organs such as the liver and heart.
Medicines called <i>iron chelators </i>are used to remove the excess iron and
reduce the risk of it causing organ damage.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>EXJADE is used to treat chronic
iron overload caused by frequent blood transfusions in patients with beta
thalassaemia major aged 6&nbsp;years and older.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>EXJADE is also used to treat
chronic iron overload when deferoxamine therapy is contraindicated or
inadequate in patients with beta thalassaemia major with iron overload caused
by infrequent blood transfusions, in patients with other types of anaemias, and
in children aged 2 to 5&nbsp;years.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>EXJADE is also used when
deferoxamine therapy is contraindicated or inadequate to treat patients aged
10&nbsp;years or older who have iron overload associated with their
thalassaemia syndromes, but who are not transfusion dependent.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>2.       What you need to know before you take EXJADE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Do not take EXJADE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
are allergic to deferasirox or any of the other ingredients of this medicine
(listed in section&nbsp;6). If this applies to you, <b>tell your doctor before
taking EXJADE</b>. If you think you may be allergic, ask your doctor for
advice.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if you have moderate or severe
kidney disease.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if you are currently taking
any other iron chelator medicines.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>EXJADE is not recommended</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if you are at an advanced
stage of myelodysplastic syndrome (MDS; decreased production of blood cells by
the bone marrow) or have advanced cancer.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>Warnings and
precautions</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>Talk to your
doctor or pharmacist before taking EXJADE:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
have a kidney or liver problem.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
have a cardiac problem due to iron overload.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
notice a marked decrease in your urine output (sign of kidney problem).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
develop a severe rash, or difficulty breathing and dizziness or swelling mainly
of the face and throat (signs of severe allergic reaction, see also section 4
Possible side effects).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='color:black'>-        if you experience a
combination of any of the following symptoms: rash, red skin, blistering of the
lips, eyes or mouth, skin peeling, high fever, flu-like symptoms, enlarged
lymph nodes (signs of severe skin reaction, see also section 4 Possible side
effects).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
experience a combination of drowsiness, upper right abdominal pain, yellowing
or increased yellowing of your skin or eyes and dark urine (signs of liver
problems).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
experience difficulty thinking, remembering information, or solving problems,
being less alert or aware or feeling very sleepy with low energy (signs of a
high level of ammonia in your blood, which may be associated with liver or
renal problems, see also section&nbsp;4 Possible side effects).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
vomit blood and/or have black stools.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
experience frequent abdominal pain, particularly after eating or taking EXJADE.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
experience frequent heartburn.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
have a low level of platelets or white blood cells in your blood test.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
have blurred vision</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><span lang=EN-GB
style='color:black'>-        if you have diarrhoea or vomiting.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>If any of these
apply to you, tell your doctor straight away.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;page-break-after:avoid;
background:white'><b><span lang=EN-GB style='font-size:11.0pt;color:black'>Monitoring
your EXJADE treatment</span></b></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>You will have regular blood and
urine tests during treatment. These will monitor the amount of iron in your
body (blood level of <i>ferritin</i>) to see how well EXJADE is working. The
tests will also monitor your kidney function (blood level of creatinine, presence
of protein in the urine) and liver function (blood level of transaminases). Your
doctor may require you to undergo a kidney biopsy, if he/she suspects
significant kidney damage. You may also have MRI (magnetic resonance imaging)
tests to determine the amount of iron in your liver. Your doctor will take
these tests into consideration when deciding on the dose of EXJADE most
suitable for you and will also use these tests to decide when you should stop
taking EXJADE.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Your eyesight and hearing will
be tested each year during treatment as a precautionary measure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>Other medicines
and EXJADE</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Tell your doctor or pharmacist if
you are taking, have recently taken or might take any other medicines. This
includes in particular:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        other
iron chelators, which must not be taken with EXJADE,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        antacids
(medicines used to treat heartburn) containing aluminium, which should not be
taken at the same time of day as EXJADE,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        ciclosporin
(used to prevent the body rejecting a transplanted organ or for other conditions,
such as rheumatoid arthritis or atopic dermatitis),</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>-        simvastatin (used to lower
cholesterol),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        certain
painkillers or anti-inflammatory medicines (e.g. aspirin, ibuprofen,
corticosteroids),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        oral
bisphosphonates (used to treat osteoporosis),</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>-        anticoagulant medicines
(used to prevent or treat blood clotting),</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>-        hormonal contraceptive
agents (birth control medicines),</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>-        bepridil, ergotamine (used
for heart problems and migraines),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        repaglinide
(used to treat diabetes),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        rifampicin
(used to treat tuberculosis),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        phenytoin,
phenobarbital, carbamazepine (used to treat epilepsy),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        ritonavir
(used in the treatment of HIV infection),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        paclitaxel
(used in cancer treatment),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        theophylline
(used to treat respiratory diseases such as asthma),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        clozapine
(used to treat psychiatric disorders such as schizophrenia),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        tizanidine
(used as a muscle relaxant),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        cholestyramine
(used to lower cholesterol levels in the blood),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        busulfan
(used as a treatment prior to transplantation in order to destroy the original
bone marrow before the transplant).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>Additional tests may be required to
monitor the blood levels of some of these medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Older people (age 65&nbsp;years
and over)</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>EXJADE can be used by people aged
65&nbsp;years and over at the same dose as for other adults. Elderly patients
may experience more side effects (in particular diarrhoea) than younger
patients. They should be monitored closely by their doctor for side effects
that may require a dose adjustment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Children and adolescents</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>EXJADE can be used in children and adolescents
receiving regular blood transfusions aged 2&nbsp;years and over and in children
and adolescents not receiving regular blood transfusions aged 10&nbsp;years and
over. As the patient grows the doctor will adjust the dose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>EXJADE is not recommended for
children aged under 2&nbsp;years.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Pregnancy and breast&#8209;feeding</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>If you are pregnant or breast&#8209;feeding,
think you may be pregnant or are planning to have a baby, ask your doctor for
advice before taking this medicine.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXJADE is not recommended during pregnancy
unless clearly necessary.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>If you are currently using an oral
contraceptive or using a patch contraceptive to prevent pregnancy, you should
use an additional or different type of contraception (e.g. condom), as EXJADE
may reduce the effectiveness of oral and patch contraceptives.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Breast&#8209;feeding is not recommended during
treatment with EXJADE.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Driving and using machines</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>If you feel dizzy after taking
EXJADE, do not drive or operate any tools or machines until you are feeling normal
again.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>3.       </span></b><b><span lang=EN-GB style='color:black'>H</span><span
lang=EN-GB style='color:black'>ow to take EXJADE</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white;text-autospace:
none'><span lang=EN-GB style='color:black'>Treatment with EXJADE will be
overseen by a doctor who is experienced in the treatment of iron overload
caused by blood transfusions.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>Always take this medicine exactly
as your doctor has told you. Check with your doctor or pharmacist if you are
not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>How much EXJADE
to take</span></b></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;page-break-after:avoid;
background:white'><span lang=EN-GB style='font-size:11.0pt;color:black'>The
dose of EXJADE is related to body weight for all patients. Your doctor will
calculate the dose you need and tell you how many tablets to take each day.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>The usual
daily dose for EXJADE film&#8209;coated tablets<span style='layout-grid-mode:
line'> at the start of the treatment</span> for patients receiving regular
blood transfusions is 14&nbsp;mg per kilogram body weight. A higher or lower
starting dose may be recommended by your doctor based on your individual
treatment needs.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>The usual daily dose for
EXJADE film&#8209;coated tablets at the start of the treatment for patients not
receiving regular blood transfusions is 7&nbsp;mg per kilogram body weight.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Depending
on how you respond to treatment, your doctor may later adjust your treatment to
a higher or lower dose.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>The maximum
recommended daily dose for EXJADE film&#8209;coated tablets is:</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:56.7pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>28&nbsp;mg
per kilogram body weight for patients receiving regular blood transfusions,</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:56.7pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>14&nbsp;mg
per kilogram body weight for adult patients not receiving regular blood
transfusions,</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:56.7pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>7&nbsp;mg
per kilogram body weight for children and adolescents not receiving regular
blood transfusions.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>Deferasirox also comes as dispersible
tablets. If you are switching from the dispersible tablets to these film&#8209;coated
tablets, you will need an adjustment of the dose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>When to take
EXJADE</span></b></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Take EXJADE
once a day, every day, at about the same time each day with some water.</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;background:
white'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Take EXJADE film&#8209;coated
tablets either on an empty stomach or with a light meal.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Taking EXJADE at the same time
each day will also help you remember when to take your tablets.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>For patients who are unable to
swallow whole tablets, EXJADE film&#8209;coated tablets may be crushed and
taken by sprinkling the full dose onto soft food such as yogurt or apple sauce
(pureed apple). The food should be immediately and completely consumed. Do not
store it for future use.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>How long to take EXJADE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><b><span lang=EN-GB style='color:black'>Continue taking EXJADE every day
for as long as your doctor tells you.</span></b><span lang=EN-GB
style='color:black'> This is a long&#8209;term treatment, possibly lasting for
months or years. Your doctor will regularly monitor your condition to check
that the treatment is having the desired effect (see also section&nbsp;2:
Monitoring your EXJADE treatment).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>If you have questions about how
long to take EXJADE, talk to your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>If you take more EXJADE than you
should</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>If you have taken too much EXJADE,
or if someone else accidentally takes your tablets, contact your doctor or
hospital for advice straight away. Show the doctor the pack of tablets. Urgent
medical treatment may be necessary. </span><span lang=EN-GB style='color:black'>You
may experience effects such as abdominal pain, diarrhoea, nausea and vomiting and
kidney or liver problems that can be serious.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>If you forget to take EXJADE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>If you miss a dose, take it as soon
as you remember on that day. Take your next dose as scheduled. Do not take a
double dose on the next day to make up for the forgotten tablet(s).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>If you stop taking EXJADE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>Do not stop taking EXJADE unless
your doctor tells you to. If you stop taking it, the excess iron will no longer
be removed from your body (see also above section How long to take EXJADE).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.       </span></b><b><span lang=EN-GB style='color:black'>Possible
side effects</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Like all medicines, </span><span
style='font-size:11.0pt;color:black'>this medicine</span><span lang=EN-GB
style='font-size:11.0pt;color:black'> can cause side effects, although not
everybody gets them. Most of the side effects are mild to moderate and will
generally disappear after a few days to a few weeks of treatment.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>Some side
effects could be serious and need immediate medical attention.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><i><span lang=EN-GB style='color:black'>These side
effects are uncommon (may affect up to 1 in 100&nbsp;people) or rare (</span></i><i><span
style='color:black'>may affect up to 1 in 1,000&nbsp;people)</span><span
lang=EN-GB style='color:black'>.</span></i></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you get
a severe rash, or difficulty breathing and dizziness or swelling mainly of the
face and throat (signs of severe allergic reaction),</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience a combination of any of the following symptoms: </span><span
style='font-size:11.0pt;color:black'>rash, red skin, blistering of the lips,
eyes or mouth, skin peeling, high fever,</span><span lang=EN-GB
style='font-size:11.0pt;color:black'> flu-like symptoms, enlarged lymph nodes,
(signs of severe skin reactions),</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
notice a marked decrease in your urine output (sign of kidney problem),</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience a combination of drowsiness, upper right abdominal pain, yellowing
or increased yellowing of your skin or eyes and dark urine (signs of liver
problems),</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience difficulty thinking, remembering information, or solving problems,
being less alert or aware or feeling very sleepy with low energy (signs of a
high level of ammonia in your blood, which may be associated with liver or
renal problems and lead to a change in your brain function),</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
vomit blood and/or have black stools,</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience frequent abdominal pain, particularly after eating or taking EXJADE,</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience frequent heartburn,</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid;background:
white'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience partial loss of vision,</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid;background:
white'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience severe upper stomach pain (pancreatitis),</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><b><span lang=EN-GB style='color:black'>stop taking this medicine and
tell your doctor straight away.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>Some side
effects could become serious.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><i><span lang=EN-GB style='color:black'>These side
effects are uncommon.</span></i></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you get
blurred or cloudy eyesight,</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid;background:
white'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you get
reduced hearing,</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><b><span
style='font-size:11.0pt;color:black'>tell your doctor as soon as possible.</span></b></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
class=Nottoc-headingsChar><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;font-weight:normal'>&nbsp;</span></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>Other side
effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><i><span lang=EN-GB style='color:black'>Very common
(may affect more than 1 in 10&nbsp;people)</span></i></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>Disturbance in kidney
function tests.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
class=Nottoc-headingsChar><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;font-weight:normal'>&nbsp;</span></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><i><span lang=EN-GB style='color:black'>Common (may
affect up to 1 in 10&nbsp;people)</span></i></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Gastrointestinal
disorders, such as nausea, vomiting, diarrhoea, pain in the abdomen, bloating,
constipation, indigestion</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Rash</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Headache</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Disturbance
in liver function tests</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Itching</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid;background:
white'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Disturbance
in urine test (protein in the urine)</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>If any of these affects you
severely, tell your doctor.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;page-break-after:avoid;
background:white'><i><span style='font-size:11.0pt;color:black'>Uncommon (may
affect up to 1 in 100&nbsp;people)</span></i></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Dizziness</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Fever</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Sore throat</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Swelling of
arms or legs</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Change in
the colour of the skin</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Anxiety</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Sleep
disorder</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid;background:
white'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Tiredness</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>If any of these affects you
severely, tell your doctor.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid;background:white'><b><span
style='font-size:11.0pt'>Frequency not known </span></b><span style='font-size:
11.0pt'>(cannot be estimated from the available data).</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>A decrease
in the number of cells involved in blood clotting (thrombocytopenia), in the
number of red blood cells (anaemia aggravated), in the number of white blood
cells (neutropenia) or in the number of all kinds of blood cells (pancytopenia)</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Hair loss</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Kidney
stones</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Low urine
output</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Tear in
stomach or intestine wall that can be painful and cause nausea</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>Severe upper stomach
pain (pancreatitis)</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>Abnormal level of acid
in blood</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid;background:white'><b><span
style='font-size:11.0pt'>Reporting of side effects</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>If you get any side effects</span><span
style='font-size:11.0pt;color:black'>, talk to your doctor or pharmacist.</span><span
style='font-size:11.0pt;color:black'> This includes</span><span lang=EN-GB
style='font-size:11.0pt;color:black'> any possible side effects not listed in
this leaflet. You can also report side effects directly <span style='background:
#D9D9D9'>via the national reporting system listed in </span></span><span
style='color:black'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='font-size:11.0pt;background:#D9D9D9'>Appendix V</span></a></span><span
lang=EN-GB style='font-size:11.0pt;color:black'>. By reporting side effects you
can help provide more information on the safety of this medicine.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>5.       </span></b><b><span lang=EN-GB style='color:black'>How
to store EXJADE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Keep this
medicine out of the </span><span style='font-size:11.0pt;color:black'>sight and</span><span
lang=EN-GB style='font-size:11.0pt;color:black'> reach of children.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Do not use </span><span
style='font-size:11.0pt;color:black'>this medicine</span><span lang=EN-GB
style='font-size:11.0pt;color:black'> after the expiry date which is stated on
the blister and the carton after EXP. The expiry date refers to the last day of
that month.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Do not use
any pack that is damaged or shows signs of tampering.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Do not
throw away any medicines via wastewater or household waste. Ask your pharmacist
how to throw away medicines you no longer use. These measures will help protect
the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.       Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>What EXJADE contains</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>The active
substance is deferasirox.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Each film&#8209;coated tablet
of EXJADE 90&nbsp;mg contains 90&nbsp;mg deferasirox.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Each film&#8209;coated tablet
of EXJADE 180&nbsp;mg contains 180&nbsp;mg deferasirox.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Each film&#8209;coated tablet
of EXJADE 360&nbsp;mg contains 360&nbsp;mg deferasirox.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>The other ingredients are microcrystalline
cellulose; crospovidone; povidone; magnesium stearate; colloidal anhydrous
silica and poloxamer. The tablet coating material contains: hypromellose;
titanium dioxide (E171); macrogol (4000); talc; indigo carmine aluminium lake
(E132).</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>What EXJADE
looks like and contents of the pack</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>EXJADE is
supplied as film&#8209;coated tablets. The film&#8209;coated tablets are ovaloid
and biconvex.</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt;
background:white'><span style='font-size:11.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>EXJADE 90&nbsp;mg film&#8209;coated
tablets are light blue and stamped 90 on one side and NVR on the other.</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt;
background:white'><span style='font-size:11.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>EXJADE 180&nbsp;mg film&#8209;coated
tablets are medium blue and stamped 180 on one side and NVR on the other.</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt;
background:white'><span style='font-size:11.0pt;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>EXJADE 360&nbsp;mg film&#8209;coated
tablets are dark blue and stamped 360 on one side and NVR on the other.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Each blister pack contains
30&nbsp;or 90&nbsp;film&#8209;coated tablets. The m</span><span
style='font-size:11.0pt;color:black'>ultipacks contain 300 (10 packs of 30)
film&#8209;coated tablets.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Not all pack sizes or strengths
may be available in your country.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>Novartis Europharm
Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>Novartis Pharma GmbH</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>Roonstra</span><span lang=PT style='color:
black'>ß</span><span style='color:black'>e 25</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>D-90429 Nuremberg</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span style='color:black'>Germany</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR-CH style='color:black;background:#D9D9D9'>Novartis Farmacéutica SA</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR-CH style='color:black;background:#D9D9D9'>Ronda de Santa Maria 158</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=ES style='color:black;background:#D9D9D9'>08210 Barberà del Vallès,
Barcelona</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=FR-CH style='color:black;background:#D9D9D9'>Spain</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>For any information about this
medicine, please contact the local representative of the Marketing
Authorisation Holder.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=FR-BE style='color:black'>België/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=FR-BE style='color:black'>Novartis Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=FR-BE style='color:black'>Tél/Tel: +32 2 246 16 11</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal;background:
  white'><span lang=FR style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=LT style='color:black'>Lietuva</span></b></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal;
  background:white'><span lang=LT style='color:black'>Novartis Pharma Services
  Inc.</span></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal;
  background:white'><span lang=LT style='color:black'>Tel: +370 5 269 16 50</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-CH style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='background:white'><b><span lang=EN-GB
  style='color:black'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='background:white'><span lang=ES style='color:black'>Novartis
  Bulgaria EOOD</span></p>
  <p class=MsoNormal style='background:white'><span lang=EN-GB
  style='color:black'>&#1058;&#1077;&#1083;</span><span lang=ES
  style='color:black'>.: +359 2 489 98 28</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=NO-BOK style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=DE-CH style='color:black'>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-CH style='color:black'>Novartis Pharma N.V</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-CH style='color:black'>Tél/Tel: </span><span lang=FR-BE
  style='color:black'>+32 2 246 16 11</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-CH style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=NO-BOK style='color:black'>&#268;eská republika</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=NO-BOK style='color:black'>Novartis s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-CH style='color:black'>Tel: +420 225 775 111</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-CH style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=HU style='color:black'>Magyarország</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=HU
  style='color:black'>Novartis Hungária Kft.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=HU
  style='color:black'>Tel.: +36 1 457 65 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=DA style='color:black'>Danmark</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=DA
  style='color:black'>Novartis Healthcare A/S</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=DA
  style='color:black'>Tlf: +45 39 16 84 00</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=MT style='color:black'>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=MT
  style='color:black'>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=MT
  style='color:black'>Tel: +</span><span style='color:black'>356 2122 2872</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=DE style='color:black'>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=DE
  style='color:black'>Novartis Pharma GmbH</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=DE
  style='color:black'>Tel: +49 911 273 0</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=DE
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=NL style='color:black'>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=NL
  style='color:black'>Novartis Pharma B.V.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=NL
  style='color:black'>Tel: +31 26 37 82 555</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=ET style='color:black'>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ET
  style='color:black'>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ET
  style='color:black'>Tel: +372 </span><span lang=EN-GB style='color:black'>66
  30 810</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ET
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=NO-BOK style='color:black'>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=NO-BOK style='color:black'>Novartis Norge AS</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=NO-BOK style='color:black'>Tlf: +47 23 05 20 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=EL style='color:black'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ET
  style='color:black'>Novartis (Hellas) A.E.B.E.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=EL
  style='color:black'>&#932;&#951;&#955;</span><span lang=ET style='color:black'>:
  +30 210 281 17 12</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ET
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=DE-AT style='color:black'>Österreich</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-AT style='color:black'>Novartis Pharma GmbH</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-AT style='color:black'>Tel: +43 1 86 6570</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=ES style='color:black'>España</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ES
  style='color:black'>Novartis Farmacéutica, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ES
  style='color:black'>Tel: +34 93 306 42 00</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ES
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=PL style='color:black'>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=PL
  style='color:black'>Novartis Poland Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=PL
  style='color:black'>Tel.: </span><span lang=NO-BOK style='color:black'>+48 22
  375 4888</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=FR style='color:black'>France</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
  style='color:black'>Novartis Pharma S.A.S.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
  style='color:black'>Tél: +33 1 55 47 66 00</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=PL style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=PT style='color:black'>Portugal</span></b></p>
  <p class=Text align=left style='margin-top:0in;text-align:left;background:
  white'><span lang=ES style='font-size:11.0pt;color:black'>Novartis Farma -
  Produtos Farmacêuticos, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=PT
  style='color:black'>Tel: +351 21 000 8600</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='background:white'><b><span lang=DE-CH
  style='color:black'>Hrvatska</span></b></p>
  <p class=MsoNormal style='background:white'><span lang=DE-CH
  style='color:black'>Novartis Hrvatska d.o.o.</span></p>
  <p class=MsoNormal style='background:white'><span lang=EN-GB
  style='color:black'>Tel. +385 1 6274 220</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='background:white'><b><span lang=IT
  style='color:black'>România</span></b></p>
  <p class=MsoNormal style='background:white'><span lang=IT style='color:black'>Novartis
  Pharma Services </span><span lang=FR style='color:#2F2F2F'>Romania SRL</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=IT
  style='color:black'>Tel: +40 21 31299 01</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=EN-GB style='color:black'>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=EN-GB style='color:black'>Novartis Ireland Limited</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=EN-GB style='color:black'>Tel: +353 1 260 12 55</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=SL style='color:black'>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SL
  style='color:black'>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SL
  style='color:black'>Tel: +386 1 300 75 50</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=IS style='color:black'>Ísland</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=IS
  style='color:black'>Vistor hf.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=IT
  style='color:black'>S</span><span lang=CS style='color:black'>í</span><span
  lang=IT style='color:black'>mi</span><span lang=IS style='color:black'>: +354
  535 7000</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=PT style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=SK style='color:black'>Slovenská republika</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SK
  style='color:black'>Novartis Slovakia s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SK
  style='color:black'>Tel: +421 2 5542 5439</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=SK style='color:black'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=IT style='color:black'>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=IT
  style='color:black'>Novartis Farma S.p.A.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=IT
  style='color:black'>Tel: +39 02 96 54 1</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=FI style='color:black'>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=FI
  style='color:black'>Novartis Finland Oy</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=FI
  style='color:black'>Puh/Tel: </span><span lang=EN-GB style='color:black'>+358
  (0)10 6133 200</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=IT style='color:black'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=EL style='color:black'>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=FR-CH style='color:black'>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=EL
  style='color:black'>&#932;&#951;&#955;: +</span><span lang=IT
  style='color:black'>357 22 690 690</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=FI
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=SV style='color:black'>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SV
  style='color:black'>Novartis Sverige AB</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SV
  style='color:black'>Tel: +46 8 732 32 00</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=FI style='color:black'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=LV style='color:black'>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=IT
  style='color:black'>SIA Novartis Baltics</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=LV
  style='color:black'>Tel: +371 67 887 070</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=LV
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=EN-GB style='color:black'>United Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=EN-GB style='color:black'>Novartis Pharmaceuticals UK Ltd.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=EN-GB style='color:black'>Tel: +44 1276 698370</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SV
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-22.45pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><b><span lang=EN-GB style='color:black'>This leaflet was last revised in</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>Detailed information on this
medicine is available on the European Medicines Agency website: </span><span
lang=EN-GB style='color:black'><a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB style='color:black'>Package leaflet:
Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB style='color:black'>EXJADE 90&nbsp;mg granules
in sachet</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB style='color:black'>EXJADE 180&nbsp;mg granules
in sachet</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><b><span lang=EN-GB style='color:black'>EXJADE 360&nbsp;mg granules
in sachet</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB style='color:black'>Deferasirox</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='color:black'><img
border=0 width=21 height=18 id="Picture 1"
src="Exjade-II-073-EN%20PI_files/image004.gif"></span><span lang=EN-GB
style='color:black'>This medicine is subject to additional monitoring. This
will allow quick identification of new safety information. You can help by
reporting any side effects you may get. See the end of section 4 for how to
report side effects.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><b><span lang=EN-GB style='color:black'>Read all of this leaflet
carefully before you start taking this medicine because it contains important
information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Keep this leaflet. You may
need to read it again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you have any further
questions, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>This medicine has been
prescribed only for you or your child. Do not pass it on to others. It may harm
them, even if their signs of illness are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you get any side effects,
talk to your doctor or pharmacist.</span><span lang=EN-GB style='color:black'> </span><span
lang=EN-GB style='color:black'>This includes</span><span lang=EN-GB
style='color:black'> any possible side effects not listed in this leaflet. See
section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><b><span lang=EN-GB style='color:black'>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>1.       What
EXJADE is and what it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>2.       What you
need to know before you take EXJADE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>3.       How to
take EXJADE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>4.       Possible
side effects</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>5.       How to
store EXJADE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>6.       Contents
of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>1.       </span></b><b><span lang=EN-GB style='color:black'>What
EXJADE is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>What EXJADE is</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>EXJADE contains an active
substance called deferasirox. It is an iron chelator<i> </i>which is a medicine
used to remove the excess iron from the body (also called iron overload). It
traps and removes excess iron which is then excreted mainly in the stools.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>What EXJADE is used for</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
style='font-size:11.0pt;color:black'>Repeated blood transfusions may be
necessary in patients with various types of anaemia (for example thalassaemia,
sickle cell disease or myelodysplastic syndromes (MDS)). However, repeated
blood transfusions can cause a build&#8209;up of excess iron. This is because
blood contains iron and your body does not have a natural way to remove the
excess iron you get with your blood transfusions. In patients with non&#8209;transfusion&#8209;dependent
thalassaemia syndromes, iron overload may also develop over time, mainly due to
increased absorption of dietary iron in response to low blood cell counts. Over
time, the excess iron can damage important organs such as the liver and heart.
Medicines called <i>iron chelators </i>are used to remove the excess iron and
reduce the risk of it causing organ damage.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>EXJADE is used to treat chronic
iron overload caused by frequent blood transfusions in patients with beta
thalassaemia major aged 6&nbsp;years and older.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>EXJADE is also used to treat
chronic iron overload when deferoxamine therapy is contraindicated or
inadequate in patients with beta thalassaemia major with iron overload caused
by infrequent blood transfusions, in patients with other types of anaemias, and
in children aged 2 to 5&nbsp;years.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>EXJADE is also used when
deferoxamine therapy is contraindicated or inadequate to treat patients aged
10&nbsp;years or older who have iron overload associated with their
thalassaemia syndromes, but who are not transfusion dependent.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>2.       What you need to know before you take EXJADE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Do not take EXJADE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
are allergic to deferasirox or any of the other ingredients of this medicine
(listed in section&nbsp;6). If this applies to you, <b>tell your doctor before
taking EXJADE</b>. If you think you may be allergic, ask your doctor for
advice.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if you have moderate or severe
kidney disease.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if you are currently taking
any other iron chelator medicines.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>EXJADE is not recommended</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>if you are at an advanced
stage of myelodysplastic syndrome (MDS; decreased production of blood cells by
the bone marrow) or have advanced cancer.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>Warnings and
precautions</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>Talk to your
doctor or pharmacist before taking EXJADE:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
have a kidney or liver problem.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
have a cardiac problem due to iron overload.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
notice a marked decrease in your urine output (sign of kidney problem).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
develop a severe rash, or difficulty breathing and dizziness or swelling mainly
of the face and throat (signs of severe allergic reaction, see also section 4
Possible side effects).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='color:black'>-        if you experience a
combination of any of the following symptoms: rash, red skin, blistering of the
lips, eyes or mouth, skin peeling, high fever, flu-like symptoms, enlarged
lymph nodes (signs of severe skin reaction, see also section 4 Possible side
effects).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
experience a combination of drowsiness, upper right abdominal pain, yellowing
or increased yellowing of your skin or eyes and dark urine (signs of liver
problems).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
experience difficulty thinking, remembering information, or solving problems,
being less alert or aware or feeling very sleepy with low energy (signs of a
high level of ammonia in your blood, which may be associated with liver or
renal problems, see also section&nbsp;4 Possible side effects).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
vomit blood and/or have black stools.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you experience
frequent abdominal pain, particularly after eating or taking EXJADE.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
experience frequent heartburn.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
have a low level of platelets or white blood cells in your blood test.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        if you
have blurred vision</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><span lang=EN-GB
style='color:black'>-        if you have diarrhoea or vomiting.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>If any of these
apply to you, tell your doctor straight away.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;page-break-after:avoid;
background:white'><b><span lang=EN-GB style='font-size:11.0pt;color:black'>Monitoring
your EXJADE treatment</span></b></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>You will have regular blood and
urine tests during treatment. These will monitor the amount of iron in your
body (blood level of <i>ferritin</i>) to see how well EXJADE is working. The
tests will also monitor your kidney function (blood level of creatinine, presence
of protein in the urine) and liver function (blood level of transaminases).
Your doctor may require you to undergo a kidney biopsy, if he/she suspects
significant kidney damage. You may also have MRI (magnetic resonance imaging)
tests to determine the amount of iron in your liver. Your doctor will take
these tests into consideration when deciding on the dose of EXJADE most
suitable for you and will also use these tests to decide when you should stop
taking EXJADE.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Your eyesight and hearing will
be tested each year during treatment as a precautionary measure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>Other medicines
and EXJADE</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>Tell your doctor or pharmacist if
you are taking, have recently taken or might take any other medicines. This
includes in particular:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        other
iron chelators, which must not be taken with EXJADE,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        antacids
(medicines used to treat heartburn) containing aluminium, which should not be
taken at the same time of day as EXJADE,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        ciclosporin
(used to prevent the body rejecting a transplanted organ or for other conditions,
such as rheumatoid arthritis or atopic dermatitis),</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>-        simvastatin (used to lower
cholesterol),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        certain
painkillers or anti-inflammatory medicines (e.g. aspirin, ibuprofen,
corticosteroids),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        oral
bisphosphonates (used to treat osteoporosis),</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>-        anticoagulant medicines
(used to prevent or treat blood clotting),</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>-        hormonal contraceptive
agents (birth control medicines),</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>-        bepridil, ergotamine (used
for heart problems and migraines),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        repaglinide
(used to treat diabetes),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        rifampicin
(used to treat tuberculosis),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        phenytoin,
phenobarbital, carbamazepine (used to treat epilepsy),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        ritonavir
(used in the treatment of HIV infection),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        paclitaxel
(used in cancer treatment),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        theophylline
(used to treat respiratory diseases such as asthma),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        clozapine
(used to treat psychiatric disorders such as schizophrenia),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        tizanidine
(used as a muscle relaxant),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        cholestyramine
(used to lower cholesterol levels in the blood),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='color:black'>-        busulfan
(used as a treatment prior to transplantation in order to destroy the original
bone marrow before the transplant).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>Additional tests may be required to
monitor the blood levels of some of these medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Older people (age 65&nbsp;years
and over)</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>EXJADE can be used by people aged
65&nbsp;years and over at the same dose as for other adults. Elderly patients
may experience more side effects (in particular diarrhoea) than younger
patients. They should be monitored closely by their doctor for side effects
that may require a dose adjustment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Children and adolescents</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>EXJADE can be used in children and
adolescents receiving regular blood transfusions aged 2&nbsp;years and over and
in children and adolescents not receiving regular blood transfusions aged
10&nbsp;years and over. As the patient grows the doctor will adjust the dose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>EXJADE is not recommended for
children aged under 2&nbsp;years.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Pregnancy and breast&#8209;feeding</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>If you are pregnant or breast&#8209;feeding,
think you may be pregnant or are planning to have a baby, ask your doctor for
advice before taking this medicine.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>EXJADE is not recommended during pregnancy
unless clearly necessary.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>If you are currently using an oral
contraceptive or using a patch contraceptive to prevent pregnancy, you should
use an additional or different type of contraception (e.g. condom), as EXJADE
may reduce the effectiveness of oral and patch contraceptives.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>Breast&#8209;feeding is not recommended during
treatment with EXJADE.</span></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Driving and using machines</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>If you feel dizzy after taking
EXJADE, do not drive or operate any tools or machines until you are feeling
normal again.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>3.       </span></b><b><span lang=EN-GB style='color:black'>H</span><span
lang=EN-GB style='color:black'>ow to take EXJADE</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;background:white;text-autospace:
none'><span lang=EN-GB style='color:black'>Treatment with EXJADE will be
overseen by a doctor who is experienced in the treatment of iron overload
caused by blood transfusions.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>Always take this medicine exactly
as your doctor has told you. Check with your doctor or pharmacist if you are
not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>How much EXJADE
to take</span></b></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;page-break-after:avoid;
background:white'><span lang=EN-GB style='font-size:11.0pt;color:black'>The
dose of EXJADE is related to body weight for all patients. Your doctor will
calculate the dose you need and tell you how many sachets to take each day.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>The usual
daily dose for EXJADE granules<span style='layout-grid-mode:line'> at the start
of the treatment</span> for patients receiving regular blood transfusions is
14&nbsp;mg per kilogram body weight. A higher or lower starting dose may be
recommended by your doctor based on your individual treatment needs.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>The usual daily dose for
EXJADE granules at the start of the treatment for patients not receiving
regular blood transfusions is 7&nbsp;mg per kilogram body weight.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Depending
on how you respond to treatment, your doctor may later adjust your treatment to
a higher or lower dose.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>The maximum
recommended daily dose for EXJADE granules:</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:56.7pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>28&nbsp;mg
per kilogram body weight for patients receiving regular blood transfusions,</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:56.7pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>14&nbsp;mg
per kilogram body weight for adult patients not receiving regular blood
transfusions,</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:56.7pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>7&nbsp;mg
per kilogram body weight for children and adolescents not receiving regular
blood transfusions.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>Deferasirox also comes as
dispersible tablets. If you are switching from the dispersible tablets to
these </span><span lang=EN-GB style='color:black'>granules</span><span
lang=EN-GB style='color:black'>, you will need an adjustment of the dose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>When to take
EXJADE</span></b></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Take EXJADE
once a day, every day, at about the same time each day.</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;background:
white'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Take EXJADE granules either with
or without a light meal.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Taking EXJADE at the same time
each day will also help you remember when to take your medicine.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>EXJADE granules should be taken
by sprinkling the full dose onto soft food such as yogurt or apple sauce
(pureed apple). The food should be immediately and completely consumed. Do not
store it for future use.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>How long to take EXJADE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><b><span lang=EN-GB style='color:black'>Continue taking EXJADE every day
for as long as your doctor tells you.</span></b><span lang=EN-GB
style='color:black'> This is a long&#8209;term treatment, possibly lasting for
months or years. Your doctor will regularly monitor your condition to check
that the treatment is having the desired effect (see also section&nbsp;2:
Monitoring your EXJADE treatment).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>If you have questions about how
long to take EXJADE, talk to your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>If you take more EXJADE than you
should</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>If you have taken too much EXJADE,
or if someone else accidentally takes your </span><span lang=EN-GB
style='color:black'>granules</span><span lang=EN-GB style='color:black'>,
contact your doctor or hospital for advice straight away. Show the doctor the
pack of </span><span lang=EN-GB style='color:black'>granules</span><span
lang=EN-GB style='color:black'>. Urgent medical treatment may be necessary. </span><span
lang=EN-GB style='color:black'>You may experience effects such as abdominal
pain, diarrhoea, nausea and vomiting and kidney or liver problems that can be
serious.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>If you forget to take EXJADE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>If you miss a dose, take it as soon
as you remember on that day. Take your next dose as scheduled. Do not take a
double dose on the next day to make up for the forgotten </span><span
lang=EN-GB style='color:black'>granules</span><span lang=EN-GB
style='color:black'>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>If you stop taking EXJADE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>Do not stop taking EXJADE unless
your doctor tells you to. If you stop taking it, the excess iron will no longer
be removed from your body (see also above section How long to take EXJADE).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>4.       </span></b><b><span lang=EN-GB style='color:black'>Possible
side effects</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Like all medicines, </span><span
style='font-size:11.0pt;color:black'>this medicine</span><span lang=EN-GB
style='font-size:11.0pt;color:black'> can cause side effects, although not
everybody gets them. Most of the side effects are mild to moderate and will
generally disappear after a few days to a few weeks of treatment.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>Some side
effects could be serious and need immediate medical attention.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><i><span lang=EN-GB style='color:black'>These side
effects are uncommon (may affect up to 1 in 100&nbsp;people) or rare (</span></i><i><span
style='color:black'>may affect up to 1 in 1,000&nbsp;people)</span><span
lang=EN-GB style='color:black'>.</span></i></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you get
a severe rash, or difficulty breathing and dizziness or swelling mainly of the
face and throat (signs of severe allergic reaction),</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience a combination of any of the following symptoms: </span><span
style='font-size:11.0pt;color:black'>rash, red skin, blistering of the lips,
eyes or mouth, skin peeling, high fever,</span><span lang=EN-GB
style='font-size:11.0pt;color:black'> flu-like symptoms, enlarged lymph nodes,
(signs of severe skin reactions),</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
notice a marked decrease in your urine output (sign of kidney problem),</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you experience
a combination of drowsiness, upper right abdominal pain, yellowing or increased
yellowing of your skin or eyes and dark urine (signs of liver problems),</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience difficulty thinking, remembering information, or solving problems,
being less alert or aware or feeling very sleepy with low energy (signs of a
high level of ammonia in your blood, which may be associated with liver or
renal problems and lead to a change in your brain function),</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
vomit blood and/or have black stools,</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience frequent abdominal pain, particularly after eating or taking EXJADE,</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience frequent heartburn,</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid;background:
white'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience partial loss of vision,</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid;background:
white'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you
experience severe upper stomach pain (pancreatitis),</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><b><span lang=EN-GB style='color:black'>stop taking this medicine and tell
your doctor straight away.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>Some side
effects could become serious.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><i><span lang=EN-GB style='color:black'>These side
effects are uncommon.</span></i></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you get
blurred or cloudy eyesight,</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid;background:
white'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>If you get
reduced hearing,</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><b><span
style='font-size:11.0pt;color:black'>tell your doctor as soon as possible.</span></b></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
class=Nottoc-headingsChar><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;font-weight:normal'>&nbsp;</span></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>Other side
effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><i><span lang=EN-GB style='color:black'>Very common
(may affect more than 1 in 10&nbsp;people)</span></i></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>Disturbance in kidney
function tests.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
class=Nottoc-headingsChar><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;font-weight:normal'>&nbsp;</span></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><i><span lang=EN-GB style='color:black'>Common (may
affect up to 1 in 10&nbsp;people)</span></i></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Gastrointestinal
disorders, such as nausea, vomiting, diarrhoea, pain in the abdomen, bloating,
constipation, indigestion</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Rash</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Headache</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Disturbance
in liver function tests</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Itching</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid;background:
white'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Disturbance
in urine test (protein in the urine)</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>If any of these affects you
severely, tell your doctor.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;page-break-after:avoid;
background:white'><i><span style='font-size:11.0pt;color:black'>Uncommon (may
affect up to 1 in 100&nbsp;people)</span></i></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Dizziness</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Fever</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Sore throat</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Swelling of
arms or legs</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Change in
the colour of the skin</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Anxiety</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Sleep
disorder</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid;background:
white'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Tiredness</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>If any of these affects you
severely, tell your doctor.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid;background:white'><b><span
style='font-size:11.0pt'>Frequency not known </span></b><span style='font-size:
11.0pt'>(cannot be estimated from the available data).</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>A decrease
in the number of cells involved in blood clotting (thrombocytopenia), in the
number of red blood cells (anaemia aggravated), in the number of white blood
cells (neutropenia) or in the number of all kinds of blood cells (pancytopenia)</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Hair loss</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Kidney
stones</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Low urine
output</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Tear in
stomach or intestine wall that can be painful and cause nausea</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>Severe upper stomach
pain (pancreatitis)</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;color:black'>Abnormal level of acid
in blood</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid;background:white'><b><span
style='font-size:11.0pt'>Reporting of side effects</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>If you get any side effects</span><span
style='font-size:11.0pt;color:black'>, talk to your doctor or pharmacist.</span><span
style='font-size:11.0pt;color:black'> This includes</span><span lang=EN-GB
style='font-size:11.0pt;color:black'> any possible side effects not listed in
this leaflet. You can also report side effects directly <span style='background:
#D9D9D9'>via the national reporting system listed in </span></span><span
style='color:black'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='font-size:11.0pt;background:#D9D9D9'>Appendix V</span></a></span><span
lang=EN-GB style='font-size:11.0pt;color:black'>. By reporting side effects you
can help provide more information on the safety of this medicine.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>5.       </span></b><b><span lang=EN-GB style='color:black'>How
to store EXJADE</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Keep this
medicine out of the </span><span style='font-size:11.0pt;color:black'>sight and</span><span
lang=EN-GB style='font-size:11.0pt;color:black'> reach of children.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Do not use </span><span
style='font-size:11.0pt;color:black'>this medicine</span><span lang=EN-GB
style='font-size:11.0pt;color:black'> after the expiry date which is stated on
the sachet and the carton after EXP. The expiry date refers to the last day of
that month.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Do not use
any pack that is damaged or shows signs of tampering.</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;background:white'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Do not
throw away any medicines via wastewater or household waste. Ask your pharmacist
how to throw away medicines you no longer use. These measures will help protect
the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;background:white'><b><span lang=EN-GB
style='color:black'>6.       Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>What EXJADE contains</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>The active
substance is deferasirox.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Each sachet of EXJADE
90&nbsp;mg granules contains 90&nbsp;mg deferasirox.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Each sachet of EXJADE
180&nbsp;mg granules contains 180&nbsp;mg deferasirox.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;background:white'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Each sachet of EXJADE
360&nbsp;mg granules contains 360&nbsp;mg deferasirox.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>The other ingredients are
microcrystalline cellulose; crospovidone; povidone; magnesium stearate;
colloidal anhydrous silica and poloxamer.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>What EXJADE
looks like and contents of the pack</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid;background:white'><span style='font-size:11.0pt;color:black'>EXJADE granules
are supplied as white to almost white granules in sachets.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Each pack contains 30&nbsp;sachets</span><span
style='font-size:11.0pt;color:black'>.</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Listlevel1 style='margin:0in;text-indent:0in;background:white'><span
lang=EN-GB style='font-size:11.0pt;color:black'>Not all strengths may be
available in your country.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><b><span lang=EN-GB style='color:black'>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid;background:white'><span lang=EN-GB style='color:black'>Novartis Europharm
Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>Ireland</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>Novartis Pharma GmbH</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>Roonstra</span><span lang=PT style='color:
black'>ß</span><span style='color:black'>e 25</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span style='color:black'>D-90429 Nuremberg</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span style='color:black'>Germany</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>For any information about this
medicine, please contact the local representative of the Marketing
Authorisation Holder.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=FR-BE style='color:black'>België/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=FR-BE style='color:black'>Novartis Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=FR-BE style='color:black'>Tél/Tel: +32 2 246 16 11</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal;background:
  white'><span lang=FR style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=LT style='color:black'>Lietuva</span></b></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal;
  background:white'><span lang=LT style='color:black'>Novartis Pharma Services
  Inc.</span></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal;
  background:white'><span lang=LT style='color:black'>Tel: +370 5 269 16 50</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-CH style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='background:white'><b><span lang=EN-GB
  style='color:black'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='background:white'><span lang=ES style='color:black'>Novartis
  Bulgaria EOOD</span></p>
  <p class=MsoNormal style='background:white'><span lang=EN-GB
  style='color:black'>&#1058;&#1077;&#1083;</span><span lang=ES
  style='color:black'>.: +359 2 489 98 28</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=NO-BOK style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=DE-CH style='color:black'>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-CH style='color:black'>Novartis Pharma N.V</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-CH style='color:black'>Tél/Tel: </span><span lang=FR-BE
  style='color:black'>+32 2 246 16 11</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-CH style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=NO-BOK style='color:black'>&#268;eská republika</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=NO-BOK style='color:black'>Novartis s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-CH style='color:black'>Tel: +420 225 775 111</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-CH style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=HU style='color:black'>Magyarország</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=HU
  style='color:black'>Novartis Hungária Kft.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=HU
  style='color:black'>Tel.: +36 1 457 65 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=DA style='color:black'>Danmark</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=DA
  style='color:black'>Novartis Healthcare A/S</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=DA
  style='color:black'>Tlf: +45 39 16 84 00</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=MT style='color:black'>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=MT
  style='color:black'>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=MT
  style='color:black'>Tel: +</span><span style='color:black'>356 2122 2872</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=DE style='color:black'>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=DE
  style='color:black'>Novartis Pharma GmbH</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=DE
  style='color:black'>Tel: +49 911 273 0</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=DE
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=NL style='color:black'>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=NL
  style='color:black'>Novartis Pharma B.V.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=NL
  style='color:black'>Tel: +31 26 37 82 555</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=ET style='color:black'>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ET
  style='color:black'>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ET
  style='color:black'>Tel: +372 </span><span lang=EN-GB style='color:black'>66
  30 810</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ET
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=NO-BOK style='color:black'>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=NO-BOK style='color:black'>Novartis Norge AS</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=NO-BOK style='color:black'>Tlf: +47 23 05 20 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=EL style='color:black'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ET
  style='color:black'>Novartis (Hellas) A.E.B.E.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=EL
  style='color:black'>&#932;&#951;&#955;</span><span lang=ET style='color:black'>:
  +30 210 281 17 12</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ET
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=DE-AT style='color:black'>Österreich</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-AT style='color:black'>Novartis Pharma GmbH</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=DE-AT style='color:black'>Tel: +43 1 86 6570</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=ES style='color:black'>España</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ES
  style='color:black'>Novartis Farmacéutica, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ES
  style='color:black'>Tel: +34 93 306 42 00</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=ES
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=PL style='color:black'>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=PL
  style='color:black'>Novartis Poland Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=PL
  style='color:black'>Tel.: </span><span lang=NO-BOK style='color:black'>+48 22
  375 4888</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=FR style='color:black'>France</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
  style='color:black'>Novartis Pharma S.A.S.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=FR
  style='color:black'>Tél: +33 1 55 47 66 00</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=PL style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=PT style='color:black'>Portugal</span></b></p>
  <p class=Text align=left style='margin-top:0in;text-align:left;background:
  white'><span lang=ES style='font-size:11.0pt;color:black'>Novartis Farma -
  Produtos Farmacêuticos, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=PT
  style='color:black'>Tel: +351 21 000 8600</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='background:white'><b><span lang=DE-CH
  style='color:black'>Hrvatska</span></b></p>
  <p class=MsoNormal style='background:white'><span lang=DE-CH
  style='color:black'>Novartis Hrvatska d.o.o.</span></p>
  <p class=MsoNormal style='background:white'><span lang=EN-GB
  style='color:black'>Tel. +385 1 6274 220</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='background:white'><b><span lang=IT
  style='color:black'>România</span></b></p>
  <p class=MsoNormal style='background:white'><span lang=IT style='color:black'>Novartis
  Pharma Services </span><span lang=FR style='color:#2F2F2F'>Romania SRL</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=IT
  style='color:black'>Tel: +40 21 31299 01</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=EN-GB style='color:black'>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=EN-GB style='color:black'>Novartis Ireland Limited</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=EN-GB style='color:black'>Tel: +353 1 260 12 55</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=SL style='color:black'>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SL
  style='color:black'>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SL
  style='color:black'>Tel: +386 1 300 75 50</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=IS style='color:black'>Ísland</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=IS
  style='color:black'>Vistor hf.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=IT
  style='color:black'>S</span><span lang=CS style='color:black'>í</span><span
  lang=IT style='color:black'>mi</span><span lang=IS style='color:black'>: +354
  535 7000</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=PT style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=SK style='color:black'>Slovenská republika</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SK
  style='color:black'>Novartis Slovakia s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SK
  style='color:black'>Tel: +421 2 5542 5439</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=SK style='color:black'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=IT style='color:black'>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=IT
  style='color:black'>Novartis Farma S.p.A.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=IT
  style='color:black'>Tel: +39 02 96 54 1</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=FI style='color:black'>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=FI
  style='color:black'>Novartis Finland Oy</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=FI
  style='color:black'>Puh/Tel: </span><span lang=EN-GB style='color:black'>+358
  (0)10 6133 200</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=IT style='color:black'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=EL style='color:black'>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=FR-CH style='color:black'>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=EL
  style='color:black'>&#932;&#951;&#955;: +</span><span lang=IT
  style='color:black'>357 22 690 690</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=FI
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=SV style='color:black'>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SV
  style='color:black'>Novartis Sverige AB</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SV
  style='color:black'>Tel: +46 8 732 32 00</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=FI style='color:black'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=LV style='color:black'>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=IT
  style='color:black'>SIA Novartis Baltics</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=LV
  style='color:black'>Tel: +371 67 887 070</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=LV
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;background:white'><b><span
  lang=EN-GB style='color:black'>United Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=EN-GB style='color:black'>Novartis Pharmaceuticals UK Ltd.</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span
  lang=EN-GB style='color:black'>Tel: +44 1276 698370</span></p>
  <p class=MsoNormal style='line-height:normal;background:white'><span lang=SV
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-22.45pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><b><span lang=EN-GB style='color:black'>This leaflet was last revised in</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;background:
white'><b><span lang=EN-GB style='color:black'>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;background:
white'><span lang=EN-GB style='color:black'>Detailed information on this
medicine is available on the European Medicines Agency website: </span><span
lang=EN-GB style='color:black'><a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;text-autospace:none'><b><span lang=EN-GB style='color:black;
text-transform:uppercase'>Annex IV</span></b></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;text-autospace:none'><span lang=EN-GB style='color:black;
text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:6.0pt;text-align:center;
line-height:normal;text-autospace:none'><b><span lang=EN-GB style='color:black;
text-transform:uppercase'>Scientific conclusions and grounds for the variation
to the terms of the marketing authorisation(s)</span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><b><span lang=EN-GB style='color:black'>Scientific conclusions</span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Taking into account the PRAC
Assessment Report on the PSUR(s) for deferasirox, the scientific conclusions of
CHMP are as follows:</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>The MAH provided a cumulative
analysis across all populations of cases of hepatic failure (serious and
non-serious) with reported medical history. The quantitative analysis
highlights the role of hepatic comorbidities and multi-organ failure in the
occurrence of hepatic failure. Cases of hepatic failure were reported with all
marketed formulations of deferasirox. An update of the EU SmPC is therefore
recommended.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>The MAH reported also 5 noteworthy
cases of GI haemorrhage/gastric ulcer. Keeping in mind that gastrointestinal
haemorrhage is associated with a high rate of mortality despite progress in
diagnosis and treatment, an update of the EU SmPC treatment recommendations is
therefore warranted.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>The CHMP agrees with the scientific
conclusions made by the PRAC.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><b><span lang=EN-GB style='color:black'>Grounds for the variation to the
terms of the marketing authorisation(s)</span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>On the basis of the scientific
conclusions for deferasirox the CHMP is of the opinion that the benefit-risk
balance of the medicinal product(s) containing deferasirox is unchanged subject
to the proposed changes to the product information.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>The CHMP recommends that the terms
of the marketing authorisation(s) should be varied.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

</div>

</body>

</html>
